UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A (RULE 14A-101)
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OFSecurities Exchange Act of 1934
(Amendment No. )
(AMENDMENT NO. ____)
Filed by the RegistrantS
☒    Filed by a Partyparty other than the Registrant£

Check the appropriate box:
£☐ Preliminary Proxy Statement
£☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
S☒ Definitive Proxy Statement
£☐ Definitive Additional Materials
£☐ Soliciting Material UnderPursuant to Rule 14a-12


dyadiclogoa051.jpgDYADIC INTERNATIONAL, INC.
(Name of Registrant as Specified in itsIn Its Charter)
(Name of Person(s) Filing Proxy Statement, if otherOther than the Registrant)

Payment of Filing Fee (Check the appropriate box):
☒ No fee required.
£ ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(l)(1) and 0-11.
(1) Title of each class of securities to which transaction applies: N/A
(2) Aggregate number of securities to which transaction applies: N/A
(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set(set forth the amount on which the filing fee is calculated and state how it was determined): N/A
(4) Proposed maximum aggregate value of transaction: N/A
(5) Total fee paid: N/A
£ ☐ Fee paid previously with preliminary materials.
£ ☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.filing:
(1) Amount Previously Paid:previously paid: N/A
(2) Form, Scheduleschedule or Registration Statementregistration statement No.: N/A
(3) Filing Party:party: N/A
(4) Date Filed: N/A








dyadiclogoa061.jpg
DYADIC INTERNATIONAL, INC.
140 Intracoastal Pointe Drive, Suite 404
Jupiter, Florida 33477
(561) 743-8333
Table of Contents


Dyadic Logo
DYADIC INTERNATIONAL, INC.
140 Intracoastal Pointe Drive, Suite 404
Jupiter, FL 33477
(561) 743-8333
Dear Stockholder:Shareholder:

You are cordially invited to attend the 2006 annual meeting2020 Virtual Annual Meeting of stockholdersShareholders (“Annual Meeting”) of Dyadic International, Inc. (“Dyadic”), which we will holdbe held on Monday, June 12, 200629, 2020 at 10:0010 a.m., local time, at Eastern Daylight Savings Time. With rising concerns around the Doubletree Hotel located at 4431 PGA Boulevard, Palm Beach Gardens, Florida 33410.spread of COVID-19 in the United States and globally, in order to mitigate health risks, this year’s meeting will be conducted in virtual format only. Shareholders can access the Annual Meeting by visiting www.virtualshareholdermeeting.com/DYAI2020. You will not be able to attend the Annual Meeting in person. We believe that a virtual meeting will provide meaningful shareholder access and participation and also protect the health and safety of our shareholders, employees and other stakeholders, and also improve meeting efficiency and reduce costs.

The mattersAt the Annual Meeting, you will be asked to be presented atconsider and vote on the meeting areproposals described in the Notice of 20062020 Virtual Annual Meeting of StockholdersShareholders and Proxy Statement which accompany this letter. We urge you to read these materials carefully. During the live virtual meeting, you will be able to submit questions real-time through the meeting portal.
We hope that you will be able to attend the meeting,virtual Annual Meeting, but whatever your plans,in all events, we ask that you please complete, sign and datevote your shares using the enclosedinternet or, if you received paper copies of the proxy materials, by calling the toll-free telephone number specified in the proxy card or completing and return itmailing the proxy card in the postage-paid envelope provided so to ensure that your shares will be represented at the meeting. Instructions on using each of these voting methods are outlined in the proxy statement. If you hold shares through a broker or other nominee, you should follow the procedures provided by your broker or nominee.

On behalf of the board of directors, I would like to express our appreciation for your continued support and interest in Dyadic International, Inc.We look forward to seeing youyour virtual participation at the meeting.
Sincerely,Annual Meeting.
                                                                Mark A. Emalfarb signature
Mark A. Emalfarb
Chairman, President and Chief Executive Officer
Sincerely,
/s/ Mark Emalfarb
Mark Emalfarb
President and Chief Executive Officer
                
Jupiter, Florida
May 12, 2020
April 28, 2006





logo11.jpg
DYADIC INTERNATIONAL, INC.
140 Intracoastal Pointe Drive, Suite 404
Jupiter, FL 33477
NOTICE OF 20062020 VIRTUAL ANNUAL MEETING OF STOCKHOLDERSSHAREHOLDERS
TO BE HELD ON MONDAY, JUNE 12, 200629, 2020
VIRTUAL MEETING ONLY - NO PHYSICAL MEETING LOCATION

To the stockholdersShareholders of Dyadic International, Inc.:

The 2006 annual meetingNOTICE IS HEREBY GIVEN that the 2020 Virtual Annual Meeting of stockholdersShareholders (“Annual Meeting”) of Dyadic International, Inc., a Delaware corporation (“Dyadic,” “we,” “us”, “our”, or the “Company”), will be held on Monday, June 12, 2006,29, 2020 at 10:0010 a.m., local time, Eastern Daylight Savings Time, via live webcast at the Doubletree Hotel located at 4431 PGA Boulevard, Palm Beach Gardens, Florida 33410,www.virtualshareholdermeeting.com/DYAI2020 for the following purposes:
1.  To elect two (2) Class II directors, each for a three-year term ending in 2009;
2.  To approve the Amended and Restated Dyadic International, Inc. 2001 Equity Compensation Plan effective as of January 1, 2005 in order to (a) reduce the number of shares of common stock reserved for issuance under the Plan to 4,478,475 shares from 5,152,447 shares, (b) conform certain provisions of the Plan to the requirements of Section 409A of the Internal Revenue Code of 1986, as amended, and (c) increase the maximum limitation of shares that may be subject to awards granted under the Plan to any one individual for any fiscal year during the term of the Plan to 1,200,000 shares from 100,000 shares;
3.  To approve the Dyadic International, Inc. 2006 Stock Option Plan;
4.  To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2006; and
5.  To transact such other business properly brought before the annual meeting and any adjournment or postponement of the meeting.
These items of business arepurposes, as more fully described in detailthe Proxy Statement accompanying this Notice:

1. To elect two Class I directors to our Board of Directors (the “Board”) to serve until the Company’s 2023 Annual Meeting of Shareholders or until their successors are duly elected and qualified;

2. To ratify the appointment of Mayer Hoffman McCann P.C., as the Company’s independent registered public accounting firm for the year ending December 31, 2020;

3. To consider an advisory vote on compensation of the Company’s Named Executive Officers; and

4. To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.

All shareholders are cordially invited to virtually attend the Annual Meeting. To participate in the accompanyingAnnual Meeting, you will need your 16-digit control number included on your Notice Regarding the Availability of Proxy Materials (“Notice”) or on your proxy statement. This notice, together with the accompanying proxy statement and enclosed proxy card and annual report to stockholders, will be mailed to stockholders on or about May 5, 2006.card.

Our board of directors has fixed the close of business on April 26, 2006 as the record date of the annual meeting. StockholdersOnly shareholders of record at the close of business on April 26, 2006May 4, 2020 are entitled to notice of, and to vote at, the annual meetingAnnual Meeting and any adjournment or postponement thereof. The stock transfer books of the annualCompany will remain open between the record date and the date of the meeting. Each share of common stock is entitled to one vote.
A list of stockholdersregistered shareholders entitled to vote at the annual meetingAnnual Meeting will be available for inspection by our stockholders,any shareholder for any purpose germane to the meeting, at the annual meeting andAnnual Meeting, during ordinaryregular business hours, beginningfor a period of ten (10) days prior to the dateAnnual Meeting, at the Company’s principal place of the annual meeting, at our executive officesbusiness at 140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477.
All stockholders If our headquarters are cordially invitedclosed for health and safety reasons related to attend the meeting in person.
COVID-19 pandemic during such period, the list of registered shareholders entitled to vote at the Annual Meeting will be made available for inspection upon request via email to: prawson@dyadic.com subject to our satisfactory verification of shareholder status. During the Annual Meeting, the list of registered shareholders entitled to vote at the Annual Meeting will be made available electronically at www.virtualshareholdermeeting.com/DYAI2020.
By Order
We encourage shareholders to vote in advance of the Board of Directors,
                         Mark A. Emalfarb signature
Mark A. Emalfarb
Chairman, President and Chief Executive Officer

Jupiter, Florida
April 28, 2006
Annual Meeting. Whether or not you expect to attend the annual meeting,Annual Meeting, please complete, date and sign the enclosed proxy and mail it promptly in the enclosed postage-paid envelope. If you are a holder of record, you may also cast your vote in personone of the ways described below:




Vote by Internet: www.proxyvote.com
Use the Internet to transmit your voting instructions and for electronic delivery of information. Vote by 11:59 p.m., Eastern Daylight Savings Time, on Sunday, June 28, 2020. Have the 16-digit control number included in your Notice or your proxy card in hand when you access the above website and follow the instructions to obtain your records and to create an electronic voting instruction form.

Vote by Telephone: 1-800-690-6903
If you received paper copies of the proxy materials, use any touch-tone telephone to transmit your voting instruction. Vote by 11:59 p.m., Eastern Daylight Savings Time, on Sunday, June 28, 2020. Have your proxy card in hand when you call and follow the instruction.

Vote by Mail.
If you received paper copies of the proxy materials, please mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.

Vote During the Annual Meeting.
You can vote your shares during the Annual Meeting at www.virtualshareholdermeeting.com/DYAI2020. To participate in the annual meeting. Annual Meeting, you will need the 16-digit control number included in your Notice or on your proxy card.

You need only vote in one way (so that, if you vote by internet or telephone, you need not return the proxy card).

If you hold your shares through a broker, bank or other nominee, you should receive separate voting instructions from the firm holding your shares describing the procedure for voting those shares. You may complete and mail a voting instruction card to your broker or nominee or, in most cases, submit voting instructions by telephone or the Internet to your broker or nominee. If you provide specific voting instructions by mail, telephone or the Internet, your broker or nominee will vote your shares as you have directed.

Should you receive more than one proxy because your shares are heldregistered in different names and addresses, each proxy should be signed and returned to ensure that all of your shares will be voted. Your proxy is revocable in accordance with the procedures set forth in the attached proxy statement.

BY ORDER OF THE BOARD OF DIRECTORS
/s/ Mark Emalfarb
Mark Emalfarb
President and Chief Executive Officer

May 12, 2020
Jupiter, Florida


INTERNET AVAILABILITY OF PROXY MATERIALS
*****IMPORTANT NOTICE*****
This Notice of Meeting, Proxy Statement and our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, are available online at a brokerage firm or bank, you must provide them with instructions on how to vote your shares.www.dyadic.com/investors and can be accessed at www.proxyvote.com.



TABLE OF CONTENTS

About the Annual Meeting
Security Ownership of Beneficial Owners and Management
Certain Relationship and Related Party Transactions
Corporate Governance and Related Matters
Compensation and Other Information Concerning Officers
Matters to be Considered at the Annual Meeting
Proposal 1: Election of Class I Directors
Proposal 2: Ratification of Selection of Independent Registered Public Accounting Firm
Proposal 3: Advisory Vote on Compensation of the Company’s Named Executive Officers
Shareholder Proposals for the 2021 Annual Meeting
Forward Looking Statement
Other Matters
Incorporation of Information by Reference







DYADIC INTERNATIONAL, INC.
140 Intracoastal Pointe Drive, Suite 404
Jupiter, Florida 33477
(561) 743-8333

PROXY STATEMENT


Jupiter, FL 33477
(561) 743-8333
________________________________________________________
20062020 VIRTUAL ANNUAL MEETING OF STOCKHOLDERSSHAREHOLDERS

JUNE 29, 2020
JUNE 12, 2006
________________________________________________________VIRTUAL MEETING ONLY - NO PHYSICAL MEETING LOCATION

The Board of Directors of the Company (the “Board”) is soliciting proxies for the 2020 Virtual Annual Meeting of Shareholders of Dyadic International, Inc. (“Annual Meeting”). This proxy statement contains important information for you to consider when deciding how to vote on the matters brought before the Annual Meeting. Please read it carefully.
PROXY STATEMENT
________________________________________________________
This proxy statement contains information related to our 2006 annual meeting of stockholdersthe Annual Meeting to be held on Monday, June 12, 2006,29, 2020 at 10:0010 a.m., local time, at the Doubletree Hotel located at 4431 PGA Boulevard, Palm Beach Gardens, Florida 33410, Eastern Daylight Savings Time, and at any adjournments or postponements thereof. This year, in light of the rising concerns around the spread of COVID-19 in the United States and globally, in order to mitigate health risks, the Annual Meeting will be conducted in virtual format only. Shareholders can access the Annual Meeting by visiting www.virtualshareholdermeeting.com/DYAI2020. Shareholders will not be able to attend the Annual Meeting in person. The approximateCompany believes that a virtual meeting will provide meaningful shareholder access and participation and also protect the health and safety of our shareholders, employees and other stakeholders, and will also improve meeting efficiency and reduce costs.

The Board set May 4, 2020, as the record date for the Annual Meeting. Shareholders who owned the Company’s common stock on that date are entitled to vote at the Annual Meeting, with each share entitled to one vote. There were 27,459,157 shares of the Company’s common stock outstanding as of the record date.

We are furnishing proxy materials to our shareholders primarily via the Internet under the SEC’s “Notice and Access” rules. On or about May 12, 2020, we expect to mail to our shareholders a Notice of Internet Availability (the “Notice”) containing instructions on how to access our proxy materials, including our Proxy Statement and Annual Report filed on Form 10-K with the SEC on March 30, 2020 (“Annual Report on Form 10-K”). The Notice also will instruct you on how to access and submit your proxy through the internet.

We are providing internet distribution of our proxy materials to expedite receipt by shareholders, reduce costs and conserve paper. However, if you would like to receive printed proxy materials, please follow the instructions on the Notice. Additionally, this proxy statement the accompanying notice of annual meeting and the enclosed form ofAnnual Report on Form 10-K are available at www.dyadic.com by clicking the “Investors” link. In accordance with Securities and Exchange Commission rules, our proxy materials posted on both our website and our 2005 annual report to stockholders are first being mailed to stockholders is May 5, 2006. We are furnishing this proxy statement to stockholders of Dyadic as part of the solicitation of proxies by Dyadic’s board of directors for use at the annual meeting. You should review this information in conjunction with our 2005 annual report to stockholders which accompanies this proxy statement.website described below do not contain any cookies or other tracking features.
________________________________________________________

INTERNET AVAILABILITY OF PROXY MATERIALS
*****IMPORTANT NOTICE*****
TABLE OF CONTENTS
PageThe Proxy Statement and Annual Report on Form 10-K are available at www.proxyvote.com

2
 6
 8
 10
 16
 20
 23
 25
 31
 35
 36
 A-1
  B-1 


ABOUTABOUT THE ANNUAL MEETING

What is the purpose of the annual meeting?Annual Meeting?

At the annual meeting,Annual Meeting, we are asking stockholders:
·  To elect two (2) Class II directors, each for a three-year term ending in 2009;
·  To approve the Amended and Restated Dyadic International, Inc. 2001 Equity Compensation Plan effective as of January 1, 2005;
·  To approve the Dyadic International, Inc. 2006 Stock Option Plan;
·  To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2006; and
·  To transact such other business properly brought before the meeting and any adjournment or postponement of the meeting.
shareholders:
To elect two Class I directors for a term ending in 2023;
To ratify the appointment of Mayer Hoffman McCann P.C., (“MHM”), as our independent registered public accounting firm for the year ending December 31, 2020;
To consider an advisory vote on compensation of the Company’s Named Executive Officers; and
To transact such other business properly brought before the meeting and any adjournment or postponement of the meeting.

Who is entitled to notice of and to vote at the annual meeting?Annual Meeting?

You are entitled to vote, in person or by proxy, at the annual meetingAnnual Meeting if you owned shares of our common stock as of the close of business (5:00 p.m. EST)Eastern Daylight Savings Time) on April 26, 2006,May 4, 2020, the record date of the annual meeting. On the record date, 23,140,467shares of our common stock were issued and outstanding and held by 154 holders of record.Annual Meeting. Holders of record of our common stock on the record date are entitled to one vote per share at the annual meeting.Annual Meeting.

Who can attend the meeting?Annual Meeting?

All stockholdersshareholders as of the record date, or their duly appointed proxies, may attend. Please note that if you hold shares in “street name” (that is, through a broker or other nominee), youShareholders will need a control number in order to bring a copy of a brokerage statement reflecting your stock ownership as ofattend the record date.
meeting. For registered shareholders, the control number can be found on their Notice or proxy card.

What shares may I vote?

You may vote all shares you owned as of the record date. These includeinclude: (1) shares owned directly in your name as stockholderthe shareholder of record and (2) shares held for you as the beneficial owner through a stockbroker, bank or other nominee.

What is the difference between holding shares as a stockholdershareholder of record and as a beneficial owner?

Most of our stockholdersshareholders hold their shares through a stockbroker, bank or other nominee rather than directly in their own name. As summarized below, there are some differences between shares held of record and those beneficially owned.

If our shares are registered directly in your name with our transfer agent, Continental Stock Transfer & Trust Company, you are considered the stockholdershareholder of record with regard to those shares. As the stockholdershareholder of record, you have the right to grant your proxy directly to us to vote your shares on your behalf at the meetingAnnual Meeting, using the control number on the Notice of Internet Availability of Proxy Materials or the right to vote in person at the meeting. We have enclosed or sent a proxy card for you to use.log into www.virtualshareholdermeeting.com/DYAI2020.

If you hold our shares in a stock brokerage account or bythrough a bank or other nominee, you are considered the beneficial owner“beneficial owner” of the shares held in “street name,”name”, and these proxy materials have been forwarded to you by your brokerstockbroker, bank or nominee, which is considered the stockholder of record with respect to those shares.other nominee. As the beneficial owner, you have the right to direct your brokerstockbroker, bank or other nominee how to vote and you are also invited to attend the annualAnnual Meeting via the Internet and vote
2




during the meeting. Beneficial owners who do not have a control number may gain access to the meeting so long as you bring a copyby logging into their brokerage firm’s website. Instructions should be provided on the voting instruction card provided by your stockbroker, bank or other nominee.

How do I vote?

Shareholders at the close of a brokerage statement reflecting your ownership as ofbusiness on May 4, 2020, can vote at the record date. However, since you are notAnnual Meeting via proxy in the stockholder of record, you may not vote thesemanner described herein.

Any shareholder who holds shares in person at“street name” through a broker, bank or other nominee should receive separate instructions from the meeting unlessfirm holding his or her shares describing the procedure for voting those shares. You should follow the voting instructions provided by your broker, bank or other nominee when voting your shares. You may complete and mail a voting instruction card to your broker, bank or other nominee or, in most cases, submit voting instructions by telephone or the Internet to your broker or nominee. If you obtain

a signed proxy fromprovide specific voting instructions by mail, telephone or the Internet, your broker or nominee givingwill vote your shares as you have directed.

Shareholders of record may vote in the rightfollowing ways:

Vote by Internet: www.proxyvote.com
Use the Internet to votetransmit your voting instructions and for electronic delivery of information. Vote by 11:59 p.m., Eastern Daylight Saving Time, on Sunday, June 28, 2020. Have the shares. Your broker16-digit control number included in our Notice or nominee has enclosed or provided ayour proxy card in hand when you access the above website and follow the instructions to obtain your records and to create an electronic voting instruction card for you to use to direct your broker or nominee how to vote these shares.
form.
What constitutes a quorum?
If a majority of the shares of our common stock outstanding on the record date is represented either in person orVote by proxy at the annual meeting, a quorum will be present at the annual meeting. Shares held by persons attending the annual meeting but not voting, and shares represented in person or by proxy and for which the holder has abstained from voting, will be counted as present at the annual meeting for purposes of determining the presence or absence of a quorum.
A broker who holds shares in nominee or “street name” for a customer who is the beneficial owner of those shares may be prohibited from giving a proxy to vote those shares on any proposal to be voted on at the annual meeting without specific instructions from such customer with respect to such proposal. Accordingly, if a broker receives voting instructions from a customer with respect to one or more, but not all, of the proposals to be voted on at the annual meeting, the shares beneficially owned by such customer will not constitute “votes cast” or shares “entitled to vote” with respect to any proposal for which the customer has not provided voting instructions to the broker. These so-called “broker non-votes” will be counted as present at the annual meeting for purposes of determining whether a quorum exists.
How do I vote?Telephone: 1-800-690-6903
If you completereceived paper copies of the proxy materials, use any touch-tone telephone to transmit your voting instruction. Vote by 11:59 p.m., Eastern Daylight Savings Time, on Sunday, June 28, 2020. Have your proxy card in hand when you call and properlyfollow the instruction.

Vote by Mail.
If you received paper copies of the proxy materials, please mark, sign and date the accompanyingyour proxy card and return it to us in the enclosedpostage-paid envelope we have provided or return envelope as soon as possible, it will be voted asto Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.

Vote During the Annual Meeting.
You can vote your shares during the Annual Meeting at www.virtualshareholdermeeting.com/DYAI2020. To participate in the Annual Meeting, you direct. If you are a registered stockholder and you attend the meeting, you may deliver your completed proxy card in person. “Street name” stockholders who wish to vote at the meeting will need to obtain a proxy from the broker16-digit control number included in your Notice or nominee that holds their shares.
All shares of our common stock represented by properly executed proxies received before or at the annual meeting will, unless revoked, be voted in accordance with the instructions indicated on those proxies. If no instructions are indicated on a properly executed proxy, the shares represented by such proxy card will be voted “FOR” the nominees for Class II directors, “FOR” the proposal to approve the Amended and Restated 2001 Equity Compensation Plan, “FOR” the proposal to approve the 2006 Stock Option Plan and “FOR” the proposal to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2006. You are urged to mark the box on your proxy to indicatecard.

You need only vote in one way (so that, if you vote by internet or telephone, you need not return the proxy card).

If you have any questions about how to vote or direct a vote in respect of your shares.Dyadic common stock, you may contact either our corporate office at 140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477, Attention:
Heidi Zosiak, telephone: (561) 743-8333 or Broadridge Financial Solutions, Inc., 51 Mercedes Way, Edgewood, NY 11717, telephone: (631) 257-4339.

Can I vote by telephone or electronically?submit questions at the Annual Meeting?

If your shares are held in “street name,” please check your proxy card or contact your broker or nominee to determine whetherYes. During the live virtual meeting, you will be able to vote by telephone or electronically.
The deadline for voting by telephone or electronically is 11:59 p.m., EDT, on June 11, 2006.
submit questions real-time through the meeting portal.

Can I change my vote after I return my proxy card?

3




Yes. Even afterIf you have submittedvoted by mail, you may revoke your proxy card,at any time before it is exercised by executing and delivering a timely and valid later-dated proxy, by voting by ballot at the meeting or by giving written notice to the Secretary. If you voted via the Internet or by phone, you may change your vote with a timely and valid later internet or telephone vote, or by voting by ballot at any timethe meeting.Attendance at the meeting will not have the effect of revoking a proxy unless (1) you give proper written notice of revocation to the Secretary before the proxy is exercised, or (2) you vote by filing with our Secretary either a notice of revocation or a duly executed proxy card bearing a later date. In such event, the later submitted vote will be recorded and the earlier vote revoked. The powers of the proxy holders will be suspended if you are a holder of record and attend the meeting in person and so request, although attendanceballot at the meeting will not by itself revoke a previously granted proxy.meeting.

If your shares are held in “streetstreet name, you should contact the institution that holds your shares to change your vote.
3

Is my vote confidential?


Before the Annual Meeting, our Board will appoint one or more inspectors of Contentselection for the meeting. The inspector(s) will determine the number of shares represented at the meeting, the existence of a quorum and the validity and effect of proxies. The inspector(s) will also receive, count, and tabulate ballots and votes and determine the results of the voting on each matter that comes before the Annual Meeting.

Abstentions and votes withheld, and shares represented by proxies reflecting abstentions or votes withheld, will be treated as present for purposes of determining the existence of a quorum at the Annual Meeting. They will not be considered as votes for or against any matter for which the shareholder has indicated their intention to abstain or withhold their vote. Broker or nominee non-votes, which occur when shares held in street name by brokers or nominees who indicate that they do not have discretionary authority to vote on a particular matter, will not be considered as votes for or against that particular matter. Broker and nominee non-votes will be treated as present for purposes of determining the existence of a quorum, and may be entitled to vote on certain matters at the Annual Meeting.


What percentage of our outstanding common stock do our directors and executive officers own?

As of May 4, 2020, our directors and executive officers owned, or have the right to acquire within 60 days through the exercise of option, approximately 24.8% of our outstanding common stock. See the discussion under the heading “Security Ownership of Certain Beneficial Owners and Managements” below for more details.

Who was our independent public accountant for the year ended December 31, 2019? Will they be represented at the Annual Meeting?

Mayer Hoffman McCann P.C is the independent registered public accounting firm that audited our financial statements for the year ended December 31, 2019. We expect a representative of Mayer Hoffman McCann P.C. to be virtually present at the Annual Meeting. The representative will have an opportunity to make a statement and will be available to answer your questions.

What are the board’sBoard’s recommendations?

The boardBoard recommends a vote “FOR”:FOR:

The nominees for Class I directors;
The proposal to ratify the appointment of Mayer Hoffman McCann P.C. (MHM), as our independent registered public accounting firm for the year ending December 31, 2020; and
The compensation of the Company’s Named Executive Officers.
·  each of the nominees for Class II directors;
4

·  the proposal to approve the Amended and Restated 2001 Equity Compensation Plan effective as of January 1, 2005;



·  the proposal to approve the 2006 Stock Option Plan; and
·  the proposal to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2006.
Unless you give other instructions on your proxy card, the personsperson named as proxiesa proxy on the proxy card will vote “FOR” each ofFOR the nominees for Class II directors and the other proposals.
proposals set forth above.
We do not expect that any other matters will be brought before the annual meeting.Annual Meeting. If, however, other matters are properly presented, the persons named as proxies will vote the shares represented by properly executed proxies in accordance with their judgment with respect to those matters, including any proposal to adjourn or postpone the annual meeting.Annual Meeting. No proxy that is voted against all of the proposals will be voted in favor of any adjournment or postponement of the annual meetingAnnual Meeting for the purpose of soliciting additional proxies.

What constitutes a quorum?

If a majority of the shares of our common stock outstanding on the record date is represented either in person or by proxy at the Annual Meeting, a quorum will be present at the Annual Meeting. Virtual attendance at the Annual Meeting constitutes presence in person for purposes of quorum at the Annual Meeting. Shares held by persons attending the Annual Meeting but not voting, and shares represented in person or by proxy and for which the holder has abstained from voting, will be counted as present at the Annual Meeting for purposes of determining the presence or absence of a quorum.
Applicable stock exchange rules determine whether a proposal presented at a shareholder meeting is routine or non-routine. If a proposal is routine, a broker or other entity holding shares for an owner in street name may vote on the proposal without receiving voting instructions from the beneficial owner. If a proposal is non-routine, the broker or other entity may vote on the proposal only if the beneficial owner has provided voting instructions. A broker non-vote occurs when a broker or other entity is unable to vote on a particular proposal and the broker or other entity has not received voting instructions from the beneficial owner. Therefore, if you do not give your broker or other entity specific instructions, your shares will not be voted on non-routine matters. However, the broker non-votes will be counted as present at the Annual Meeting for purposes of determining whether a quorum exists. The election of directors is considered a non-routine proposal. The proposal to ratify the appointment of MHM to serve as our independent auditor is considered routine proposals.

What vote is required to approve the proposal?proposals?

Proposal 1: Election of Class II DirectorsI Directors. . The affirmative vote of a plurality of the votes cast, either in person or by proxy, at the annual meetingAnnual Meeting is required for the election of each of the Class III director nominees. You may vote “for”for or “withheld”withheld with respect to the election of one or more of the directors.either director. Only votes “for”for or “withheld”withheld are counted in determining whether a plurality has been cast in favor of a director. AbstentionsVotes withheld and broker non-votes are not counted for purposes of the election of directors, although they are counted for purposes of determining whether there is a quorum. StockholdersShareholders do not have the right to cumulate their votes for directors.

Proposal 2: ApprovalRatification of Amended and Restated 2001 Equity Compensation Plan. Appointment of MHM as our Independent Registered Public Accounting Firm. The affirmative vote of the holders of a majority of all shares casting votes, either in person or by proxy, at the annual meetingAnnual Meeting is required to approveratify the Amended and Restated 2001 Equity Compensation Plan effectiveappointment of MHM as our independent registered public accounting firm for the fiscal year ending December 31, 2020. We are not required to submit this matter to a vote of January 1, 2005. This approvalshareholders for ratification; however, our Board is required (i)doing so, based upon the recommendation of its audit committee, as a matter of good corporate practice. You may vote for, purposesagainst, or abstain with respect to the ratification of compliance with certain exclusions from the limitationsappointment of Section 162(m) of the Internal Revenue Code of 1986,MHM as amended, and (ii) by the applicable rules of the American Stock Exchange.our independent registered public accounting firm. A properly executed proxy marked “abstain”abstain with respect to this proposal will not be voted for or against the proposal, although it will be counted for purposes of determining whether there is a quorum. Abstentions and brokerBroker non-votes will have the same effect as a vote against this proposal.
Proposal 3:Approval of 2006 Stock Option Plan. The affirmative vote of the holders of a majority of all shares casting votes, either in person or by proxy, at the annual meeting is required to approve the 2006 Stock Option Plan. This approval is required (i) for purposes of compliance with certain exclusions from the limitations of Section 162(m) of the Internal Revenue Code of 1986, as amended, (ii) for purposes of compliance with the requirements of incentive stock options under Section 422 of the Internal Revenue Code, and (iii) by the applicable rules of the American Stock Exchange. A properly executed proxy marked “abstain” with respect to this proposal will not be voted,considered as votes cast for or against this proposal, although it will be counted for purposes of determining whether there is a quorum. Abstentions andBrokers have discretion to vote shares with respect to this proposal, unless a shareholder directs their broker non-votes will haveotherwise.

Proposal 3: Advisory Vote on Named Executive Officers Compensation. The votes that shareholders cast “for” must exceed the same effect as avotes that unit owners cast “against” to approve the advisory vote on compensation of our Named Executive Officers. You may vote for, against, this proposal.
Proposal 4: Ratification of Appointment of Ernst & Young LLP as our Independent Registered Public Accounting Firm. The affirmativeor abstain with respect to the advisory vote on compensation of the holders of a majority of all shares casting votes, either in person or by proxy, at the annual meeting is required to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2006. We are not required to submit this matter to a vote of stockholders for ratification. However, our board is doing so, based upon the recommendation of the audit committee, as a matter of good corporate practice. As such, the voting approval threshold is required by the


applicable rules of the American Stock Exchange.Company’s Named Executive Officers. A properly executed proxy marked “abstain”abstain with respect to this
5




proposal will not be voted for or against the proposal, although it will be counted for purposes of determining whether there is a quorum. Abstentions and brokerBroker non-votes will have the same effectnot be considered as a votevotes cast for or against this proposal.
proposal, although it will be counted for purposes of determining whether there is a quorum.

Other Items.In the event other items are properly brought before the annual meeting,Annual Meeting, the affirmative vote of a majority of the votes cast, either in person or by proxy, at the meeting will be required for approval. A properly executed proxy marked “abstain”abstain with respect to any such matter will not be voted for or against such items, although it will be counted for purposes of determining whether there is a quorum. Accordingly, an abstention

Because your votes are advisory on Proposal 3, they will havenot be binding on the effect of a negative vote.
AsBoard or the Company. However, the Board and the Compensation Committee will review the voting results and take them into consideration when making future decisions regarding the Named Executive Officers’ compensation or regarding the frequency of the record date, our directors and executive officers and their affiliates owned and were entitled toadvisory vote approximately 5,943,765 shares of our common stock, which represented approximately 25.8% of our common stock outstanding on that date. We currently anticipate that all of these persons will vote their and their affiliates’ shares in favor of the Class II director nominees and the other proposals.
Named Executive Officers’ compensation.

Who pays for the preparation of the proxy and soliciting proxies?

We will pay the cost of preparing, assembling and mailing the proxy statement and the accompanying noticeNotice of annual meeting,Annual Meeting and proxy card and annual report to stockholders.card. In addition to the use of mail, our directors, officers and employees may solicit proxies by telephone or other electronic means or in person. These persons will not receive additional compensation for soliciting proxies. Arrangements also will be made with brokerage houses and other custodians, nominees and fiduciaries for the forwarding of solicitation materials to the beneficial owners of stock held of record by these persons, and we will reimburse them for reasonable out-of-pocket expenses.

What should I have received to enable me to vote?

In additionWe are furnishing proxy materials to this proxy statement, you should have receivedour shareholders primarily via the accompanying notice of annual meeting, a proxy card,internet under the SEC’s “Notice and our 2005 annual report to stockholders. The mailing date of these materials is onAccess” rules. On or about May 5, 2006.
12, 2020, we expect to mail to our shareholders a Notice of Internet Availability (the “Notice”) containing instructions on how to access our proxy materials, including our Proxy Statement and Annual Report on Form 10-K. The Notice also will instruct you on how to access and submit your proxy through the internet.

We are providing internet distribution of our proxy materials to expedite receipt by shareholders, reduce costs and conserve paper. However, if you would like to receive printed proxy materials, please follow the instructions on the Notice.

How can I obtain additional copies?

The Notice of Meeting, Proxy Statement and our Annual Report on Form 10-K are available online athttp://www.dyadic.com/investorsand may be accessed athttps://materials.proxyvote.com/26745T.

For additional copies of any of this proxy statement and the enclosed proxy card, and annual report to stockholders, you shouldplease contact either our corporate office at 140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477, Attention: Alexander (Sasha) Bondar,Heidi Zosiak, telephone: (561)743-8333 or Continental Stock Transfer & Trust Company, 17 Battery Place, New York,Broadridge Financial Solutions, Inc., 51 Mercedes Way, Edgewood, NY 10004,11717, telephone: (212) 509-4000.(631) 257-4339.



SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS DIRECTORS
AND EXECUTIVE OFFICERS
MANAGEMENT
The following table below sets forth certain information regarding the beneficial ownership of our common stock as of April 26, 2006,May 4, 2020 (except as noted below), by:
each person known by us to be the following individuals or groups:beneficial owner of more than 5% of the outstanding shares of our common stock;
each of our directors, named executive officers; and
·  each person or entity who is known by us to own beneficially more than 5% of our common stock;
all of our directors and executive officers as a group.

·  each of our directors and nominees for director;
·  each of our named executive officers; and
·  all of our directors, director nominees and executive officers as a group.
BeneficialThe amounts and percentages of common stock beneficially owned are reported on the basis of regulations of the SEC governing the determination of beneficial ownership is determined in accordance withof securities. Under the rules of the SEC, a person is deemed to be a “beneficial owner” of a security if that person has or shares voting power, which includes the power to vote or direct the voting of a security, or investment power, which includes the power to dispose of or to direct the disposition of a security. A person is also deemed to be a beneficial owner of any securities of which that person has a right to acquire beneficial ownership within sixty (60) days of May 4, 2020. Securities that can be so acquired are deemed to be outstanding for purposes of computing such person’s ownership percentage, but not for purposes of computing any other person’s percentage. Under these rules, more than one person may be deemed a beneficial owner of the same securities and Exchange Commission (“SEC”)a person may be deemed to be a beneficial owner of securities as to which such person has no economic interest. Except as otherwise indicated in these footnotes, each of the beneficial owners listed has, to our knowledge, sole voting and generally includes voting or investment power with respect to securities. Sharesthe indicated shares of ourcommon stock.

As of May 4, 2020, the Company has 39,712,659 shares of common stock issued and 27,459,157 shares of common stock outstanding with the remaining 12,253,502 shares held in treasury. The beneficial ownership table below includes those shares of common stock underlying options that are subject to our options, warrants and convertible notes that are presentlycurrently exercisable or exercisable within 60sixty (60) days of April 26, 2006 are deemedMay 4, 2020, but excludes those shares issued or repurchased subsequent to be outstanding and beneficially owned by the person holding any of such convertible securities for the purpose of computing the percentage of ownership of that person, but are not treatedMay 4, 2020:
Name and Address of Beneficial Owner (1)
Number of Common Shares HeldOptions Exercisable within 60 DaysNumber of Common Share Equivalents Beneficially Owned
Percentage of Common Share Equivalents Beneficially Owned (%) (2)
5% Shareholders:
Mark A. Emalfarb (3)
4,166,987  1,220,000  5,386,987  18.8%
The Francisco Trust U/A/D February 28, 1996 (4)
3,781,849  —  3,781,849  13.8%
Named Executive Officers and Directors:
Mark A. Emalfarb (3)
4,166,987  1,220,000  5,386,987  18.8%
Michael P. Tarnok188,929  223,750  412,679  1.5%
Jack L. Kaye72,707  209,688  282,395  *
Seth J, Herbst, M.D.30,000  293,750  323,750  1.2%
Arindam Bose, Ph.D.—  185,313  185,313  *
Barry C. Buckland, Ph.D.—  38,125  38,125  *
Ping W. Rawson18,500  298,918  317,418  1.1%
Ronen Tchelet, Ph.D.—  410,000  410,000  1.5%
Matthew S. Jones—  240,000  240,000  *
All current executive officers and directors as a group4,477,123  3,119,544  7,596,667  24.8%
(9 persons)
7




______________
Notes:
(*) Less than 1%.
(1)Except as outstanding for the purpose of computing the percentage of any other person.
Unless indicated otherwise below,noted, the address of our directors and executive officersfor each shareholder is c/o Dyadic International, Inc., 140 Intracoastal Pointe Drive, Suite 404, Jupiter, FloridaFL 33477. Except as indicated below, the persons named in the table have sole voting and investment power with respect to all
(2)Based on 27,459,157 shares of common stock beneficially owned by them. Asoutstanding as of April 26, 2006, we hadMay 4, 2020. Shares of common stock subject to options that are currently exercisable or exercisable within 60 days are deemed outstanding 23,140,467 sharesfor purposes of our common stock.
 
Name and Address of Beneficial Owner
 
Number
 of Shares
 
Percentage
Ownership
 
Mark A. Emalfarb (1)(9)(10)  7,098,559  28.9%
The Francisco Trust U/A/D February 28, 1996 (2)  4,769,578  20.5%
The Pinnacle Fund, L.P.  Barry M. Kitt (3)  2,277,494  9.9%
Stephen J. Warner (4)(11)  461,050  2.0%
Glenn E. Nedwin, Ph.D. (9)  11,990  * 
Robert B. Shapiro (5)(9)  34,688  * 
Richard J. Berman (5)(9)  56,250  * 
Harry Z. Rosengart (5)(11)  34,167  * 
Wayne Moor (5)(10)  277,889  1.2%
Ratnesh (Ray) Chandra (6)(10)  103,716  * 
Kent M. Sproat (7)(10)  143,716  * 
Alexander V. Bondar (8)(10)  73,716  * 
All directors, director nominees and executive officers as a group (10 persons)  8,295,741  32.7%
_____________________
*Denotes less than 1%computing the percentage of the person holding such options but are not deemed outstanding for purposes of computing the percentage of any other person.


(1)(3)Includes 5,570,8274,166,987 shares held by Mark A. Emalfarb beneficially through the Mark A. EmalfarbMAE Trust U/A/D October 1, 1987, of which Mr. Emalfarb is the sole beneficiary and serves as sole trustee. Also includes 1,276,434In addition, Mr. Emalfarb holds 1,220,000 shares issuable issuable upon the exercise of warrants presently exercisable and 251,298 shares issuable upon the exercise of a convertible note presently exercisable.
(2)Includes 222,537 shares issuable upon the exercise of a convertible notecommon stock underlying options that are presently exercisable. Based on the information available to us, the address of the MAE Trust U/A/D October 1, 1987 is 193 Spyglass Court, Jupiter, 33477.
(4)The trustee of the Francisco Trust U/A/D February 28, 1996 is Robert S. Levin, Esq.Adam Morgan, and the beneficiaries thereof are the spouse and descendants of Mark A. Emalfarb. The address of the Francisco Trust U/A/D February 28, 1996 is c/o Robert S. Levin, Esq., 180 N. LaSalle, Suite 3200, Chicago, Illinois 60601.
(3)Information is based on a Schedule 13G/A dated February 8, 2006 filed by The Pinnacle Fund, L.P. (“Pinnacle”) and Barry M. Kitt.3128 San Michele Drive, Palm Beach Gardens, Florida 33418. Mr. Kitt may be deemed the beneficial owner of the shares by virtue of being the sole member of Pinnacle Fund Management, LLC, which is the general partner of Pinnacle Advisers, L.P., which is the general partner of Pinnacle. Mr. KittEmalfarb disclaims beneficial ownership of thesesuch shares. Does not include 435,746 shares underlying



CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

Our Board has determined that the audit committee of the Board (the “Audit Committee”) is best suited to review and approve transactions with related persons. Prior to entering into a warrant held by Pinnacle to purchase 500,000 shares. The 435,746 underlying shares are not includedtransaction with a related person, (a) the director, executive officer, nominee or significant holder who has a material interest (or whose immediate family member has a material interest) in the aggregate number of shares beneficially owned by Pinnacle because that portiontransaction or (b) the business unit or function/department leader responsible for the potential transaction with a related person is required to provide notice to the Chairman of the warrantAudit Committee of the Company (“Audit Committee Chairman”) of the material facts and circumstances of the potential transaction with a related person and such information concerning the transaction as the Audit Committee Chairman may reasonably request. If the Audit Committee Chairman determines that the proposed transaction is a related person transaction, the proposed related person transaction must be submitted to the Audit Committee for consideration at the next Audit Committee meeting or, in those instances in which the Audit Committee Chairman determines that it is not presently exercisable. practicable or desirable for the Company to wait until the next Audit Committee meeting, the Audit Committee Chairman possesses delegated authority to act between Committee meetings.

The number of shares of common stock underlying the warrant that may be acquired upon the exerciseAudit Committee will consider all of the warrantrelevant facts and circumstances available to the Audit Committee, including (if applicable) but not limited to: (a) the benefits to the Company; (b) the availability of other sources for comparable products or services; (c) the terms of the transaction; and (d) the terms available to unrelated third parties or to employees generally. No member of the Audit Committee will participate in any review, consideration or approval of any related person transaction if such member, or any of his or her immediate family members, is the related person. The Audit Committee or Audit Committee Chairman, as applicable, will convey the approval or disapproval of the transaction to the Chief Executive Officer or Secretary, who will convey the decision to the appropriate persons within the Company. The Audit Committee Chairman will report to the Audit Committee at the next Audit Committee meeting any approval under this policy made by the chairperson pursuant to delegated authority.

In the event we become aware of a related person transaction that has not been previously approved or previously ratified under this procedure, and such transaction is pending or ongoing, it will be submitted to the Audit Committee or Audit Committee Chairman, as applicable, promptly, and the Audit Committee or Audit Committee Chairman will consider all of the relevant facts and circumstances available to the Audit Committee or Audit Committee Chairman as provided above. Based on the conclusions reached, the Audit Committee or Audit Committee Chairman, as applicable, will evaluate all options, including but not limited to, 64,254 sharesratification, amendment or termination of the common stockrelated person transaction.


8




CORPORATE GOVERNANCE AND RELATED MATTERS

General

The following discussion summarizes certain corporate governance matters relating to insure that, following such exercise, the total numberCompany, including information about director independence, Board and Committee structure, function and composition, charters, policies and procedures. For additional information on the Company’s corporate governance, including copies of sharesthe charters approved by the Board for the Audit Committee, the compensation committee of common stock then beneficially owned by Pinnaclethe Board (“Compensation Committee”), the nominating and governance committee of the Board (“Nominating Committee”), the sciences and technology committee of the Board (“Science and Technology Committee”), and the Company’s Code of Conduct and Ethics, please visit the “Investors” section of the Company’s web site at http://www.dyadic.com/investors under Corporate Governance.


Board of Directors and Committees

Board of Directors

The Board is responsible for directing and overseeing the business and affairs of the Company. The Board represents the Company’s shareholders and its affiliatesprimary purpose is to build long-term shareholder value. The Board meets on a regularly scheduled basis during the year to review significant developments affecting the Company and other persons whose beneficial ownership of common stock would be aggregatedto act on matters that, in accordance with Pinnacle’s for purposes of Section 13(d) of the Act, does not exceed 9.999% of the total numbergood corporate governance, require Board approval. It also holds annual meetings and acts by unanimous written consent when an important matter requires Board action between scheduled meetings. The Board held five (5) meetings during 2019 and each of our issued and outstanding shares. The addressdirectors attended all of Pinnacle and Mr. Kitt is 4965 Preston Park Blvd., Suite 240, Plano, Texas 75093.
those meetings in person or by teleconference.
(4)
Includes 274,800 shares held by Bioform, LLC, of which Mr. Warner is the managing member. Also includes 150,000 shares issuable upon the exercise of presently exercisable warrants held by Bioform, LLC and 36,250 shares issuable upon the exercise of presently exercisable options held by Mr. Warner.
(5)Represents shares issuable upon the exercise of options presently exercisable.
(6)Includes 75,000 shares issuable upon the exercise of options presently exercisable.
(7)Includes 90,000 shares issuable upon the exercise of options presently exercisable.
(8)Includes 70,000 shares issuable upon the exercise of options presently exercisable.
(9)The named person is a director.
(10)The named person is a named executive officer.
(11)The named person is a Class II director nominee.



PROPOSAL 1: ELECTION OF CLASS II DIRECTORS
General
We have a staggered board of directorsclassified Board currently fixed at six members. Our board is divided into three classes, each class consisting of one-thirdThe Board has four committees: Audit Committee, Compensation Committee, Nominating Committee, and Science and Technology Committee. Currently, Mr. Michael Tarnok serves as Chairman of the total numberBoard and Chairman of directors constituting the entire boardCompensation Committee. Mr. Jack Kaye serves as Audit Committee Chairman, Dr. Seth Herbst serves as Chairman of directors. One classthe Nominating Committee, and Dr. Arindam Bose serves as Chairman of each director is elected each year at our annual meeting of stockholders forthe Science and Technology Committee.

The Board’s Role in Risk Oversight
Our Board, as a three-year term. The Class II directors’ terms expirewhole and also at the 2006 annual meeting.
The nominating committee level, has an active role in overseeing management of the board has recommended,Company’s risks. The Board regularly reviews information regarding the Company’s business and the board has nominated, each of Stephen J. Warner and Harry Z. Rosengart to stand for re-election as a Class II director, each for a three-year term expiring in 2009.
We expect each nominee for election as a Class II director to be able to serve if elected. If any nominee is not able to serve, proxies will be voted in favor of the other nominee and may be voted for substitute nominees, unless the board chooses to reduce the number of Class II directors serving on the board.
Vote Required
The affirmative vote of a plurality of the votes cast, either in person or by proxy, at the annual meeting by the holders of shares of our common stock entitled to vote at the annual meeting is required for the election of these nominees as Class II directors.
Recommendation of the Board
Dyadic’s board of directors recommends stockholders vote “FOR” the election of the two nominees as Class II directors.
Nominees for Election as Directors
The following information is givenoperations, including with respect to liquidity, financial reporting, governance and compliance, as well as the nominees for election as Class II directors at the annual meeting, as of April 26, 2006.
risks associated with these activities.
Stephen J. Warner
, 66, has been on our board
Independence of directors since October 2004, and a directorDirectors

In evaluating the independence of Dyadic International (USA), Inc., our wholly-owned subsidiary (“Dyadic-Florida”), since August 15, 2004. Mr. Warner currently is the managing member of Bioform LLC, which beneficially owns 274,800 shares of our common stock. Mr. Warner also serves as chairman of Maxim TEP, Inc. a private energy company based in Houston, Texas, and Search Energy Solutions, Inc., a private company offering energy savings services for large air conditioning systems based in Palm Beach Gardens, Florida. He also serves as a director of UCT Coatings Inc., a private, metal finishing technology company in Stuart, Florida, and AOI Medical, Inc., a private medical device company in Orlando, Florida. Mr. Warner has over 25 years of venture capital experience. In 1981, Mr. Warner founded Merrill Lynch Venture Capital Inc., a wholly-owned subsidiary of Merrill Lynch & Co. Inc. in New York and served as its President and Chief Executive Officer from 1981 to 1990. Under his leadership, Merrill Lynch Venture Capital managed over $250 million and made over 50 venture capital investments. In 1999, Mr. Warner co-founded, and became Chairman and CEO, of Crossbow Ventures Inc., a private equity fund that invests in early and expansion stage technology companies primarily located in Floridamembers and the Southeast, with over 20 venture capital investments in Florida. Mr. Warner earned a B.S. degree from the Massachusetts Institute of Technology and an MBA from the Wharton School of Business, University of Pennsylvania.
Harry Z. Rosengart, age 56, has been on our board of directors since April 2005. During the past five years, Mr. Rosengart has served (and currently serves) as the President and Chief Executive Officer of HK & Associates, an investment and consulting firm which provides advice to small and medium-sized life sciences companies. Mr. Rosengart is a founder of several privately held companies, including: LigoChem, Inc., a DNA\RNA and macromolecule bioseparations company founded in 1995, of which he is a former President and Chief Executive Officer and a current member of its board of directors; SunPharm Corporation, a polyamine based anti-cancer drug development-stage


company founded in 1991, of which he is a former Chief Operating Officer, Chief Financial Officer and member of its board of directors; and Syncom Pharmaceuticals, Inc, a contract sales force organization founded in 1991, of which he has had a variety of interim positions and served on its board of directors. Between 1981 and 1990, Mr. Rosengart spent almost 10 years as a banker and investment banker with the Chase Manhattan Bank, NA focused on the pharmaceutical and chemical industries. Prior to joining Chase Manhattan Bank, Mr. Rosengart spent over 10 years with several pharmaceutical and multinational chemical companies in various managerial positions. Mr. Rosengart holds a B.S. in Chemical Engineering and an MBA from Rutgers University.
Directors Continuing in Office
The following information is provided with respect to the directors who are not nominees for election as directors at the annual meeting, as of April 26, 2006.
Name
Age
Class
Term Expiring
    
Richard J. Berman63I2008
Robert B. Shapiro67I2008
Mark A. Emalfarb51III2007
Glenn E. Nedwin, Ph.D.50III2007

Richard J. Bermanhas been on our board of directors since January 2005, and acts as our so-called “Lead Director.” In that capacity, he is responsible for meeting regularly with our chairman of the board and chief executive officer to review monthly financials, agenda and minutes of committee meetings and pertinent Board issues, presiding, if requested by the board, as chairman of anycomposition of the committees of the boardBoard, the Board utilizes the definition of independence as that term is defined under the published listing requirements of NASDAQ. The NASDAQ independence definition includes a series of objective tests. For example, an independent director may not be employed by us and presiding at any meetingsmay not engage in certain types of business dealings with the Company. In addition, as further required by NASDAQ rules, the Board has made a subjective determination as to each independent director that no relation exists which, in the opinion of the independent and non-employee directors. In the last five years, Mr. Berman has served as a professional director and/or officer of about a dozen public and private companies. He is currently Chief Executive Officer of Nexmed, Inc., a small public biotech company; Chairman of National Investment Managers, a public company in pension administration and investment management; and Chairman of Candidate Resources, a private company delivering HR services over the web. The eight other public companies that Mr. Berman is a director of are International Microcomputer Software, Inc., Internet Commerce Corporation, MediaBay, Inc., NexMed, Inc., GVI Security Solutions Inc., National Investment Managers, Nayna Networks, Inc. and Advaxis, Inc. From 1998 - 2000, he was employed by Internet Commerce Corporation as Chairman and Chief Executive Officer. Previously, Mr. Berman worked at Goldman Sachs; was Senior Vice President of Bankers Trust Company, where he started the M&A and Leveraged Buyout Departments; created the largest battery company in the world by merging Prestolite, General Battery and Exide to form Exide (NYSE); helped create what is now Soho (NYC) by developing five buildings; and advised on over $4 billion of M&A transactions. He is a past Director of the Stern School of Business of NYU where he obtained his B.S. and M.B.A. He also has US and foreign law degrees from Boston College and The Hague Academy of International Law, respectively.
Robert B. Shapirohas been on our board of directors since March 2005. During the past five years Mr. Shapiro has served as a member of the Board, of Directors of the New York Stock Exchange (on which he still serves), Citigroup, Inc. and Rockwell International, as Chairman of Pharmacia Corporation’s Board of Directors and, prior to its merger with Phamacia & Upjohn, as Chairman and Chief Executive Officer of Monsanto Company (1995 through 2001). Prior to becoming the Chairman and Chief Executive Officer of Monsanto, Mr. Shapiro served in various executive capacities with Monsanto from 1985, and with G.D. Searle & Company, a diversified electronics company, first as its general counsel (1972 through 1982), and then as President of its newly formed NutraSweet Group (1982 to 1985). Mr. Shapiro is a 1959 graduate of Harvard College and a 1962 graduate of Columbia University School of Law.
Mark A. Emalfarbhas been on our board of directors and our Chairman, President and Chief Executive Officer since October 2004 and has been the President, Chief Executive Officer and Chairman of the Board of Directors of our wholly-owned subsidiary Dyadic International (USA), Inc., a Florida corporation (“Dyadic-Florida”), since its inception. Since founding Dyadic-Florida in 1979, Mr. Emalfarb has successfully led and managed the evolution of Dyadic-Florida—from its origins as a pioneer and leader in providing ingredients used in stone-washing of blue jeans—to the discovery, development, manufacturing and commercialization of specialty enzymes used in various


industrial applications and the development of the C1 Expression System. Mr. Emalfarb is an inventor of over 25 U.S. and foreign biotechnology patents and patent applications resulting from discoveries related to Dyadic-Florida’s proprietary C1 microorganism, and has been the architect behind its formation of several strategic research and development, manufacturing and marketing relationships with U.S. and international partners. Mr. Emalfarb earned a B.A. degree from the University of Iowa.
Glenn E. Nedwin, Ph.D. has been on our board of directors and our Chief Scientific Officer and Executive Vice President and President of our Biosciences Business since March 2006. Before joining us, Dr. Nedwin co-founded and served as President of Novozymes, Inc. since 1991. At Novozymes, Inc., a Davis, California-based research & development subsidiary of Novozymes A/S (CSE:NZYMb.CO), Denmark, a global leader in enzymes and microorganisms with over $1 billion in worldwide revenues, Dr. Nedwin was responsible for all scientific, financial and administrative activities, and was a member of Novozymes A/S global R&D management team and its biosolutions strategy group, and was involved in technology/product licensing. From 1989 to 1991, Dr. Nedwin served as Vice President of Corporate Development, Xoma Corporation (NASDAQ:XOMA), a biotechnology company based in Berkeley, California. Earlier, he was Vice President, Business Development and co-founder of Ideon Corporation, Redwood City, California, and Senior Research Scientist and co-founder of Molecular Therapeutic, Inc. (now Bayer Pharmaceuticals Corporation), West Haven, Connecticut. Dr. Nedwin received his Bachelor of Science degree in Biochemistry from the State University of New York at Buffalo and his Ph.D. in Biochemistry from the University of California, Riverside. Dr. Nedwin did his postdoctoral fellowship in molecular biology at Genentech, Inc. Dr. Nedwin also holds an M.S. in the Management of Technology from the Massachusetts Institute of Technology and is currently a Co-Editor of the Industrial Biotechnology Journal.
CORPORATE GOVERNANCE
The board of directors is committed to good business practices, transparency in financial reporting and the highest level of corporate governance. The board of directors, which is elected by the stockholders, is our ultimate decision-making body except with respect to those matters reserved to our stockholders. It selects the senior management team, which is charged with the conduct of our business. Having selected the senior management team, the board of directors acts as an advisor and counselor to senior management and ultimately monitors its performance.
Board of Directors Independence
In accordance with the American Stock Exchange corporate governance listing standards, it is our policy that the board of directors consists of a majority of independent directors. Our board of directors reviews the relationships that each director has with us and other parties. Only those directors who do not have any of the categorical relationships that preclude them from being independent within the independence requirements of the American Stock Exchange corporate governance listing standards and who the board of directors affirmatively determines have no relationships that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director, are considereddirector. In making these determinations, the Board reviewed and discussed information provided by the directors and by the Company with regard to beeach director’s business and personal activities as they may relate to the Company and the Company’s management. We believe that Drs. Herbst, Bose and Buckland, as well as Messrs. Kaye and Tarnok qualify as independent directors. The board of directors has reviewed a number of factors to evaluate the independence of each of its members. These factors include its members' current and historic relationships with us andIn addition, our subsidiaries; their relationships with management and other directors; the relationships their current and former employers have with us and our subsidiaries; and the relationships between us and other companies of which our board members are directors or executive officers. After evaluating these factors, the board of directorsBoard has determined that foureach member of its six members are “independent” within the independence requirementsour Audit Committee is independent and is otherwise qualified to be a member of the American Stock Exchange corporate governance listing standards, all applicableAudit Committee in accordance with the rules and regulations of the SEC and for purposes of Rule 162(m) of the Internal Revenue Code of 1986, as amended. These four directors are: Richard J. Berman, Robert B. Shapiro, Stephen J. Warner and Harry Z. Rosengart.NASDAQ.

Independent members of our board of directors meet in executive session without management present, and are scheduled to do so at least two times per year. The board of directors has designated Mr. Berman as the presiding director for these meetings.



Stockholder Communications
Our board of directors believes that it is important for our stockholders to have a process to send communications to the board. Accordingly, stockholders desiring to send a communication to the board of directors, or to a specific director, may do so by delivering a letter to the Secretary of Dyadic at 140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477. The mailing envelope must contain a clear notation indicating that the enclosed letter is a "stockholder-board communication" or "stockholder-director communication." All such letters must identify the author as the stockholder and clearly state whether the intended recipients of the letter are all members of our board of directors or certain specified individual directors. The Secretary will open such communications and make copies, and then circulate them to the appropriate director or directors.
Policy Concerning Director Attendance at Annual Stockholders' Meetings
While we encourage all members of our board of directors to attend our annual stockholders' meetings, there is no formal policy as to their attendance at annual stockholders' meetings. All of the then members of our board of directors attended the 2005 annual stockholders' meeting.
Codes of Ethics
The board of directors has adopted a Code of Business Conduct and Ethics that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller and persons performing similar functions. The Code of Business Conduct and Ethics is available at our website at www.dyadic-group.com.
We intend to satisfy the disclosure requirements under Item 5.05 of Form 8-K regarding an amendment to, or a waiver from, a provision of our Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions by posting such information on our website at www.dyadic-group.com.
Meetings and Committees of the Board

The boardBoard has established an Audit Committee, a Compensation Committee, a Nominating Committee and a Science and Technology Committee to devote attention to specific subjects and to assist the Board in the discharge of directors held eleven (11) meetings during 2005,its responsibilities. The following table provides membership and meeting information for each of the directors attended at least seventy-five percent (75%) of the total number of meetings of the board of directors and committee (if any) on which he served. The board of directors has a standing audit committee, compensation committee and nominating committee. Each of the committees has a written charter which can be found on our website at Board committees:
NameAuditCompensationNominatingScience and Technology
Michael P. TarnokX  X*X
Seth J. Herbst, M.D.X  X*X
Arindam Bose, Ph.D.X  X*
Jack L. Kaye  X*X
Barry C. Buckland, Ph.D.XX
Mark A. EmalfarbX

* Committee Chairman
www.dyadic-group.com.Currently, Messrs. Warner, Berman and Rosengart are the members of each of the audit committee and compensation committee and Messrs. Warner, Berman and Shapiro are the members of the nominating committee. Mr. Berman, as Lead Director, serves as the chairman of each committee.
Audit Committee. The board of directors has determined that each ofAudit Committee held four (4) meetings during the members of the audit committee is independent, as defined by Rule 10A-3 of the Exchange Act of 1934, as amended (the “Exchange Act”) and the corporate governance listing standards of the American Stock Exchange.year ended December 31, 2019. The board of directors also has determined that Mr. Berman is an “audit committee financial expert” as defined in Item 401(e) of Regulation S-B of the Securities Act of 1933, as amended.
The audit committeeAudit Committee has oversight responsibility for quality and integrity of our consolidated financial statements. A copy of the Charter of the Audit Committee is available on our website, located at www.dyadic.com. The committeeAudit Committee meets privately with members of our independent registered public accounting firm, has the sole authority to retain and dismiss the independent registered public accounting firm and reviews theirits performance and independence from management. The independent registered public accounting firm has unrestricted access and reports directly to the committee. The audit committee met five (5) times during 2005.Audit Committee. The primary functions of the audit committeeAudit Committee are to oversee:oversee (i) the audit of our consolidated financial statements provided to the SEC and our security holders and (ii) our internal financial and accounting processes.

The SEC and NASDAQ have established rules and regulations regarding the composition of audit committees and the qualifications of audit committee members. Our Board has examined the composition of our Audit Committee and the qualification of our Audit Committee members in light of the current rules and regulations governing audit committee. Based upon this examination, our Board has determined that each member of our Audit Committee is independent and is otherwise qualified to be a member of our Audit Committee in accordance with the rules of the SEC and NASDAQ.

Additionally, the SEC requires that at least one member of the audit committee have a heightened level of financial and accounting sophistication. Such a person is known as the “audit committee financial expert” under the SEC’s rules. Our Board has responsibilities and authority necessary to comply with Rule 10A-3(b) (2)determined that Mr. Kaye is an “audit committee financial expert”, (3), (4), and as defined in Item 407(d)(5) of Regulation S-K and is an independent member of our Board and our Audit Committee. Please see Mr. Kaye’s biography included in this proxy statement for a description of his relevant experience.

Compensation Committee. The Compensation Committee held three (3) meetings during the Exchange Act, concerningyear ended December 31, 2019. The duties and responsibilities of the Compensation Committee are set forth in the Charter of the Compensation Committee. A copy of the Charter of the Compensation Committee is available on our website, located at www.dyadic.com. As discussed in its charter, among other things, the duties and responsibilities relating to: (a) registered public accounting, (b) complaintsof the Compensation Committee include evaluating the performance of the Chief Executive Officer, Chief Financial Officer and other key personnel of the Company, including, but not limited to, our incentive and equity-based plans. The Compensation Committee evaluates the performance of the Chief Executive Officer, Chief Financial Officer and other key personnel of the Company on an annual basis and reviews and approves on an annual basis all compensation programs and awards relating to accounting, internal accounting controls or auditing matters, (c) authority to engage advisorssuch officers and (d) funding. These and other
aspects of the audit committee’s authority are more particularly describedkey personnel. The Compensation Committee applies discretion in the audit committee charter.determination of individual executive compensation packages to ensure compliance with the Company’s compensation philosophy. The Chief Executive Officer makes recommendations to the Compensation Committee with respect to the compensation packages for officers other than himself.




Compensation Committee. All members of the compensation committee are independent within the corporate governance listing standards of the American Stock Exchange. The compensation committee is responsible for reviewing and approving all compensation arrangements for our executive officers, and is also responsible for administering our equity compensation plans. During 2005, the compensation committee met one (1) time and otherwise acted by unanimous written consent.
Nominating Committee.All members of The Nominating Committee held two (2) meeting during the nominating committee are independent within the corporate governance listing standards of the American Stock Exchange.year ended December 31, 2019. The nominating committee’sNominating Committee’s functions include: establishing criteria for the selection of new directors to serve on the board of directors;Board; identifying individuals believed to be qualified as candidates to serve on the board of directors;Board; recommending for selection by the board of directors the candidates for all directorships to be filled by the board of directorsBoard or by the stockholdersshareholders at an annual or special meeting; reviewing the board of director’sBoard’s committee structure and recommending to the board of directorsBoard the directors to serve on the committees of the board;Board; recommending members of the board of directorsBoard to serve as the respective chairs of the committees of the board of directors;Board; developing and recommending to the board of directors,Board, for its approval, an annual self-evaluation process of the board of directorsBoard and its committees and, based on those results, making recommendations to the board of directorsBoard regarding those board processes; and performing any other activities consistent with the committee’s charter, our bylaws and applicable law as the committee or the board of directorsBoard deems appropriate. During 2005,A copy of the nominating committee acted solely by unanimous written consent.Charter of the Nominating Committee is available on our website, located at www.dyadic.com.

The nominating committeeNominating Committee does not currently have any formal minimum qualification requirements that must be met by a nominee to serve as a member of the board of directors.Board. The nominating committeeNominating Committee will take into account all factors they considerit considers appropriate, which may include experience, accomplishments, education, understanding of the business and the industries in which we operate, specific skills, general business acumen and the highest personal and professional integrity. The Nominating Committee generally seeks individuals with broad experience at the policy-making level in business, or with particular industry expertise. While we do not have a formal diversity policy for Board membership, we look for potential candidates that help ensure that the Board has the benefit of a wide range of attributes. We believe that all of our directors should be committed to enhancing shareholder value and should have sufficient time to carry out their duties and to provide insight and practical wisdom based on experience. Each director must also represent the interests of all shareholders.

The nominating committeeNominating Committee currently has no fixed process for identifying new nominees for election as a director, thereby retaining the flexibility to adapt its process to the circumstances. The nominating committeeNominating Committee has the ability, if it deems it necessary or appropriate, to retain the services of an independent search firm to identify new director candidates. The nominating committeeNominating Committee has determined that it will give consideration toconsider any potential candidate proposed by a member of our boardBoard or senior management. Any director candidate so proposed will be personally interviewed by at least one member of the nominating committeeNominating Committee and our chief executive officerChief Executive Officer and their assessment of his or her qualifications will be provided to the full nominating committee.Nominating Committee. For this annual stockholders’ meeting,the Annual Meeting, the nominating committee received no proposals for new director candidates, and considered only and nominated the incumbent Class III directors to serve as the nominees for re-election.

Our policy and procedures regarding director candidates recommended by stockholdershareholders are contained in the nominating committee’sNominating Committee’s charter. The nominating committeeNominating Committee may consider for inclusion in its nominations for new directors any candidates recommended by stockholders,shareholders, but must consider any candidate for director recommended by (i) any stockholdershareholder beneficially owning more than 5% of our outstanding common stock for at least one year as of the date the recommendation was made or (ii) a group of stockholdersshareholders that beneficially owned, in the aggregate, more than 5% of our outstanding common stock, with each of the shares used to calculate that ownership held for at least one year as of the date the recommendation was made. The nominating committeeNominating Committee will consider the candidate based on the same criteria established for selection of director nominees generally. The nominating committeeNominating Committee reserves the right to reject any candidate in its discretion, including, without limitation, rejection of a candidate who has a special interest agenda other than the best interests of usthe Company and our stockholders,the shareholders, generally. Any stockholdershareholder who wishes to recommend for the nominating committee’sNominating Committee’s consideration a director candidate should followabide by the following procedures:

Submit the following written information about the candidate by mail to the Nominating Committee, c/o Dyadic International, Inc., 140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477, Attention: Chair of Nominating Committee, the name, mailing address, telephone number, e-mail address, resume, business history, listing of other past and present directorships and director committees, any biotech industry experience and other relevant information;
·  
Submit the following written information about the candidate by mail to the nominating committee, c/o Dyadic International, Inc., 140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477, Attention: chairperson of nominating committee, the name, mailing address, telephone number, e-mail address, resume, business history, listing of other past and present directorships and director committees, any biotech industry experience and other relevant information;
11
·  Explain in the submission why the stockholder believes the candidate would be an appropriate member of our board of directors and the benefits and attributes that the candidate will provide to us in serving as a director;
·  Provide evidence of the requisite ownership of our common stock along with the recommendation; and
·  Indicate whether we may identify the stockholder in any public disclosures that we make regarding the consideration of the director candidate.


Explain in the submission why the shareholder believes the candidate would be an appropriate member of our Board and the benefits and attributes that the candidate will provide to us in serving as a director;
Provide evidence of the submitting party’s requisite ownership of our common stock along with the recommendation; and
Indicate whether we may identify the shareholder in any public disclosures that we make regarding the consideration of the director candidate.

For a director candidate to be considered by the nominating committeeNominating Committee for nomination at the 2007 annual meeting of stockholders,Annual Meeting, the submission must behave been received by us no later than December 28, 2006.
March 9, 2020. No such submissions were received.
Compensation
Science and Technology Committee. The Science and Technology Committee held two (2) meetings during the year ended December 31, 2019. The duties and responsibilities of Directorsthe Science and Technology Committee are set forth in the Charter of the Science and Technology Committee. A copy of the Charter of the Science and Technology Committee is available on our website located at
www.dyadic.com. As discussed in its charter, among other things, the duties and responsibilities of the Science and Technology Committee are following:

In January 2005,1)Review, evaluate and report to the Board regarding the performance of the Vice-President, Research and Development (and, his or her team), the contract research organizations being considered or working on behalf of the Company in achieving the strategic goals and objectives and the quality and direction of the Company’s biopharmaceutical research and development programs.
2)Identify and discuss significant emerging science and technology issues and trends.
3)Review the Company’s approaches to acquiring and maintaining a range of distinct technology positions (including but not limited to contracts, grants, collaborative efforts, alliances and capital investments).
4)Evaluate the soundness/risks associated with the technologies in which the Company is investing its research and development efforts.
5)Periodically review the Company’s overall patent strategies.

Shareholder Communications

Our Board believes that it is important for our boardshareholders to have a process to send communications to the Board. Accordingly, shareholders desiring to send a communication to the Board, or to a specific director, may do so by delivering a letter to the Secretary of directorsthe Company at 140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477. The mailing envelope must contain a clear notation indicating that the enclosed letter is a “shareholder-director communication.” All such letters must identify the author as the shareholder and clearly state whether the intended recipients of the letter are all of the members of our Board or certain specified individual directors. The Secretary will open such communications, make copies, and then circulate them to the appropriate director or directors.

Policy Concerning Director Attendance at Annual Meetings of Shareholders

While we encourage all members of our Board to attend our Annual Meeting of our shareholders, there is no formal policy as to their attendance at such meetings. All members of the Board attended the 2019 Annual Meeting of Shareholders.

Code of Conduct and Ethics

We have adopted a directorCode of Conduct and Ethics, as amended, that applies to all employees, key consultants, officers, and directors of our company, including our principal executive officer, principal financial officer and principal accounting officer, or persons performing similar functions. Our Code of Conduct and Ethics is available on the “Corporate Governance” page of the “Investors” section of our website at www.dyadic.com. A copy of our Code of Conduct and Ethics can also be obtained free of charge by contacting our Secretary, c/o Dyadic
12




International, Inc, 140 Intracoastal Pointe Drive, Suite 404, Jupiter, FL 33477. We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding any amendment to, or waiver from, a provision of our Code of Conduct and Ethics by posting such information on our website.

Compensation of Directors

The following table sets forth the total compensation policy. for our non-employee directors for the year ended December 31, 2019:
Name
Fees earned or paid in cash (1)
Stock awards ($)
Options awards
($) (1)(2)(3)
Non-equity incentive plan compensation ($)Nonqualified deferred compensation earnings ($)All other compensation ($)Total ($)
Michael P. Tarnok$73,500  $—  $80,500  $—  $—  $—  $154,000  
Jack L. Kaye (4)
$72,300  $—  $94,000  $—  $—  $—  $166,300  
Seth J. Herbst, MD$60,000  $—  $27,000  $—  $—  $—  $87,000  
Arindam Bose, Ph.D.(4)
$67,500  $—  $94,000  $—  $—  $—  $161,500  
Barry C. Buckland, Ph.D.$60,000  $—  $27,000  $—  $—  $—  $87,000  
___________________
Notes:
(1) Directors who are also employees or officers of usthe Company or any of ourits subsidiaries do not receive any separate compensation as a director. Non-employee directors receive $2,000 per month cashan annual retainer for Board service of $60,000, paid in equal monthly installments. The annual stock option award for non-employee directors is 50,000 options. Prior to June 25, 2019, a director who served as Chairman of the Board also received an additional annual retainer of $12,000 paid in equal monthly installments and a director who served as Chair of the Audit Committee also received an additional annual retainer of $9,600 paid in equal monthly installments. All options granted to directors prior to June 25, 2019 vest 25% upon grant and the remaining 75% will vest annually in equal installments over four years. Effective June 25, 2019, the following changes were made: (1) a director who serves as Chairman of the Board, Chair of the Audit Committee, and Chair of the Science and Technology Committee shall each receive an additional annual retainer of $15,000 and 25,000 stock options, and (2) all options granted to directors will vest upon the one-year anniversary subsequent to the grant date. Accordingly, additional 25,000 options were granted to Mr. Tarnok, Mr. Kaye and Dr. Bose on June 25, 2019, and monthly installments based on the new annual retainer rate were applied starting from July 2019.
(2) The Stock Option Awards represented the grant date fair market value of each option granted in 2019, computed in accordance with FASB ASC Topic 718. These amounts do not correspond to the actual value that will be recognized by the named directors. The assumptions used in the valuation of these awards are consistent with the valuation methodologies specified in the notes to our consolidated financial statements.
(3) Options to purchase 280,000 shares (Mr. Tarnok), 280,000 shares (Mr. Kaye), 350,000 shares (Mr. Herbst), 280,000 shares (Mr. Bose), and 85,000 shares (Mr. Buckland) were outstanding at December 31, 2019.
(4) In January 2019, the following special awards were granted: (1) additional 25,000 options were granted to Mr. Kaye in recognition of the level of effort required of him in his role as the Chair of the Audit Committee and member of the Compensation Committee, and (2) additional 25,000 options were granted to Dr. Bose in recognition of his contributions to the Company’s R&D strategies and accomplishments.

COMPENSATION AND OTHER INFORMATION CONCERNING OFFICERS

Philosophy and Objectives
The philosophy underlying our executive compensation program is to provide an attractive, flexible and market-based total compensation program tied to performance and aligned with the interests of our shareholders. Our objective is to recruit and retain the caliber of executive officers and other key employees necessary to deliver sustained high performance to our shareholders, customers, and communities where we have a strong presence. Our executive compensation program is an important component of these overall human resources policies. Equally important, we view compensation practices as a means for communicating our goals and standards of conduct and
13




performance and for motivating and rewarding employees in relation to their achievements.  The organization’s executive compensation program is designed to:
Encourage the attraction and retention of high-caliber executives.
Provide a competitive total compensation package, including benefits.
Reinforce the goals of the organization by supporting teamwork and collaboration.
Ensure that pay is perceived to be fair and equitable.
Be flexible to potentially reward individual accomplishments as well as organizational success.
Ensure that the program is easy to explain, understand, and administer.
Balance the needs of both the Company and employees to be competitive with the limits of available financial resources.
Ensure that the program complies with state and federal legislation.
From time to time, the Company will consult with a compensation specialist to determine whether its overall compensation practices and policies are appropriate for the specific market conditions for the Company and the industries in which it operates.
Summary Compensation Table
The following table summarizes the compensation paid or accrued to our “named executive officers” (as defined by the SEC’s disclosure requirements) during the fiscal years 2019 and 2018:
Name and Principal PositionYearSalary ($)Bonus ($)(1)Stock Awards ($)Option Awards ($)(2)(3)Nonequity incentive plan compensation ($)Nonqualified deferred compensation earnings ($)All other payments ($) (4)Total ($)
Mark A. Emalfarb (*)
2019$440,000  $250,000  $—  $156,000  $—  $—  $228,049  $1,074,049  
President, CEO and Director2018$393,012  $200,000  $—  $99,900  $—  $—  $468,891  $1,161,803  
Ping W. Rawson (5)
2019$220,000  $56,250  $—  $114,250  $—  $—  $8,807  $399,307  
Chief Financial Officer2018$199,755  $—  $—  $34,600  $—  $—  $7,996  $242,351  
Ronen Tchelet, Ph.D. (6)
2019$207,647  $41,193  $—  $57,000  $—  $—  $—  $305,840  
VP of Research and Business Development2018$212,320  $—  $—  $23,400  $—  $—  $11,759  $247,479  
Matthew S. Jones (7)
2019$269,450  $82,954  $—  $57,000  $—  $—  $—  $409,404  
Managing Dir. of Bus. Dev and Licensing2018$273,058  $—  $—  $40,000  $—  $—  $—  $313,058  
___________________
Notes:
(*) Mr. Emalfarb also serves on the Board, for which he receives no direct, indirect or incremental compensation.
(1) All 2019 bonuses were accrued at December 31, 2019 and paid in January 2020. Mr. Emalfarb’s 2018 bonus was accrued at December 31, 2018 and paid in January 2019.
(2) The Option Awards amount reported in this column represented stock options granted in 2018 and 2019 (including annual share-based compensation awards for all named executives, and Ms. Rawson’s awards upon promotions for 2019 and 2018 in the amount of $55,250 and $22,000, respectively), vesting upon grant, or the one or four-year anniversary in accordance with their individual employment agreement or consulting agreement.
(3) The Option Awards amount reported in this column represented the grant date fair market value of each option granted, computed in accordance with FASB ASC Topic 718. These amounts do not correspond to the actual value that will be recognized by the named executive officers. The assumptions used in the valuation of these awards are consistent with the valuation methodologies specified in the notes to our consolidated financial statements. The table above does not include the value of the following performance-based vesting stock options, as the achievement of
14




the conditions was not deemed probable at the grant date and the value of the awards was deemed zero in accordance with ASC 718.
Upon the Company’s uplisting to the NASDAQ in April 2019, 400,000 shares of performance-based vesting stock options granted to Mr. Emalfarb in 2016 became vested, and the related estimated value of the awards at the grant date in the amount of $392,000 was recorded in 2019 in accordance with FASB ASC Topic 718.
Upon the achievements of different conditions in 2019, 175,000 shares of performance-based vesting stock options granted to Ms. Rawson in 2018 became vested, and the related estimated value of the awards at the grant date in the amount of $91,250 was recorded in 2019 in accordance with FASB ASC Topic 718.
(4) Other payments includes following:
Mr. Emalfarb received $12,891 for car allowance in both years. The Company’s contribution to the 401(k) retirement plan were $11,200 and $11,000 for 2019 and 2018, respectively. He also received $204,000 and $445,000 for installment payments relating to his prior employment agreement for 2019 and 2018, respectively.
Ms. Rawson received $8,807 and $7,996 for the Company’s contribution to the 401(k) retirement plan in 2019 and 2018, respectively.
Mr. Tchelet received $11,759 for sales commission earned in 2018.
(5) Ms. Rawson was promoted to Chief Financial Officer in June 2019, and she previously served as the Company’s Chief Accounting Officer since March 2018. Prior to that, Ms. Rawson was the Company’s Director of Financial Reporting.
(6) The amounts represent the compensation for services of Mr. Tchelet for the year ended December 31, 2018 and 2019, in accordance with the Sky Blue Biotech Agreement indicated below.
(7) The amounts represent the compensation for services of Mr. Jones for the year ended December 31, 2018 and 2019, in accordance with the Jones Consultant Agreement indicated below.

Employment Arrangements
Mark A. Emalfarb
On June 21, 2016, the Company entered into an employment agreement (the “Emalfarb Agreement”) with Mr. Emalfarb. The Emalfarb Agreement has an initial term of three years and automatic renewals of two years at the end of each term, unless either party provides a notice of nonrenewal, and provides that Mr. Emalfarb be employed as our President and Chief Executive Officer and that we will cause Mr. Emalfarb to be elected as a member of the Board. The material terms of the Emalfarb Agreement are summarized below:
Base Salary and Bonus. The Emalfarb Agreement provided for an annual base salary of $375,000, which was increased to $405,000 in January 2019, to $475,000 in June 2019, and to $500,000 in January 2020, in recognition of his successful efforts in every area of the business in 2018 and 2019. The Emalfarb Agreement also provided for an annual bonus award, with the timing and amount of any such bonus determined in the sole discretion of the Compensation Committee of the Board, which determined to award Mr. Emalfarb a cash bonus of $200,000 for 2018 and $250,000 for 2019.

Performance Stock Options. The Emalfarb Agreement provided Mr. Emalfarb the opportunity to be awarded annual stock option grants. Each such annual option incentive stock option grant will be to purchase up to three hundred thousand (300,000) shares of common stock under(the “Maximum Option Bonus”) based on performance achievements. Performance incentives will be based solely on the Dyadic International, Inc. 2001 Equity Compensation Plan. The chairmanCommittee’s evaluation of Mr. Emalfarb’s performance during that time period.

For fiscal years 2019 and 2018, Mr. Emalfarb received a stock option grant to purchase 300,000 shares of common stock for his annual performance, representing 100% of the audit committee receives an additional $800 per month cash retainer.Maximum Option Bonus. All non-employee directors also are reimbursedoptions granted to Mr. Emalfarb for their reasonable travel costs relatedfiscal year 2018 vested immediately upon grant and have a five-year term from the date of grant. All options granted to attendance at board and/or committee meetings. Upon joining our board,Mr. Emalfarb for fiscal year 2019 vest annually in equal installments over four years and have a non-employee director receives optionsten-year term from the date of grant.

15




Stock Exchange Stock Option. In addition, Mr. Emalfarb received a stock option grant to purchase 30,000up to four hundred thousand (400,000) shares of our common stock at an exercise price of $1.67, equal to the fair market valueclosing price of Dyadic common stock on June 21, 2016. The stock option would vest and become exercisable only if the Company’s shares of common stock commence trading on the NASDAQ Capital Markets or other stock exchange approved by the Board. The Stock Exchange stock option grant has a five-year term. All 400,000 stock options granted to Mr. Emalfarb in 2016 became vested, upon the Company’s uplisting to the NASDAQ in April 2019.

Licensing/Collaboration Transaction Stock Options. A stock option to purchase up to six hundred thousand (600,000) shares of common stock shall be proportionally awarded, vest and become exercisable when each of three (3) Bona Fide Licensing / Collaboration Transactions are entered into with the Company. A Bona Fide transaction is defined as a license, joint venture or other collaboration for a specific biologic with the intent to commercialize and/or a license agreement that generates a cumulative five million dollars in non-refundable cash, or when either the vaccine or biologics pharmaceutical business categories are sold. On November 12, 2019, the Company entered into an amendment (the “Amendment”) to the Emalfarb Agreement. Pursuant to the Amendment, the stock options to be awarded to Mr. Emalfarb upon the Company entering into a first or second licensing and/or collaboration transaction, as provided in the Emalfarb Agreement, shall each be awarded on the date of grant. Upon joining our board, the lead director receivesrelevant licensing and/or collaboration transaction and shall each have a fixed exercise date on the tenth anniversary of the date of grant.

Severance Terms. Mr. Emalfarb will be eligible for severance benefits comparable to other executives at his level. In addition, if Mr. Emalfarb’s employment is terminated by the Company without cause, by Mr. Emalfarb for good reason, or due to Mr. Emalfarb’s death or disability, then the Company shall fulfill its obligations as for annual base salary through the effective date of termination and he will be entitled to receive his accrued but unpaid vacation through the date thereof plus, in the sole discretion of the Compensation Committee, the Maximum Option Bonus and performance incentive may be awarded. In addition, all of Mr. Emalfarb’s unvested Stock Exchange Stock Options and Licensing/Collaboration Transaction Stock Options will vest immediately in the event milestones for which the options would have been awarded are achieved within one year from the date of termination or upon a change of control.

Change of Control. In the sole discretion of the Compensation Committee, Mr. Emalfarb may be awarded an additional bonus on or before the occurrence of a change of control.

Side Letter. In connection with the execution of the Emalfarb Agreement, the Company and Mr. Emalfarb entered into a separate agreement (the “Side Letter”) under which the Company agreed to purchase 50,000 shares our common stock at an exercise pricepay Mr. Emalfarb in monthly installments over the initial term of the Emalfarb Agreement, $1,335,000, equal to the fair market valueamount of the severance payments that would have been payable under his previous employment agreement if Mr. Emalfarb resigned for “good reason” in connection with a change in control. All payments under this Side Letter have been made, and the Company has no additional obligation associated with this Side Letter as of June 2019.

Ping W. Rawson
In connection with Ping Rawson’s appointment as the Company’s Chief Financial Officer in June 2019, the Board approved her base salary at $225,000 per year, which was increased to $231,750 per year in January 2020, which increase was consistent with annual increases for the majority of the Company’s employees. Ms. Rawson will also receive discretionary annual cash bonuses and other equity compensation as determined by the Company.
For fiscal year 2019, Ms. Rawson received stock option grants to purchase 100,000 shares of common stock for her annual performance in January 2019 and additional 25,000 options associated with her promotion to the CFO in June 2019. Ms. Rawson also received a cash bonus of $56,250 based on her annual performance.

In connection with Ms. Rawson’s appointment as the dateCompany’s Accounting Officer in March 2018, the Company granted Ms. Rawson a sign-on award of grant. In all cases, 25% of these50,000 stock options that will vest upon grant, while the remaining portion vestannually in equal installments over four years, and a four-year periodconditional award of 50,000 stock options that would vest upon the Company’s becoming an SEC reporting entity. In November 2018, the Company granted Ms. Rawson a special performance-based award of 125,000 options, which would vest upon the Company’s successful uplisting to the NASDAQ or a national stock
16




exchange. Ms. Rawson will be eligible for twelve (12) months of severance benefits, if her services are no longer required due to a change of control or any reason other than for cause. A total of 175,000 of the options vested upon the Company becoming an SEC reporting entity and listing on the NASDAQ in 2019.

Ronen Tchelet, Ph.D.

We entered into a consulting agreement with Sky Blue Biotech kft, dated January 1, 2016 (the “Sky Blue Biotech Agreement”), to engage Mr. Tchelet to serve as our Vice President of Research and Business Development. The engagement term of the Sky Blue Biotech Agreement is one year and will renew annually on the anniversary date of the agreement, unless the Company or Mr. Tchelet provides notice of non-renewal any time after the one year anniversary date with not less than 90 days’ notice. Mr. Tchelet is subject to an annual performance evaluation and adjustment of his base consulting fees, in the director’s continued service. Thesole discretion of the Company. Mr. Tchelet was compensated EUR €180,000 per annum in 2018 for the consulting services provided, which was increased to EUR €185,400 per annum in January 2019, and to EUR €190,962 in January 2020, which increase was consistent with annual increases for the majority of the Company’s employees.
Mr. Tchelet is also eligible for a discretionary annual target bonus of up to 40% of his base contract amount if specific performance targets are met. For fiscal year 2019, Mr. Tchelet received a cash bonus of EUR €37,080. For fiscal years 2019 and 2018, Mr. Tchelet received stock option grants to purchase 75,000 and 100,000 shares of common stock for his annual performance, respectively. All options generally expire fivegranted to Mr. Tchelet for fiscal years 2019 and 2018 vest upon the one-year anniversary and have a ten-year term from the date of grant or earliergrant.

During the engagement period, Mr. Tchelet shall be entitled to reimbursement of all business travel, entertainment and other business expenses reasonably incurred in the event serviceperformance of his duties for the Company. Additionally, if the Company enters into a licensing agreement or research and development agreement sourced and developed by Mr. Tchelet during the engagement period, Mr. Tchelet shall receive the following: (i) a commission of up to 1% of the up-front licensing revenue and (ii) a commission of up to 2.5% of the research and development revenue. Commissions will be paid quarterly within 30 days of the Company’s receipt of payment.

Mr. Tchelet is subject to certain restrictive covenants, including Company ownership of Mr. Tchelet’s work product which shall remain the sole and exclusive property of the Company, non-disclosure for five years following the date of execution of the agreement or for three years following the termination of agreement whichever is last to occur, and non-solicitation for five years following the termination of the Sky Blue Biotech Agreement.

Matthew S. Jones
We entered into a consulting agreement with Novaro Ltd. dated March 31, 2017 (the “Jones Consultant Agreement”) to engage Mr. Jones as our Managing Director Business Development and Licensing. The engagement term of the Jones Consultant Agreement is one year and will renew annually on the anniversary date of the agreement, unless the Company or Novaro Ltd. provides notice of non-renewal any time after the first annual anniversary date with then not less than 90 days’ notice. Mr. Jones is subject to an annual performance evaluation and adjustment of his base consulting fees, in the sole discretion of the Company. Mr. Jones was compensated GBP £203,528 per annum in 2018 for the consulting services provided, which was increased to GBP £209,634 per annum in January 2019, and to GBP £215,923 in January 2020, which increase was consistent with annual increases for the majority of the Company’s employees.
Mr. Jones is also eligible for a director ceases. Atdiscretionary annual target bonus of up to 40% of the beginningbase contract value if specific performance targets are met as specified in the Jones Consultant Agreement. For fiscal year 2019, Mr. Jones received a cash bonus of each year, non-employee directors will receive additional optionsGBP £62,890. For fiscal years 2019 and 2018, Mr. Jones received stock option grants to purchase 25,00050,000 and 100,000 shares of our common stock orfor his annual performance, respectively. In March 2018, the Company granted Mr. Jones a pro rata portion based onspecial award of 50,000 stock options in recognition of his achievements in business development. All options granted to Mr. Jones during fiscal years 2019 and 2018 vest upon the numberone-year anniversary and have a ten-year term from the date of months thatgrant.

17




During the director served on the board during the preceding year, subjectengagement period, Mr. Jones shall be entitled to the same vesting provisionsreimbursement of all business travel, entertainment and other conditions as described above. On February 10, 2006, non-employee directors Messrs. Berman, Rosengart, Shapiro and Warner received option grantsbusiness expenses reasonably incurred in the performance of 25,000, 16,667, 18,750 and 25,000, respectively, at an exercise price of $2.36 per share.
Report of the Audit Committee
The following report of the audit committee does not constitute soliciting material and should not be deemed filed with the Securities and Exchange Commission nor shall this report be incorporated by reference into any of our filings under the Securities Act of 1933 or the Securities Exchange Act of 1934.
The audit committee oversees our financial reporting processhis duties on behalf of the boardCompany. Mr. Jones is subject to certain restrictive covenants, including Company ownership of directors. Management hasMr. Jones’ work product which shall remain the primary responsibility for the financial statementssole and the reporting process including the systems of internal controls. In fulfilling its oversight responsibilities, the audit committee has reviewed and discussed the audited financial statements in the annual report with management including a discussionexclusive property of the quality, not justCompany, non-disclosure for five years following the acceptability,date of execution of the accounting principles,agreement or for three years following the reasonablenesstermination of significant judgments,agreement whichever is last to occur, and non-solicitation for five years following the claritytermination of disclosures in the financial statements.
The audit committee also has reviewed and discussed with our independent registered public accounting firm Ernst & Young LLP, which is responsible for expressing an opinion on the conformity of those financial statements with generally accepted accounting principles, their judgments as to the quality, not just the acceptability, of our accounting principles and such other matters as are required to be discussed with the committee by Statement of Auditing Standards 61. In addition, the audit committee has received the written disclosures and the letter from Ernst & Young LLP required by Independence Standards Board No. 1 and has discussed with Ernst & Young LLP their independence from management and the Company, and has considered the compatibility of nonaudit services with Ernst & Young LLP’s independence.
The audit committee discussed with Ernst & Young LLP the overall scope and plans for their audit. The audit committee met with Ernst & Young LLP, with and without management present, to discuss the results of their examination, their evaluation of our internal controls, and the overall quality of our financial reporting.
In reliance on the reviews and discussions referred to above, the audit committee recommended to the board of directors (and the board has approved) that the audited financial statements for 2005 be included in our annual report on Form 10-KSB for the year ended December 31, 2005, as filed with the Securities and Exchange Commission.
agreement.
AUDIT COMMITTEE
Richard J. Berman (chairman)
Stephen J. Warner
Harry Z. Rosengart
Executive Officers
Outstanding Equity Awards at Fiscal Year-End
The following table presents information with respectsummarizes the outstanding equity award holdings held by our “named executive officers” (as defined by the SEC’s disclosure requirements) at December 31, 2019.
 Option AwardsStock Awards
 Number of
Securities
Underlying
Unexercised
Options
Number of
Securities
Underlying
Unexercised
Options
Equity
Incentive
Plan
Awards:
Number of
Securities
Underlying
Unexercised
Unearned Options
Option
Exercise Price
Option Expiration DateNumber
of
Shares
or Units
of
Stock
That
Have
Not Vested
Market
Value
of
Shares
or
Units
of
Stock
That
Have
Not Vested
Equity
Incentive
Plan
Awards:
Number
of
Unearned
Shares,
Units or
Other
Rights
That
Have Not Vested
Equity
Incentive
Plan
Awards:
Market
or Payout
Value of
Unearned
Shares,
Units or
Other
Rights
That
Have Not Vested
Name(#) exercisable(#) unexercisable(#)($)(#)($)(#)($)
Mark A. Emalfarb100,000  —  —  1.67  6/20/2021—  —  —  —  
400,000  —  —  1.67  6/20/2021—  —  —  —  
150,000  —  —  1.63  1/3/2022—  —  —  —  
270,000  —  —  1.39  1/2/2023—  —  —  —  
300,000  —  —  1.87  1/2/2024—  —  —  —  
Ping W. Rawson(1)18,750  6,250  —  1.62  6/26/2026—  —  —  —  
(1)5,945  5,945  —  1.63  1/3/2027—  —  —  —  
(1)7,500  22,500  —  1.39  1/2/2028—  —  —  —  
 50,000  —  —  1.44  3/19/2028—  —  —  —  
(1)12,500  37,500  —  1.44  3/19/2028—  —  —  —  
 125,000  —  —  1.76  11/16/2028—  —  —  —  
(1)—  100,000  —  1.87  1/2/2029—  —  —  —  
25,000  —  —  6.26  6/28/2029—  —  —  —  
Ronen Tchelet, Ph.D.(1)150,000  50,000  —  1.57  1/18/2026—  —  —  —  
50,000  —  —  1.63  1/3/2027—  —  —  —  
 60,000  —  —  1.39  1/2/2028—  —  —  —  
(2)—  100,000  1.87  1/2/2029—  —  —  —  
Matthew S. Jones40,000  —  —  1.63  1/3/2027—  —  —  —  
 50,000  —  —  1.39  1/2/2028—  —  —  —  
 50,000  —  —  1.44  3/19/2028—  —  —  —  
(2)—  100,000  —  1.87  1/2/2029—  —  —  —  
___________________
Notes:
(1) The options vest annually in equal installments over four years subsequent to our executive officers and key employees, as of April 26, 2006.the grant date.
(2) The options will vest upon the one-year anniversary subsequent to the grant date.

Name
Age
Position
Executive Officers:
18
Mark A. Emalfarb
51
Chairman of the Board, President and Chief Executive Officer
Glenn E. Nedwin, Ph.D
50
Chief Scientific Officer and Executive Vice President, President, Biosciences Business and a Director
Wayne Moor
54
Chief Financial Officer and Vice President
Kent M. Sproat
59
Executive Vice President, Enzyme Business
Ratnesh (Ray) Chandra
58
Senior Vice President, Marketing-Biotechnology Systems
Alexander (Sasha) Bondar
34
Vice President, Strategy & Corporate Development
Key Employees:
Richard Burlingame, Ph.D.
53
Executive Director, Research & Development
Daniel Michalopoulos, Ph.D.
53
Vice President, Pulp & Paper
Charles W. Kling IV
49
Vice President of Sales and Marketing-Enzymes
See “Proposal 1: Election of Directors—“Directors Continuing in Office” for information concerning Mr. Emalfarb and Dr. Nedwin.


Wayne Moor has been our Chief Financial Officer and Vice President since January 2005. During the past five years Mr. Moor has served as a Chief Financial Officer of several public companies, and has over 25 years experience in real estate and hotel operations, asset management, debt restructurings, recapitalizations and developing strategic turnaround plans. From October 2002 through December 2004, Mr. Moor served as the Senior Vice President, Treasurer and Chief Financial Officer of Boca Resorts, Inc, a hospitality company. From October 2001 to October 2002, Mr. Moor was Senior Vice President and Chief Financial Officer for ANC, the parent company of Alamo and National rental car companies. In November 2001, following the terrorist attacks of September 11, 2001, ANC and its U.S. operating subsidiaries voluntarily filed petitions for reorganization under Chapter 11 of the U.S. Bankruptcy Code in Wilmington, Delaware. From September 2000 to October 2001, Mr. Moor was Senior Vice President and Chief Financial Officer for Gerald Stevens, Inc., a floral products marketer and retailer. In April 2001, Gerald Stevens, Inc. and certain operating subsidiaries voluntarily filed petitions for reorganization under Chapter 11 of the U.S. Bankruptcy Code in Miami, Florida. From June 1997 to January 2000, Mr. Moor was Executive Vice President and Chief Financial Officer for US Diagnostic, Inc., an operator of outpatient medical diagnostic imaging and related facilities. Prior to that, Mr. Moor held the position of Chief Financial Officer or Executive Vice President for a number of privately and publicly held financial institutions and real estate operating companies. He began his career in public accounting.
Kent M. Sproat has been our Executive Vice President, Enzyme Business, responsible for all manufacturing, applications, sales, and marketing functions of our enzymes business activities, since April 2005. Mr. Sproat served as our Vice President, Manufacturing from 1997 through March 2005. Mr. Sproat joined Dyadic-Florida in 1997 from Genencor International, where since 1996 he served as its Elkhart Site Manager. From 1990 to 1996, Mr. Sproat was Vice President, Manufacturing, of Solvay Enzymes, Inc. From 1989 to 1990, he was Director of International Manufacturing of the Enzyme Division of Miles, Inc. Between 1981 and 1990, he served as Plant Manager of Miles’ Elkhart, Indiana and Clifton, New Jersey-based enzyme plants. Between 1973 and 1981, Mr. Sproat was a Production Superintendent at Miles’ Citric Acid Division; Start Up Manager of Miles’ citric acid facility in Brazil; and Production Supervisor and Project Engineer. Mr. Sproat is the recipient of a patent for his design in the purification process of amylases. Mr. Sproat is a chemical engineer with a B.S. degree from Purdue University.
Ratnesh (Ray) Chandra has been our Senior Vice President, Marketing-Biotechnology Systems, responsible for business development for the Company’s biosciences business activities, since April 2005. Mr. Chandra served as our Vice President, Marketing - BioSciences from 2000 through March 2005. Mr. Chandra joined Dyadic-Florida from Genencor International in 2000. He had served at Genencor as the Director, New Business Development since 1993. From 1987 to 1993, he was with Merck & Co. holding the positions of Director, Business/Market Intelligence and Director, Business Systems in their Human Health Marketing Division. From 1976 to 1987, he was with Schering-Plough Corp. in the positions of Director Economic Analysis, Manager Capital Planning and Senior Operations Analyst. Mr. Chandra has an M.B.A. from New York University and an M.S. in engineering from Columbia University.
Alexander (Sasha) Bondar  has been our Vice President, Strategy & Corporate Development, with primary responsibility for corporate development, organization planning, merger & acquisition opportunities, fund-raising activities and investor and public relations, and secondarily, when requested, for assisting in business development for the Company’s biosciences and enzyme businesses, since April 2005. Mr. Bondar served as our Executive Director, Business Development from May 2003 through March 2005. Mr. Bondar joined Dyadic-Florida in May 2003 from The Aurora Funds, a venture capital firm based in Research Triangle Park, North Carolina, where he was focused on investing in early stage life sciences companies.  Prior to that, from 1996 to 2001, Mr. Bondar served in a variety of management roles at Incyte Genomics, now Incyte Corporation, in Palo Alto, California, and from 1999 to 2001 as Associate Director, Corporate Business Development.  From 1997 to 1999, he served as Manager, Pharmacogenomics Business Development, and was a major contributor to the successful launch of Incyte’s pharmacogenomics program. From 1996 to 1997, he served as Technical Advisor to the intellectual property group at Incyte, contributing to the creation of the largest portfolio of gene patents in the world.  Mr. Bondar holds a B.S. degree in Biotechnology Management from Menlo College and an M.B.A. in Corporate Finance and Health Sector Management from Duke University’s Fuqua School of Business.
Richard P. Burlingame, PhD. has been our Executive Director, Research & Development, responsible for management of the day-to-day research and development activities engaged in by us worldwide, since joining us in October 2001. Dr. Burlingame is focused on leading the Dyadic R&D team in its development of the C1 Expression System and C1 Host Technology. Prior to joining us, Dr. Burlingame was a research manager at BioTechnical Resources, Inc., or BTR, from 1989 to 2001, leading a number of programs in the areas of metabolic engineering, biocatalysis, gene expression, and strain and process development for the production of fungal enzymes. He was the primary liaison and chief scientific officer for BTR’s collaborations with Dyadic. Between 1986 and 1989, Dr. Burlingame was a researcher at Bio-Technical International, Inc. where he was primarily involved with generating recombinant strains for the production of amino acids and development of genetic engineering tools. His postdoctoral work was at the University of Wisconsin-Madison in the area of bacteriophage genetics and molecular biology. Dr. Burlingame received his Ph.D. degree in biochemistry from the University of Minnesota, where he studied microbial biochemistry, physiology, and genetics and his B.S. degree, also in biochemistry, from the University of Illinois.
Daniel Michalopoulos, Ph.D. has been our Vice President, Pulp & Paper since joining us in February 2005 and is focused on growing our pulp and paper effort. Prior to joining us, he served as Senior Program Manager for Hercules’ Pulp and Paper Division from 1998 to 2005 where he managed a staff of 40 people with an annual budget of $8 million. Prior to that, he served as Research Director at BetzDearborn Pulp and Paper Division and held other research and management positions at Betz PaperChem. Dr. Michalopoulos conducted his post-doctoral work at Rice University, received his Ph.D. in Chemistry from Colorado State University and his B.S. in Chemistry from Lowell Technological Institute.
Charles W. Kling IV has been our Vice President of Sales and Marketing-Enzymes since joining us in July 2005. Prior to joining us, Mr. Kling served as Group Manager of Hercules, Inc.’s Pulp & Paper division, with full P&L responsibility and management of staff of over 60 people, from 1998 to 2005. Prior to Hercules, from 1990 to 1998, Mr. Kling served as Global Director, Technical Marketing for BetzDearborn Inc.'s Pulp & Paper division. From 1986 to 1990, he was Division Manager, S.D. Warren division of Scott Paper. Prior to that, he served as Production Manager for Buckeye Cellulose, a division of Proctor and Gamble, Inc. Mr. Kling received his B.S. degree in Civil Engineering from University of Alabama.
Our officers are elected annually by our board of directors at a meeting held following each annual meeting of stockholders, or as necessary and convenient in order to fill vacancies or newly created offices. Each officer serves at the discretion of our board of directors, subject to the contractual rights, if any, of such officer. See “—Employment Agreements.”
We are not aware of any family relationship among any of our directors or officers.
EXECUTIVE COMPENSATION
Pension Benefits
The following table sets forth the total compensation earned, accrued or paid to our Chief Executive Officer and each of our four most highly compensated executive officers who served in such capacities as of December 31, 2005, collectively referred to below and throughout this proxy statement as the “named executive officers,” for the years ended December 31, 2005, 2004 and 2003.
Summary Compensation Table
 
Annual Compensation (1)
 
Long-Term
Compensation Awards
 
Name and Principal Position
 
Year
 
Salary ($)
 
Bonus ($)
 
Restricted
Stock
Awards
 
Securities
Underlying
Option Awards
 
Mark A. Emalfarb(2)
Chairman, President and Chief Executive Officer
2005300,000--      -
2004300,00075,000
-
      -
2003300,00035,970
-
      -
     
Wayne Moor(3) 
Chief Financial Officer and Vice President
 
2005
 
207,120
 
-
 
-
 
307,889
 
 
 
 
 
 
Ratnesh (Ray) Chandra (4)
Senior Vice President, Marketing - Biotechnology Systems
2005165,517--  30,000
2004149,85630,000
-
  60,000
2003144,00423,250
-
  15,000
 
 
 
 
 
Kent M. Sproat (5)
Executive Vice President,
Enzyme Business
2005179,154--  30,000
2004145,20630,000
-
  80,000
2003139,50523,250
-
  10,000
     
Alexander (Sasha) Bondar (6)
Vice President, Strategy & Corporate Development
2005139,755--  20,000
2004138,10525,000
-
  45,000
200374,15723,250
-
  25,000

_____________________
(1)Annual compensation does not include the cost to us of benefits certain executive officers receive in addition to salary and cash bonuses. The aggregate amounts of such personal benefits, however, did not exceed the lesser of either $50,000 or 10% of the total annual salary and bonus reported for such named executive officer. Any bonus amount reported for each of the named executive officers, other than Mr. Emalfarb, was actually paid in the succeeding fiscal year.
(2)Mr. Emalfarb’s bonus for 2004Company has been accrued, and will be paid upon the first to occur of (i) the closing of either (x) our next significant financing transaction or (y) a transaction in which we receive a significant influx of cash, as determined by the compensation committee in its reasonable discretion, or (ii) the date on which the percentage of our outstanding shares held by Mr. Emalfarb falls below 50% of what that percentage is on the date hereof. Mr. Emalfarb’s bonus for 2003 was accrued in such year, but was not paid until January 2005.
(3)Mr. Moor received the following awards under the Dyadic International, Inc. 2001 Equity Compensation Plan (the “2001 Equity Compensation Plan”): (a) in April 2006, options to purchase 30,000 shares of common stock at an exercise price of $4.60 per share for services rendered in 2005, which vest at the rate of 25% per year on the day preceding each anniversary of the date of grant subject to his continued employment with us; and (b) in May 2005, options to purchase 277,889 shares at an exercise price of $3.68 per share, which are fully vested. Mr. Moor’s employment with us commenced in January 2005.
(4)Mr. Chandra has received the following awards under the 2001 Equity Compensation Plan: (a) in April 2006, options to purchase 30,000 shares of common stock at an exercise price of $4.60 per share for services rendered in 2005, which vest at the rate of 25% per year on the day preceding each anniversary of the date of grant subject to his continued employment with us; (b) in March 2005, options to purchase 50,000 shares of common stock at an exercise price of $3.025 per share for services rendered in 2004, which are fully vested; (c) in July 2004, options to purchase 10,000 shares of common stock at an exercise price of $3.33 per share for services rendered in 2003 and 2004, which are fully vested; (d) in July 2004, 3,716 shares of common stock, valued at $3.33 per share on the date of issuance, for services rendered in 2003, which are fully vested; and (e) in July 2003, options to purchase 15,000 shares of common stock at an exercise price of $4.50 per share for services rendered in 2003 and 2002, which are fully vested.
(5)Mr. Sproat has received the following awards under the 2001 Equity Compensation Plan: (a) in April 2006, options to purchase 30,000 shares of common stock at an exercise price of $4.60 per share for services rendered in 2005, which vest at the rate of 25% per year on the day preceding each anniversary of the date of grant subject to his continued employment with us; (b) in March 2005, options to purchase 70,000 shares of common stock at an exercise price of $3.025 per share for services rendered in 2004, which are fully vested; (c) in July 2004, options to purchase 10,000 shares of common stock at an exercise price of $3.33 per share for services rendered in 2003 and 2004, which are fully vested; (d) in July 2004, 3,716 shares of common stock, valued at $3.33 per share on the date of issuance, for services rendered in 2003, which are fully vested; and (e) in July 2003, options to purchase 10,000 shares of common stock at an exercise price of $4.50 per share for services rendered in 2003 and 2002, which are fully vested.
(6)Mr. Bondar has received the following awards under the 2001 Equity Compensation Plan: (a) in April 2006, options to purchase 20,000 shares of common stock at an exercise price of $4.60 per share for services rendered in 2005, which vest at the rate of 25% per year on the day preceding each anniversary of the date of grant subject to his continued employment with us; (b) in March 2005, options to purchase 35,000 shares of common stock at an exercise price of $3.025 per share for services rendered in 2004, which are fully vested; (c) in July 2004, options to purchase 10,000 shares of common stock at an exercise price of $3.33 per share for services rendered in 2003 and 2004, which are fully vested; (d) in July 2004, 3,716 shares of common stock for services rendered in 2003, valued at $3.33 per share on the date of issuance, which are fully vested; and (e) in July 2003, options to purchase 25,000 shares of common stock at an exercise price of $4.50 per share for services rendered in 2003, which are fully vested.


Stock Option Grants
The following table sets forth grants of stock options to acquire shares of our common stock made during the year ended December 31, 2005 to the named executive officers. No stock appreciation rights were granted to these individuals during that year.
Individual Grants
Name
Number of Securities
Underlying Options
Granted (#)
% of Total Options
Granted to Employees
in Fiscal Year
Exercise or Base Price
($/SH)
Expiration
Date
Mark A. Emalfarb
 
-
 
-
 
-
 
-
 
Wayne Moor
 
277,889
 
28%
 
3.68
 
01/31/10
 
Ratnesh (Ray) Chandra
 
50,000
 
5%
 
3.025
 
03/30/10
 
Kent M. Sproat
 
70,000
 
7%
 
3.025
 
03/30/10
 
Alexander (Sasha) Bondar
 
35,000
 
4%
 
3.025
 
03/30/10
 

Option Exercises and Holdings
The following table provides summary information regarding stock options held by the named executive officers as of December 31, 2005. No named executive officer exercised stock options during 2005.
Number of Securities Underlying
Unexercised Options at
December 31, 2005 (#)
Value of Unexercised
In-The-Money Options at
December 31, 2005 ($) (2)
Name
Exercisable
Unexercisable
Exercisable
Unexercisable
Mark A. Emalfarb(1)
-
-
-
-
Wayne Moor
277,889
-
-
-
Ratnesh (Ray) Chandra
75,000
-
-
-
Kent M. Sproat
90,000
-
-
-
Alexander (Sasha) Bondar
70,000
-
-
-
___________________________
(1)Excludes Bridge Loan Warrants held by Mr. Emalfarb. See “Certain Relationships and Related Transactions.”
(2)The values of unexercised in-the-money options are based on the product of the (a) difference between the closing sale price per share of our common stock of $2.00 as reported by the American Stock Exchange on December 30, 2005 and (b) number of shares of common stock underlying the options.

Benefit Plans
2001 Equity Compensation Plan. The Dyadic International, Inc. 2001 Equity Compensation Plan was adopted by Dyadic-Florida’s board of directors and stockholders and assumed by us on October 29, 2004 upon consummation of the merger between us and Dyadic-Florida. The purpose of the 2001 Equity Compensation Plan is to retain and attract key management, employees, nonemployee directors and consultants by providing those persons with a proprietary interest in us. The compensation committee administers the Equity Compensation Plan and may grant stock options, which may be incentive stock options or nonqualified stock options that do not comply with Section 422 of the Internal Revenue Code, stock awards and performance units to eligible persons with such terms and conditions as are determined by the committee. The committee may grant one or more types of awards in any combination to an eligible person in a particular year, subject to certain limitations. The Equity Compensation Plan was recently amended and restated by our board of directors effective as of January 1, 2005 to (a) reduce the number of shares of common stock reserved for issuance under the Plan to 4,478,475 shares from 5,152,447 shares , (b) to conform certain provisions of the Plan to the requirements of Section 409A of the Internal Revenue Code of 1986, as amended, and (c) increase the maximum limitation of shares that may be subject to awards granted under the Plan to any one individual for any fiscal year during the term of the Plan to 1,200,000 shares from 100,000 shares. For a description of the 2001 Equity Compensation Plan as amended and restated for which we are seeking stockholder approval at the annual meeting, see “Proposal 2: Approval of Amended and Restated 2001 Equity Compensation Plan” on page 25.
401(k) Retirement Plan. We have established a tax qualified employee savings and retirement plan, or 401(k) defined contribution plan (the “401(k) Plan”) in place, under which all employees are eligible to participate. Participantsparticipants may elect to defer up to 80%100% of their compensation up to a maximum amount determined annually pursuant to Internal Revenue Service regulations. Employee contributions may begin on90 days after the date of hire and are immediately vested. The 401(k) Plan provides a safe harbor basic match contribution for all eligible employees who make salary deferrals. The match contribution is equal to 100% of the employee’s salary deferral up to 4% of such employee’s annual deferred compensation. This match contribution is credited to the employee’s account and is 100% vested at the time of contribution.

MATTERS TO BE CONSIDERED AT THE ANNUAL MEETING

PROPOSAL 1 - ELECTION OF CLASS I DIRECTORS

General

We have the discretion to make matching contributions to this retirement plan, but have not done so ever.
2006 Stock Option Plan. The Dyadic International, Inc. 2006 Stock Option Plan was adopted by our boarda classified Board currently fixed at six members. Our Board is divided into three classes currently consisting of two Class I directors, two Class II directors, and two Class III directors. One class of directors in April 2006is elected each year at our Annual Meeting of Shareholders for which we are seeking stockholder approvalan approximate three-year term. The term of the Class I directors expires at the annual meeting.Annual Meeting.

Our Nominating Committee is charged with identifying, evaluating and recommending director nominees to the Board. There are no minimum qualifications for nomination of directors. The purposeNominating Committee generally seeks individuals with broad experience at the policy-making level in business, or with particular industry expertise. While we do not have a formal diversity policy for board membership, we look for potential candidates that help ensure that the Board has the benefit of a wide range of attributes. We believe that all of our directors should be committed to enhancing shareholder value and should have sufficient time to carry out their duties and to provide insight and practical wisdom based on experience. Each director must also represent the interests of all shareholders.

The Board has nominated Seth J. Herbst, M.D. and Arindam Bose, Ph.D. to stand for re-election as Class I directors. If elected, Dr. Herbst and Dr. Bose will serve for a term expiring in 2023.

We expect each such nominee for election as Class I directors to be able to serve, if elected. If either is unable to serve, proxies may be voted for a substitute nominee so designated by the present Board.

Vote Required

The affirmative vote of a plurality of the Stock Option Plan is to retain and attract key management, employees, nonemployee directors and consultantsvotes cast, by providing those persons with a proprietary interest in us. The compensation committee will administerproxy, at the Stock Option Planand may grant stock options, which may be incentive stock options or nonqualified stock options that do not comply with Section 422Annual Meeting by the holders of the Internal Revenue Code. The Stock Option Plan provides for 2,700,000 shares of our common stock being reservedentitled to vote at the Annual Meeting is required for issuance under the plan. For a descriptionelection of the Stock Option Plan, see “Proposal 3: Approval of 2006 Stock Option Plan” on page 31.


EQUITY COMPENSATION PLANS
The following table provides informationeach nominee as of December 31, 2005,Class I director. You may vote FOR or WITHHELD with respect to our equity compensation plan in effect as of December 31, 2005, namely the Dyadic International, Inc. 2001 Equity Compensation Plan.
Plan Category
 
Number of Securities to be
Issued upon Exercise of Outstanding Options, Warrants and Rights (a)
 
Weighted Average
Exercise Price of
Outstanding
Options, Warrants and Rights (b)
 
Number of Securities Remaining Available
for Future Issuance Under Equity
Compensation Plans (Excluding Securities Reflected in Column (a) (c)
       
Equity compensation plans approved by security holders (1) (3) 1,597,639 $3.62 
3,536,184 (2)
       
Equity compensation plans not approved by security holders 
N/A
 
 
N/A
 
 
N/A
 
Total 1,597,639 $3.62 
3,536,184 (2)
___________________________
(1)
Consists of Dyadic International, Inc. 2001 Equity Compensation Plan, which the Company assumed in connection with the Merger consummated on October 29, 2004.
(2)Excludes 18,624 shares that were awarded to Dyadic-Florida employees under the Dyadic International, Inc. 2001 Equity Compensation Plan in 2004.
(3)
Excludes 65,000 options to purchase common stock granted to nonemployees prior to the Equity Compensation Plan's adoption.
Employment Agreements
We have employment agreements with each of our named executive officers. In April 2001, Dyadic-Florida and Mark A. Emalfarb, our Chief Executive Officer and the founder of Dyadic-Florida, entered into an employment agreement pursuant to which he has been employed by Dyadic-Florida as its President and Chief Executive Officer which we assumed incident to the consummation of the merger with Dyadic-Florida. The initial term of Mr. Emalfarb’s employment was for three years with an automatic two-year renewal unless either party furnishes the other a notice of non-renewal not less than 60 days prior to the expiration of the then term. On March 16, 2006, we and Mr. Emalfarb amended his employment agreement to extend the term of Mr. Emalfarb’s employment by one year, from March 30, 2006 to March 30, 2007, and add an automatic renewal provision for succeeding one year terms unless either party gives the other a notice of non-renewal not less than 90 days prior to the expiration of the then term. The terms and conditions of Mr. Emalfarb’s employment agreement are otherwise the same as were in effect prior to being amended.
Mr. Emalfarb’s base annual compensation was initially fixed at $300,000. He is eligible to earn a bonus annually based upon goals and objectives mutually agreed upon by him and our board of directors. Mr. Emalfarb has received no salary increases since the employment agreement was executed. The employment agreement is terminable only on account of Mr. Emalfarb’s death or disability, by us only “for Cause,” and by Mr. Emalfarb only “for Good Reason.” The phrase “for Cause” is defined to include failure to substantially perform assigned duties for a period of 20 days following a written demand for his substantial performance that identifies the manner in which he has failed to substantially perform, a material breach of the employment agreement, a material breach of his proprietary rights agreement with us, his illegal or gross misconduct which is willful and causes damages to us, the conviction of a felony or plea of no contest, substance abuse or violation of our policies against racial or sexual discrimination. The phrase “for Good Reason” is defined to mean the assignment of duties to Mr. Emalfarb inconsistent with his position, our failure to honor our compensation commitments to Mr. Emalfarb fixed by his employment agreement, our failure to cause Mr. Emalfarb to be elected to our board of directors and our demotion of Mr. Emalfarb. If Mr.

Emalfarb’s employment is terminated by us other than “for Cause” or by Mr. Emalfarb “for Good Reason,” he is entitled to receive a one year severance benefit plus an amount equal to a portion of his annual bonus for the preceding year, prorated for the portion of the current year worked. For its benefit, Dyadic-Florida also maintains a term life insurance policy insuring Mr. Emalfarb’s life in the face amount of $5,000,000.
On January 31, 2005, we hired Mr. Wayne Moor to become our Chief Financial Officer and a Vice President pursuant to the terms of an employment agreement of that date. The initial term of Mr. Moor’s employment expires December 31, 2007, with automatic one-year renewals unless either party furnishes the other a notice of non-renewal not less than 90 days prior to the expiration of the then term. Mr. Moor’s annual base compensation is $225,000, and he is eligible to earn a bonus each year of up to 40% of his annual base compensation based upon a bonus plan to be adopted and maintained by the compensation committee for such year.
On March 30, 2005, we entered into employment agreements with three of our named executive officers, Kent M. Sproat, Ratnesh (Ray) Chandra and Alexander (Sasha) Bondar. In the case of Mr. Chandra, his employment agreement replaced a previously existing employment agreement dated May 1, 2000. The initial term of employment under all three employment agreements expires December 31, 2007, with automatic one-year renewals unless either party furnishes the other a notice of non-renewal not less than 90 days prior to the expiration of the then term. The annual base compensation of Messrs. Sproat, Chandra and Bondar is $190,000, $172,250 and $143,000, respectively, and each of them is eligible to earn a bonus each year of up to 40% of his annual base compensation based upon a bonus plan to be adopted and maintained by the compensation committee for such year.
Each of the employment agreements for the executives, other than Mr. Emalfarb, is terminable on account of the executive’s death or disability, or by the Company without cause or “for Cause.” The phrase “for Cause” is defined to include a material breach of the employment agreement, acts of disloyalty to the Company (including but not limited to acts of dishonesty or diversion of corporate opportunities), the unauthorized disclosure of the Company’s confidential information, or acts determined in good faith by the Compensation Committee to be detrimental to the Company’s interests, provided that the executive must be afforded an opportunity to have a face-to-face meeting with the Compensation Committee before any determination is made by it that he was guilty of “for Cause” conduct. If the executive’s employment is terminated by the Company other than “for Cause,” upon the condition that he furnish the Company with a full general release, he is entitled to receive a severance benefit of his then monthly base compensation for the lesser of six months or until he has obtained other full or part-time employment as an employee or consultant. Under each employment agreement, the Company is also obligated to indemnify the subject executive to the fullest extent permitted by applicable law. Further, the Company agrees to advance expenses he may spend as a result of any proceeding against him as to which he could be indemnified.
Mr. Sproat’s and Mr. Chandra’s employment agreements also include provisions that might entitle them to extended severance benefits following the occurrence of a “Change of Control” of the Company, in the case of Mr. Chandra, and following the occurrence of a “Change of Control” of either the Company or Dyadic-Florida, in the case of Mr. Sproat, as those terms are defined in their respective agreements. Under both agreements, upon a termination of the executive’s employment by the Company or its successor-in-interest other than “for Cause,” or a termination of his employment by the executive which is a “Constructive Termination of Employment Without Cause” within 12 months following the occurrence of a Change of Control, he will become entitled to a severance benefit of his then monthly base compensation for the lesser of 18 months, or until he has obtained other full or part-time employment as an employee or consultant. The phrase “Change of Control” means: (i) a sale, lease, exchange or other transfer of all or substantially all of the assets of the Company; (ii) a merger or consolidation of the Company in which less than a majority of the outstanding voting securities of the surviving corporation are not owned by stockholders of the Company immediately prior to such merger or consolidation; (iii) a “person” or “group” (as those terms are defined in Section 13(d) and 14(d) of the Exchange Act of 1934, as amended) not beneficial owners of voting securities of the Company on March 30, 2005 become the beneficial owners, directly or indirectly, of more than 50% of the outstanding voting securities of the Company other than as a result of the purchase of such voting securities from the Company in a transaction or series of transactions approved by the affirmative vote of a majority of the directors who were members of the Board one month prior to the date of such transaction; (iv) a sale, lease, exchange or other transfer of all or substantially all of the assets of the Company’s Enzyme Business (in the case of Mr. Sproat) or the BioSciences Business (in the case of Mr. Chandra) in a transaction in which, following such transaction, the transferee is not an affiliate of the Company; or (v) a consolidation or merger of any subsidiary or affiliate of 


the Company that owns substantially all of the assets used in the conduct of the Company’s Enzyme Business (in the case of Mr. Sproat) or the BioSciences Business (in the case of Mr. Chandra) with another party, the survivor of which is not an affiliate of the Company. The phrase “Constructive Termination of Employment Without Cause” in both agreements is defined to mean a termination of employment at the election of the executive made within 12 months followingsuch director. Only votes FOR or WITHHELD are counted in determining whether a Change of Control and within 60 days following the occurrence of any of the following events: (i) a material demotionplurality has been cast in his office, duties or responsibilities; (ii) a reduction in his annual base compensation or potential annual bonus; (iii) the impositionfavor of a requirement that he relocate his principal residence outside a 50 mile radius of the Company’s current principal place of business; or (iv) the failure of the Company or its successor-in-interest to comply with the terms of his employment agreement.
Incident to the consummation of the merger with Dyadic-Florida in October 2004, we assumed the rightsdirector. Votes WITHHELD and obligations of Dyadic-Florida under confidential information, inventions assignment and non-compete agreements between Dyadic-Florida and each of Messrs. Emalfarb, Chandra, Sproat and Bondar. Under the terms of these agreements, each executive confers upon us customary proprietary rights in respect of our confidential information and intellectual work product contributed to by them, as well as his covenant not to compete with our business while employed by us and for three years after the termination of his employment. These agreements with Messrs. Chandra, Sproat and Bondar were superceded by their new employment agreements, except to the extent therein expressly provided.
On March 16, 2006, we entered into an employment agreement with Glenn E. Nedwin, Ph.D., pursuant to which he became our Chief Scientific Officer and Executive Vice President, the President of the BioSciences business of Dyadic-Florida and a member of our board of directors effective March 22, 2006. The initial term of Dr. Nedwin’s employment is approximately 2 years and 9 months (ending December 31, 2008), with automatic one-year renewals unless either party furnishes the other a notice of non-renewal not less than 120 days prior to the expiration of the then term. Dr. Nedwin’s annual base salary is $300,000, and he is eligible to earn a bonus each year of up to 25% of his then annual base salary based upon a bonus plan adopted and maintained by the compensation committee for such year. Upon Dr. Nedwin signing his employment agreement, we granted to him 11,990 fully vested shares of our common stock under our 2001 Equity Compensation Plan valued at $50,000.
The employment agreement is terminable on account of Dr. Nedwin’s death or disability, by Dr. Nedwin for “Good Reason” or by us without cause or “for Cause.” The phrase “Good Reason” is defined to mean a termination of Dr. Nedwin’s employment by him upon his delivery of a written notice to us within thirty (30) days following the occurrence of any of the following events: (i) the imposition of a requirement on Dr. Nedwin that he relocate his principal residence outside a radius that is more than 50 miles from Davis, California, unless he consents, in his discretion; (ii) our significant and material reduction to Dr. Nedwin’s position, duties or responsibilities without his approval, provided that he must give us reasonable advance written notice of the basis for his belief that such a reduction has occurred and afford us an opportunity to cure same; (iii) our material reduction of Dr. Nedwin’s compensation or benefits, measured against such compensation or benefits as of March 22, 2006, unless all of our executive officers suffer reasonably comparable reductions in their compensation or benefits at substantially the same time; or (iv) Dr. Nedwin is not nominated by the nominating committee to stand for re-election other than on account of his unwillingness or inability to stand for re-election. The phrase “for Cause” is defined to include a material breach of the employment agreement, acts of disloyalty to us (including but not limited to acts of dishonesty or diversion of corporate opportunities), the unauthorized disclosure of our confidential information, or acts determined in good faith by the compensation committee to be detrimental to our interests, provided that Dr. Nedwin must be afforded an opportunity to have a face-to-face meeting with the compensation committee before any determination is made by it that Dr. Nedwin was guilty of “for Cause” conduct. If Dr. Nedwin’s employment is terminated by us other than “for Cause,” upon the condition that he furnish us with a full general release, he is entitled to receive a severance benefit of monthly installments in the amount of 1/12th of his then annual base salary for the eighteen (18) month period following that termination (the “severance period”), provided that the amount of his severance benefits are reduced on a dollar-for-dollar basis by the amount of any remuneration he may earn during the severance period for the performance of services as an employee, or independent contractor or agent. Under the employment agreement, we are also obligated to indemnify Dr. Nedwin to the fullest extent permitted by applicable law. Further, we have agreed to advance expenses Dr. Nedwin may spend as a result of any proceeding against him as to which he could be indemnified.
On March 16, 2006, we granted Dr. Nedwin two stock options in accordance with the 2001 Equity Compensation Plan: (i) an option to purchase 445,022 shares of our common stock at an exercise price of $2.96 per share, the fair market value on our common stock on the date of grant (the “time-vested option”) and (ii) an option to purchase 667,533 shares of our common stock at an exercise price of $5.92 per share, two times the fair market value of our common stock on the date of grant (the “performance-vested option”). Each option agreement is consistent with our current standard form 2001 Equity Compensation Plan employee option agreement, except as to the vesting of the performance-vested option, and each indicates therein that it is an Incentive Stock Option to the extent permitted by the terms of the 2001 Equity Compensation Plan, and a non-qualified stock option as to the balance of the shares

that may be purchased thereunder. The time-vested option becomes exercisable, conditioned upon Dr. Nedwin’s continued service as an employee of ours, as to 25% of the underlying shares on each of the next four anniversaries of March 16, 2006, and expires on March 16, 2011, but provides for the complete acceleration of vesting of that option upon a termination of Dr. Nedwin’s employment either by the Company without Cause or by Dr. Nedwin for Good Reason. The performance-vested option becomes exercisable incrementally, conditioned upon Dr. Nedwin’s continued service as an employee of ours, based upon the our achievement during the initial period of his employment of various specified performance benchmarks (e.g., the launching of new products, the enhancement of existing products, our entry into corporate and strategic alliances), and expires on March 16, 2011.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Our President and Chief Executive Officer, Mark A. Emalfarb, is the trustee and beneficiary of the Mark A. Emalfarb Trust, which is our largest stockholder. The Mark A. Emalfarb Trust and our second largest stockholder, The Francisco Trust, whose sole beneficiaries are the spouse and descendants of Mr. Emalfarb, have made loans to Dyadic-Florida, which we assumed in connection with our merger with Dyadic-Florida (the “Merger”). The trustee for The Francisco Trust is not related to or affiliated with Mr. Emalfarb or the Mark A. Emalfarb Trust. The aggregate amount of our indebtedness to the Mark A. Emalfarb Trust and The Francisco Trust is approximately $4.0 million, as of December 31, 2005, which is owed to them pursuant to the terms of three separate debt instruments:
·  $836,824 pursuant to a promissory note made payable to the Mark A. Emalfarb Trust dated May 30, 2001, bearing interest at the rate of 6% per annum and originally convertible into shares of Dyadic common stock, which we refer to as the Emalfarb Convertible Note;
·  
$741,048 pursuant to a promissory note made payable to the Francisco Trust dated May 30, 2001, bearing interest at the rate of 6% per annum and originally convertible into shares of Dyadic common stock , which we refer to as the Francisco Convertible Note; and
·  $2,424,941 pursuant to a revolving note made payable to the Mark A. Emalfarb Trust dated May 29, 2003 and bearing interest at the rate of 8% per annum, secured by all of our assets, which we refer to as the Bridge Loan Note. In connection with the Bridge Loan Note, warrants, which we refer to as the Bridge Loan Warrants, were issued to purchase 1,500,000 shares of Dyadic-Florida common stock for the lesser of $4.50 or the conversion price of the Series A convertible preferred stock of Dyadic-Florida then outstanding, which we refer to as the Bridge Loan Warrants.
In August 2004, the Mark A. Emalfarb Trust and Dyadic-Florida entered into an agreement to facilitate the consummation of the merger. In accordance with this agreement, subject to consummation of the merger:
·  The Mark A. Emalfarb Trust agreed to exchange indebtedness of Dyadic-Florida to the trust in the amount of $1,225,000 for 367,868 shares of our common stock and warrants to purchase 183,934 shares of our common stock;
·  Each of the Emalfarb Convertible Note, the Francisco Convertible Note and the Bridge Loan Note were amended to extend their due date from January 1, 2005 to January 1, 2007 and to permit their prepayment in whole or part by Dyadic-Florida without premium or penalty;
·  The conversion prices under the Emalfarb Convertible Note and Francisco Convertible Note were amended to fix the conversion price at $3.33 per share in lieu of the then current fair market value of shares of Dyadic-Florida common stock; and
·  The Bridge Loan Warrants were amended to fix their exercise price at $3.33 per share.
The amendments to the convertible notes and the Bridge Loan Warrants caused us to recognize for accounting purposes additional borrowing costs of approximately $350,000, which will be amortized over the period from October 30, 2004 through January 1, 2007, and to recognize for accounting purposes a beneficial conversion feature of $554,000 which will be amortized over the same period. All accrued and unpaid interest due under the Emalfarb Convertible Note, the Francisco Convertible Note and the Bridge Loan Note on the date of the completion of the merger were added to the principal amount due under those notes. Interest under the notes accruing after October 29, 2004, is payable on a quarterly basis until the principal sum is paid in full.

Our six directors Mark A. Emalfarb, Stephen J. Warner, Richard J. Berman, Robert B. Shapiro, Harry Z. Rosengart and Glenn E. Nedwin, Ph.D. are each parties to indemnification agreements pursuant to which we agreed to indemnify them against any liability arising out of their performance of their duties to us in their capacities as directors (except that Dr. Nedwin’s indemnification agreement is contained in his employment agreement). The agreements with Messrs. Emalfarb and Warner were entered into by Dyadic-Florida on August 19, 2004 and assumed by us incident to the merger. Incident to the consummation of the merger, they were amended to substitute applicable Delaware law for any references contained in those agreements to Florida law. The agreements with Mr. Berman, Mr. Shapiro and Mr. Rosengart were entered into directly with us in 2005 when they became directors. The agreement with Dr. Nedwin was entered into in March 2006 when he became a director. All of these indemnification agreements indemnify our directors in addition to the indemnification provided by our restated certificate of incorporation and amended and restated bylaws. Among other things, these agreements indemnify our directors for certain expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by them in any action or proceeding, including any action by or in the right of Dyadic arising out of such person’s services to us or to any of our subsidiaries or any other company or enterprise to which such person provides services at our request. Further, we agree to advance expenses they spend as a result of any proceeding against them as to which they could be indemnified (subject to an undertaking that they will repay such advances if it is ultimately determined that theybroker non-votes are not entitled to indemnification). Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to our directors and executive officers pursuant to our amended and restated certificate of incorporation and amended and restated bylaws, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.
At present, there is no pending litigation or proceeding involving any of our directors where indemnification will be required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for such indemnification.

PROPOSAL 2: APPROVAL OF AMENDED AND RESTATED 2001 EQUITY COMPENSATION PLAN
At the annual meeting, stockholders will be asked to approve the Amended and Restated Dyadic International, Inc. 2001 Equity Compensation Plan effective as of January 1, 2005. Our board of directors adopted the Amended and Restated 2001 Equity Compensation Plan, subject to stockholder approval, for the following purposes:
(i)to reduce the number of shares reserved for issuance under the Plan to 4,478,475 shares from 5,152,447 shares;
(ii)to conform certain provisions of the Plan to the requirements of Section 409A of the Internal Revenue Code of 1986, as amended; and
(iii)to increase the maximum limitation of shares that may be subject to awards granted under the Plan to any one individual for any fiscal year during the term of the Plan to 1,200,000 shares from 100,000 shares.
These purposes are discussed in greater detail below under “Purposes of Adopting the Amended and Restated 2001 Equity Compensation Plan.”
As of April 26, 2006, we had outstanding options under the 2001 Equity Compensation Plan covering 3,258,361 shares of common stock and two fully vested stock awards totalling 30,614 shares, and there were 1,832,722 shares remaining available for issuance, which we are seeking to reduce to 1,158,750 shares.
The purpose of the 2001Equity Compensation Plan is to retain and attract key management, employees, nonemployee directors and consultants by providing those persons with a proprietary interest in us.
The 2001 Equity Compensation Plan is not subject to any provision of the Employee Retirement Income Security Act of 1974, as amended, and is not qualified under Section 401(a) of the Internal Revenue Code of 1986, as amended (the “Code”).
Vote Required
The affirmative vote of the holders of a majority of all shares casting votes, either in person by proxy, at the annual meeting is required to approve the Amended and Restated 2001 Equity Compensation Plan effective as of January 1, 2005.
This approval is required (i)counted for purposes of compliance with certain exclusions from the limitationselection of Section 162(m) of the Code and (ii) by the applicable rules of the American Stock Exchange. A properly executed proxy marked “abstain” with respect to this proposal will not be voted,directors, although it will bethey are counted for purposes of determining whether there is a quorum. Abstentions and broker non-votes willShareholders do not have the same effect as a vote against this proposal.
right to cumulate their votes for directors.

Recommendation of the Board

The Board recommends shareholders vote FOR the election of the nominees as Class I directors.
Dyadic’s board of directors unanimously recommends a vote “FOR” this proposal.
Nominees for Election as Directors
Purposes of Adopting the Amended and Restated 2001 Equity Compensation Plan
19
Reduction in Share Reserve



The board deems it advisable to reduce the share reserve under the Plan for two reasons. First, assuming stockholders approve the 2006 Stock Option Plan under Proposal 3 at the annual meeting, the board intends to use the 2006 Stock Option Plan as the primary (but not exclusive) vehicle to make equity-based awards. Second, the board believes there will be a sufficient number of shares beyond the reserve (as reduced) that will become available again for grant under the Plan from time to time by reason of the expiration, forfeiture, termination and cancellation of unexercised outstanding stock options, as well as the forfeiture of other types of equity awards, such as performance units and restricted stock.


Conformance to Requirements of Section 409A of the Code
The board deems it advisable to conform certain provisions of the Plan to the requirements of Section 409A of the Code to avoid certain tax penalties that could be imposed by Section 409A upon plan participants.
Section 409A of the Code (enacted in 2004) requires all amounts deferred under a nonqualified deferred compensation plan, such as the 2001 Equity Compensation Plan, to comply, in form and operation, with rules governing (i) prohibitions on acceleration of benefits, (ii) distributions and (iii) initial and subsequent elections as to the timing of the distribution of benefits. Violation of these rules will cause a participant to recognize deferred compensation on a current basis to the extent itfollowing information is not subject to substantial risk of forfeiture. Additionally, if a violation of the Section 409A rules occurs, a plan participant is required to pay retroactive interest (the underpayment rate plus 1%) and a 20% penalty. Section 409A of the Code does not apply to amounts earned and vested on or before December 31, 2004. Accordingly, a participant is exempt from the rules of Section 409A of the Codegiven with respect to any deferred compensation that (i) he had a legally binding right tothe nominees for election as Class I directors at the Annual Meeting:

Seth J. Herbst, M.D., 63, has been on or before that datethe Board since June 2008 and (ii) was not subject to substantial risk of forfeiture on that date. However, because a special rule applies to certain equity-based compensation, including stock options, options that were immediatelyexercisable on or before December 31, 2004 are treatedcurrently serves as earned and vested, even if they would terminate upon the participant’s termination of his or her services.
In order to conform certain provisionschairman of the 2001 EquityCompany’s Nominating Committee. Heals serves on the Company’s Compensation Plan withCommittee. He is a board-certified obstetrician/gynecologist who is also board certified in advanced laparoscopic and minimally invasive gynecologic surgery.  Dr. Herbst is the requirements of Section 409Afounder and President of the Code,Institute for Women’s Health and Body (“IWHB”) which was founded in May of 1997, an OB/GYN practice with multiple locations in Palm Beach County, Florida.  He is the Amendedco-founder of Visions Clinical Research which was founded in 1999, and Restated 2001 Equity Compensation Plan incorporates certain changes toperforms medical and surgical clinical trials throughout the following SectionsUnited States. Dr. Herbst founded IWHB of Palm Beach, a Physician Management Group that currently employs 43 providers, which he actively directs the Plan:
·  Section 1(b) was amended to comply with the Proposed Treasury Regulations §1.409A (“Prop. Regs.”) and satisfy the good faith compliance standard created by the Prop. Regs.;
·  Section 5(b)(ii) was amended to make mandatory, instead of permissive, the requirement that all stock options have an exercise price of not less than the fair market value of our common stock on the date of the grant of the stock option, which is now fixed as the trading price of our shares as of the close of trading on that date;
·  Section 6(e) was amended to remove a provision providing for the payment of dividends or other distributions paid on such restricted stock grants while they remain subject to forfeiture, in order to comply with the Prop. Regs. and satisfy the good faith compliance standard created by the Prop. Regs.;
·  Section 7, pertaining to “Performance Units,” was amended to comply with the Prop. Regs. and satisfy the good faith compliance standard created by the Prop. Regs.;
·  Section 8, pertaining to “Qualified Performance Based Compensation” (another category of performance-based compensation), was amended to comply with the Prop. Regs. and satisfy the good faith compliance standard created by the Prop. Regs.;
·  Section 9 contains payment deferral provisions that were conformed to the provisions of Section 409A(a)(3) of the Code;
·  the definition of a “Change of Control” set forth in Section 12 has been amended both to conform to a guidance issued under IRS Notice 2005-1 and the Prop. Regs., and to delete a change of control alternative pertaining to the composition of the our board of directors rendered obsolete by our implementation of a classified board;
·  Section 15 was amended to (i) require the compensation committee to act in a manner consistent with the provisions of Section 409A, and (2) provide that no compensation committee action may be taken which would cause the application of the 20% penalty or immediate tax recognition under Section 409A; and
·  a new section 21(c) was added to make null and void any provision in the 2001 Equity Compensation Plan that would have the effect of causing the application of a 20% penalty or immediate tax recognition under Section 409A of the Code.
Increase in Individual Annual Limitoperations on Shares Awards Under Section 162(m) of the Code
The board deems it advisable to increase the maximum limitation of shares that may be subject to awards granted under the Plan to any one individual for any fiscal year during the term of the Plan to 1,200,000 shares from 100,000 shares in order to avoid the $1 million compensation deductibility limitation of Section 162(m) of the Code. The board believes it is in the best interests of the Company and its stockholders that the limitations on the deductibility on compensation to named executives imposed by the provisions of Section 162(m) of the Code be avoided. Section 162(m) of the Code generally limits to $1 million the amount that may be deducted as compensation expense (including options and restricted stock awards) paid in one year to a named executive officer. However, an exception to this limitation applies if the compensation is (1) “performance-based compensation,” (2) awarded pursuant to a compensation plan which has received stockholder approval and (3) the plan includes a maximum limitation of shares that may be subject to awards to any one individual for any fiscal year. Since the compensation committee has made awards to two members of senior management that exceed the 2001 Equity Compensation Plan’s annual limitation of 100,000 shares, the Amended and Restated 2001 Equity Compensation Plan increases the annual limitation to 1,200,000 shares effective as of January 1, 2005, so that the awards to such members of senior management will qualify for the exemption from the application of the $1 million compensation deductibility limitation of Section 162(m) of the Code. However, the increased annual limitation will not be effective unless the Amended and Restated 2001 Equity Compensation Plan is approved by stockholders at the annual meeting.
Effectiveness of the Amended and Restated 2001 Equity Compensation Plan
The Amended and Restated 2001 Equity Compensation Plan is effective as of January 1, 2005, subject to stockholder approval.
Summary of Material Provisions of the Amended and Restated 2001 Equity Compensation Plan
The followingdaily basis. Dr. Herbst is a summary of the material provisions of the Amended and Restated 2001 Equity Compensaion Plan. This summary is qualified in its entirety by reference to the Amended and Restated 2001 Equity Compensation Plan, the full text of which is attached as Annex A to this proxy statement. You are urged to read the full text of the Amended and Restated 2001 Equity Compensation Plan, which we refer to as the “2001 Equity Compensation Plan” in this summary.

Plan Administration. The compensation committee of our board of directors serves as the “plan administrator” of the 2001 Equity Compensation Plan. In order to adhere to the rules of the American Stock Exchange, and to assure that awards made thereunder qualify as “performance based compensation” within the meaning of Section 162(m) of the Code, not less than a majority of the members of our compensation committee are “outside directors” within the meaning of Section 162(m) of the Code and “independent directors” within the meaning of the rules of the American Stock Exchange. The compensation committee is authorized to:
·  select persons eligible to receive awards;
·  determine the type and number of awards to be granted and the number of shares underlying the awards;
·  specify times at which such awards will be exercisable (including performance conditions that may be required to be satisfied as a condition to exercisability);
·  set other terms and conditions of awards;
·  prescribe forms of award agreements;
·  interpret and specify rules and regulations relating to the 2001 Equity Compensation Plan; and
·  make all other decisions and determinations as the compensation committee may deem necessary or advisable for the administration of the 2001 Equity Compensation Plan.
Eligibility. All of our and our subsidiaries’ officers, employees, directors, and certain consultant determined by the compensation committee to be “Key Advisors” are eligible to be granted awards under the 2001 Equity Compensation Plan.
Types of Awards. The 2001 Equity Compensation Plan provides for the award of a broad variety of share-based compensation alternatives, including: (i) options intended to qualify as incentive stock options (“ISOs”) under Section 422 of the Code, to our employees, (ii) non-statutory stock options (“NSOs,” and together with “ISOs,” collectively, “options”) to our and our subsidiaries’ directors, employees and Key Advisors; (iii) shares of our common stock; (iv) performance units; and (v) qualified performance-based performance units of share awards. The maximum number of shares which may be the subject of an award to any individual in a single year is 1,200,000 shares.

The exercise price for all options may not be less than the closing trading price of our common stock on the date the option is granted, except for ISOs granted to 10% stockholders, which must have an exercise price of not less than 110% of the fair market value of our common stock on the date the option is granted. ISOs have a maximum term of ten years, except for 10% stockholders who are subject to a maximum term of five years. Options are not transferable other than by will and the laws of descent and distribution. Options generally expire not later than 90 days following a termination of employment, 12 months following the optionee’s disability, or not later than 12 months following the optionee’s death. In the administration of the 2001 Equity Compensation Plan, the compensation committee is proscribed from taking any action which would have the effect of causing the provisions of Section 409A of the Code to apply.
The exercise price for an option is payable in (a) cash, (b) with the approval of the compensation committee, by delivering shares of our common stock owned by the optionee (including shares acquired in connection with the exercise of an option) and having a fair market value on the date of exercise equal to the exercise price or to the ownership of shares, have a fair market value on the date of exercise equal to the exercise price (c) payment through a broker in accordance with procedures permitted by Regulation T of the Federal Reserve, or (d) by such other method as the compensation committee may approve.
Each award or option granted under the 2001 Equity Compensation Plan is required to be evidenced by a written agreement between us and the recipient of the award or option. If the Dyadic International, Inc. 2006 Stock Option Plan under Proposal 3 is approved by stockholders at the annual meeting, the compensation committee anticipates limiting awards under the 2001 Equity Compensation Plan principally to shares of restricted stock, as and when the compensation committee determines that such awards are preferable to grants of options (which would otherwise be made under the 2006 Stock Option Plan).
Shares Available for Awards. The 2001 Equity Compensation Plan has 4,478,475 shares reserved for issuance thereunder. If an option expires or is terminated or canceled without having been exercised or settled in full, or in the case of shares, is forfeited back to or repurchased by us, the terminated portion of the option (or forfeited or repurchased shares subject to the award) will become available for future grant or sale under the 2001 Equity Compensation Plan (unless it has terminated). Shares are not deemed to be issued under the 2001 Equity Compensation Plan with respect to any portion of an option that is settled in cash. If the exercise or purchase price of an Option is paid for through the tender of shares, or withholding obligations are met through the tender or withholding of shares, those shares tendered or withheld will again be available for issuance under the 2001 Equity Compensation Plan.
Change in Control. The 2001 Equity Compensation Plan permits the compensation committee, at the time of the grant of an award, to provide in the agreement evidencing that award for any of the following alternatives in the event of a change of control: (i) that a full vesting of all unvested rights occur; (ii) that a grantee holding performance units shall receive a payment in settlement of the performance units in an amount determined by the committee; (iii) that the optionee surrender his or her outstanding options in exchange for a payment by us, in cash or shares as determined by the committee, in an amount equal to the amount by which the then fair market value of the shares subject to the optionee’s unexercised options exceeds the exercise price of the options; or (iv) after affording the grantee of an option an opportunity exercise that option, terminate any or all unexercised options at such time as the committee deems appropriate. The term “change in control” is defined under the 2001 Equity Compensation Plan to mean:
·  a sale of all or substantially all of our assets;
·  a merger or consolidation in which our stockholders immediately prior to the transaction own less than a majority of the voting securities of the surviving corporation;
·  the sale or disposition of assets equal to or greater than 40% of the total gross fair market value of our assets immediately prior to such sale or disposition; or
·  any person (other than our existing stockholders who beneficially own, directly or indirectly, more than 20% of the voting power of our outstanding shares of common stock) coming to own more than 50% of the voting power of our outstanding shares of common stock.
Except to the extent an award agreement provides otherwise, if we are not the surviving corporation in a change in control (or survive only as a subsidiary of another corporation), unless the compensation committee determines otherwise, all outstanding options that are not exercised shall be assumed by, or replaced with comparable options or rights by the surviving corporation (or a parent of the surviving corporation), and other outstanding awards shall he converted to similar grants of the surviving corporation (or a parent of the surviving corporation).
Amendment and Termination. The 2001 Equity Compensation Plan may be amended or terminated at any time by our board of directors, except that no amendment may be made without stockholder approval if such approval is necessary to comply with any tax or regulatory requirement.
Federal Income Tax Consequences
The following discussion of certain relevant federal income tax consequences applicable to stock options granted under the 2001 Equity Compensation Plan is a brief summary only, and reference is made to the Code and the regulations and interpretations issued thereunder for a complete statement of all relevant federal tax consequences. This summary is not intended to be exhaustive and does not address state, local or foreign tax consequences.
Incentive Stock Options. ISOs are intended to be eligible for the favorable federal income tax treatment accorded “incentive stock options” under the Code. There generally are no federal income tax consequences to the optionee or the Company by reason of the grant or exercise of an ISO. However, the exercise of ISOs may increase the optionee’s alternative minimum tax liability, if any.
If an optionee holds stock acquired through exercise of an ISO for at least two years from the date on which the Option is granted and at least one year from the date on which the shares are transferred to the optionee upon exercise of the option, any gain or loss on a disposition of such stock will be long-term capital gain or loss. Generally, if the optionee disposes of the stock before the expiration of either of these holding periods (a “disqualifying disposition”), at the time of disposition, the optionee will realize taxable ordinary income equal to the lesser of (a) the excess of the stock’s fair market value on the date of exercise over the exercise price, or (b) the optionee’s actual gain, if any, on the purchase and sale. The optionee’s additional gain, or any loss, upon the disqualifying disposition will be a capital gain or loss. Capital gains currently are generally subject to lower tax rates than ordinary income. Slightly different rules may apply to optionees who acquire stock subject to certain repurchase options.
To the extent the optionee recognizes ordinary income by reason of a disqualifying disposition, we will generally be entitled (subject to the requirement of reasonableness and the satisfaction of a tax reporting obligation) to a corresponding business expense deduction in the tax year in which the disqualifying disposition occurs.
Non-Statutory Stock Options. Generally, there are no tax consequences to the optionee or us by reason of the grant of an NSO. Upon exercise of an NSO, the optionee normally will recognize taxable ordinary income equal to the excess of the stock’s fair market value on the date of exercise over the option exercise price. Generally, with respect to employees, the Company is required to withhold payroll and income taxes from regular wages or supplemental wage payments in an amount based on the ordinary income recognized. Subject to the requirement of reasonableness and the satisfaction of a reporting obligation, we will generally be entitled to a business expense deduction equal to the taxable ordinary income realized by the optionee. Upon disposition of the stock, the optionee will recognize a capital gain or loss equal to the difference between the selling price and the purchase price (to the extent not recognized as taxable income as described above). Slightly different rules may apply to optionees who acquire stock subject to certain repurchase options or who are subject to Section 16(b) of the Securities Exchange Act of 1934, as amended.
Stock Awards. Where the award has no vesting, the grantee will recognize taxable ordinary income equal to the stock’s fair market on the date of grant. For an award subject to vesting, the grantee will normally recognize taxable ordinary income equal to the excess, if any, of the stock’s fair market on the date of stock vests over the purchase price paid for the shares, if any. To the extent that the grantee files a “Section 83(b) election” pursuant to Section 83(b) of the Code, the grantee will recognize ordinary taxable income at the time of the receipt or purchase of the shares of stock equal to the fair market of the stock on the date of receipt or purchase less the amount, if any, paid by the grantee for the stock. With respect to our employees, we generally are required to withhold an amount based on ordinary income recognized. Generally, we will be entitled to an income tax deduction equal to the amount of taxable ordinary income recognized by the grantee of the award.
Performance Units and Qualified Performance-Based Compensation. The designation of an award as performance units or as qualified Performance-Based Compensation will not change the tax treatment described above with respect to stock awards.
Options Outstanding under the Amended and Restated 2001 Equity Compensation Plan
As of April 26, 2006, options granted under the 2001 Equity Compensation Plan to purchase (i) an aggregate of 3,032,944 shares of common stock were outstanding to approximately 90 employees and consultants (ii) 225,417 shares of common stock were outstanding to non-employee directors. The options were granted at exercise prices ranging from $1.83 to $7.13 per share.
On April 26, 2006, the last reported sale price per share of Dyadic common stock on the American Stock Exchange was $5.84.
The table below indicates, as of April 26, 2006, the aggregate number of options outstanding under the 2001 Equity Compensation Plan to each of our named executive officers and directors and the groups indicated. There are no stock awards or performance units outstanding under the 2001 Equity Compensation Plan other than as described in footnotes 2 and 3 to the table and the issuance of 7,476 shares of common stock in July 2004 to certain employees of Dyadic-Florida for a payment of a portion of accrued bonuses.
Option Grantee
Number of
Options
Outstanding
Mark A. Emalfarb(1)
Chairman, President and Chief Executive Officer 
                           --
Glenn E. Nedwin, Ph.D.(2)
Chief Scientific Officer, Executive Vice President and Director 
                         1,112,555
Wayne Moor
Chief Financial Officer and Vice President 
                            307,889
Kent M. Sproat (3)
Executive Vice President, Enzyme Business
                            120,000
Ratnesh (Ray) Chandra (3)
Senior Vice President, Marketing-Biotechnology Systems
                            105,000
Alexander (Sasha) Bondar (3)
Vice President, Strategy & Corporate Development
                              90,000
Richard J. Berman
Director
                              75,000
Harry Z. Rosengart
Director
                             46,667
Robert J. Shapiro
Director
                              48,750
Stephen J. Warner
Director
             55,000
All current executive officers as a group (6  persons)
                         1,735,444
All current directors who are not executive officers as a group (4 persons)
            225,417
All employees and consultants, other than executive officers (approximately 84)
                         1,357,500
___________
(1)Excludes Bridge Loan Warrants held by Mr. Emalfarb. See “Certain Relationships and Related Transactions.”
(2)Excludes a fully vested stock award of 11,990 shares granted to Dr. Nedwin in March 2006 under the 2001 Equity Compensation Plan at the inception of his employment with us.
(3)Excludes a fully vested stock award of 3,716 shares granted to each of Messrs. Sproat, Chandra and Bondar, respectively, in July 2004 under the 2001 Equity Compensation Plan for a portion of accrued bonuses related to 2003.

PROPOSAL 3: APPROVAL OF 2006 STOCK OPTION PLAN
On April 19, 2006, the board of directors adopted the Dyadic International, Inc. 2006 Stock Option Plan. The purpose of the 2006 Stock Option Plan is to retain and attract key management, employees, nonemployee directors and consultants by providing those persons with a proprietary interest in us. At the annual meeting, stockholders will be asked to approve the 2006 Stock Option Plan.
Our board of directors adopted the 2006 Stock Option Plan, subject to stockholder approval, because it believes that it is in the best interests of us and our stockholders that we rely principally upon the issuance of stock options at exercise prices of not less than the price of the underlying shares on the date of grant (discussed further below) as our primary equity compensation vehicle, and that the plan administrator of the plan, the compensation committeemember of the board of directors be affordedof Palms West Hospital in Loxahatchee, Florida. Dr. Herbst is also a consultant for multiple medical device companies in the greatest amountUnited States and a member of discretionmedical advisory boards for these and other companies. He received his B.S. degree from American University in administering1978 and his medical degree from Universidad del Noreste School of Medicine in Tampico, Mexico in 1983.  Dr. Herbst completed his OB/GYN residency and was Chief Resident at Long Island College Hospital in Brooklyn, New York.
Arindam Bose, Ph.D., 67, joined the 2006 Stock Option PlanBoard on August 15, 2016 and currently serves as chairman of the Company’s Science and Technology Committee. He also serves on the Company's Audit Committee. Dr. Bose retired from Pfizer Worldwide Research & Development in 2016 after 34 years in leadership roles in bioprocess development and clinical manufacturing. Dr. Bose’s final position at Pfizer was Vice-President, Biotherapeutics Pharmaceutical Sciences External Affairs and Biosimilar Strategy with responsibility for external sourcing, competitive intelligence and external influencing as well as for executing the technical development plan for Pfizer’s entry into biosimilars. He is permittedwidely recognized as a Key Thought Leader in the biopharmaceutical industry. Dr. Bose has served as the Chair of the Biologics and Biotechnology Leadership Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA), the chief advocacy arm of the US pharmaceutical industry. His outstanding accomplishments and service to the profession have been recognized by applicable income tax laws.his election as “Fellow” of 3 leading professional organizations: American Chemical Society, American Institute of Chemical Engineers and American Institute for Medical and Biological Engineering. Dr. Bose was elected to the US National Academy of Engineering in February 2017 for innovative research in biologics manufacturing. Dr. Bose currently provides consulting services in bioprocessing to several start-up biotechnology companies including a part-time process development management role at Akero Therapeutics (NASDAQ: AKRO). He received a Ph.D. in chemical engineering from Purdue University, a M.S. from the University of Michigan, Ann Arbor and a B. Tech from the Indian Institute of Technology, Kanpur.
There are currently no outstanding options under the 2006 Stock Option Plan.
Directors Continuing in Office
The 2006 Stock Option Planfollowing information is not subject to any provision of the Employee Retirement Income Security Act of 1974, as amended, and is not qualified under Section 401(a) of the Code.
Vote Required
The affirmative vote of the holders of a majority of all shares casting votes, either in person by proxy, at the annual meeting is required to approve the 2006 Stock Option Plan.
This approval is required (i) for purposes of compliance with certain exclusions from the limitations of Section 162(m) of the Code, (ii) for purposes of compliance with the requirements of incentive stock options under Section 422 of the Code, and (iii) by the applicable rules of the American Stock Exchange. A properly executed proxy marked “abstain”provided with respect to this proposal willthe directors who are not be voted, although it will be countednominees for purposeselection as directors at the Annual Meeting:
NameAgeClassTerm ExpiringDate of Appointment
Jack L. Kaye76II2021May 2015
Barry C. Buckland, Ph.D.72II2021January 2018
Michael P. Tarnok, Chairman65III2022June 2014
Mark A. Emalfarb65III2022October 2004

Mark A. Emalfarb, President, Chief Executive Officer and Director
Mark A. Emalfarb is the founder of determining whether thereDyadic, and currently serves as the Chief Executive Officer and a member of the Board and Science and Technology Committee. He has been a member of the Board and has
20




previously served as its Chairman from October 2004 until April 2007 and from June 2008 until January 2015. Since founding the predecessor to Dyadic in 1979, Mr. Emalfarb has served as a Director, President and Chief Executive Officer for substantially all of that time and has successfully led and managed the evolution of Dyadic from its origins as a pioneer and leader in providing ingredients used in the stone-washing of blue jeans to the discovery, development, manufacturing and commercialization of specialty enzymes used in various industrial applications and the development of an integrated technology platform based on Dyadic’s patented and proprietary C1 fungal microorganism. Mr. Emalfarb is an inventor of over 25 U.S. and foreign biotechnology patents and patent applications resulting from discoveries related to the patented and proprietary C1 fungus and has been the architect behind its formation of several strategic research and development, manufacturing and marketing relationships with U.S. and international partners. Mr. Emalfarb earned his B.A. degree from the University of Iowa in 1977.
Michael P. Tarnok, Chairman, Director
Michael P. Tarnok joined the Board on June 12, 2014 and currently serves as chairman of the Company’s Compensation Committee. He also serves on the Company’s Audit and Nominating Committees, and on January 12, 2015 Mr. Tarnok was appointed Dyadic’s Chairman of the Board. Mr. Tarnok is also currently a board member of Ionetix, Inc. In addition, Mr. Tarnok’s previously served as a board member for Global Health Council, and Keryx Biopharmaceuticals, Inc., where he also served as Chairman of the board of directors. Mr. Tarnok is a quorum. Abstentionsseasoned finance and broker non-votes will haveoperational executive with extensive pharmaceutical industry experience in a wide range of functional areas. He spent the same effectmajority of his career at Pfizer Inc., which he joined in 1989 as Finance Director-US Manufacturing and from 2000 to 2007 served as a vote againstSenior Vice President in Pfizer’s US Pharmaceutical Division. In this proposal.
position, Mr. Tarnok managed multiple responsibilities for the division including, finance, access contracting, trade management, information technology, Sarbanes-Oxley compliance and the Greenstone generics division. Prior to joining Pfizer, Mr. Tarnok worked primarily in financial disciplines for ITT Rayonier, Inc., Celanese Corporation and Olivetti Corporation of America. Mr. Tarnok earned an M.B.A. in Marketing from New York University and a B.S. in Accounting from St. John’s University.
RecommendationJack L. Kaye, Director
Jack L. Kaye joined the Board in May 2015 and currently serves as chairman of the Board
Dyadic’s board of directors unanimously recommends a vote “FOR” this proposal.
Summary of Material ProvisionsCompany’s Audit Committee. He also serves on the Company’s Compensation Committee. Mr. Kaye is currently the Chairman of the 2006 Stock Option Plan
The following isaudit committee and a summary of the material provisions of the 2006 Stock Option Plan. This summary is qualified in its entirety by reference to the 2006 Stock Option Plan, the full text of which is attached as Annex B to this proxy statement. You are urged to read the full text of the 2006 Stock Option Plan, which we refer to as the “Option Plan” in this summary.
Plan Administration. The compensation committee of our board of directors will serve as the “plan administrator” of the Option Plan. In order to adhere to the rules of the American Stock Exchange, and to assure that awards made thereunder qualify as “performance based compensation” within the meaning of Section 162(m) of the Code, not less than a majority of the members of our compensation committee are “outside directors” within the meaning of Section 162(m) of the Code and “independent directors” within the mean of the rules of the American Stock Exchange. The compensation committee is authorized to:
·  select persons eligible to receive awards of options;
·  determine the type of option and number of shares as to which the option relates;
·  specify times at which such options will be exercisable (including performance conditions that may be required to be satisfied as a condition to exercisability);
·  set other terms and conditions of option awards;
·  prescribe forms of option award agreements;
·  interpret and specify rules and regulations relating to the Option Plan; and
·  make all other decisions and determinations as the compensation committee may deem necessary or advisable for the administration of the 2006 Option Plan.
Eligibility. All of our and our subsidiaries’ officers, employees and directors, and certain consultants determined by the compensation committee to be “Key Advisors” are eligible to be granted options under the Option Plan.
Types of Options. The 2006 Option Plan provides for the grant of options intended to qualify as incentive stock options (“ISOs”) under Section 422 of the Code, to employees of us and our subsidiaries and non-statutory stock options (“NSOs,” and together with “ISOs,” collectively, “options”) to directors, employees and Key Advisors to us and our subsidiaries.
Exercise Prices and Exercisability. The exercise price for options cannot be less than the closing trading price of our common stock on the date the option is granted, except for ISOs granted to 10% stockholders, which must have an exercise price of not less than 110% of the closing trading price of our common stock on the date the option is granted. ISOs have a maximum term of ten years, except for 10% stockholders who are subject to a maximum term of five years. Options are not transferable other than by will and the laws of descent and distribution. Options generally expire not later than 90 days following a termination of employment, 12 months following the optionee’s disability, or not later than 12 months following the optionee’s death. In the administration of the Option Plan, the compensation committee is proscribed from taking any action which would have the effect of causing the provisions of Section 409A of the Code to apply.
Options shall vest and become exercisable as determined by the Committee. The exercise price for an option is payable in (a) cash, (b) with the approvalmember of the compensation committee and special transaction pricing committee of uniQure B.V. where he has served since May 2016. Mr. Kaye’s prior board service includes Keryx Biopharmaceuticals Inc., a position he has held from 2006 to May 2016 where he served as Chairman of the audit committee and he was also a member of their nominating and governance committee. He also served on the boards of Tongli Pharmaceuticals (USA) Inc. and Balboa Biosciences, Inc., where he served as Chairman of both audit committees. In the past, Mr. Kaye was selected to participate on several dissident board slates which included the Astellas, Inc./OSI, Roche Pharmaceuticals, Inc./Illumina and the Horizon, Inc./Depomed M&A transactions. Mr. Kaye was a partner at Deloitte LLP from 1978 until May 2006, when he retired. At Deloitte, Mr. Kaye was responsible for serving a diverse client base of public and private, global and domestic companies in a variety of industries. Mr. Kaye has extensive experience consulting with clients on accounting and reporting matters, private and public debt financings, SEC rules and regulations and corporate governance/ Sarbanes-Oxley issues. In addition, he has served as Deloitte’s Tristate liaison with the banking and finance community and assisted clients with numerous merger and acquisition transactions. Mr. Kaye served as Partner-in-Charge of Deloitte’s Tri-State Core Client practice, a position he held for more than twenty years. He earned a B.B.A. from Baruch College and is a Certified Public Accountant.
Barry C. Buckland, Ph.D., Director
Barry Buckland, Ph.D. joined the Board in January 2018 and currently serves on the Company's Science and Technology Committee. Dr. Buckland retired from Merck Research Laboratories in 2009 after 28 years of contributions to the Bioprocess R&D group, including more than 12 years as leader in the position of Vice President. Since leaving the Merck Research Laboratories, Dr. Buckland has headed up his own consulting company (BiologicB, LLC). He also is President of Engineering Conferences International (ECI), a not-for-profit organization which organizes prestigious conferences with an engineering focus. Dr. Buckland has chaired successful conference
21




such as Microbial Engineering I and Vaccine Technology Conferences I to IV. He is also a visiting professor at University College London in the Biochemical Engineering Department and is the author or co-author of more than 70 publications. His previous board experience includes Enumeral Biomedical and Mucosis. Dr. Buckland was a Senior Advisor to Protein Sciences until they were purchased by delivering sharesSanofi in 2017. Dr. Buckland became Executive Director of NIIMBL (National Institute for Innovation for Manufacturing Biopharmaceuticals) in 2017. Dr. Buckland was elected to the USA National Academy of Engineering in 1997. In 2008, Dr. Buckland was awarded the ACS Marvin Johnson award for Biotechnology. In 2009, Dr. Buckland was awarded the Discoverers Award by the Pharmaceutical Research and Manufacturers of America (PhRMA) for his role in the discovery and development of GARDASIL, an effective vaccine against HPV. He was one of three recipients.
Our directors hold office for terms of approximately three years or until the earlier of their death, resignation or removal or until their successors have been elected and qualified. Our officers are elected annually by the Board and serve at the discretion of the Board (see Executive Officers). There are no family relationships among our directors and executive officers. Our directors have neither been convicted in any criminal proceeding during the past 10 years nor are parties to any judicial or administrative proceeding during the past 10 years that resulted in a judgment, decree or final order enjoining them from future violations of, or prohibiting activities subject to, federal or state securities laws or a finding of any violation of federal or state securities laws or commodities laws. Similarly, no bankruptcy petitions have been filed by or against any business or property of any of our common stock owned by the optionee (including shares acquired in connection with the exercise of an option) and havingdirectors or officers, nor has any bankruptcy petition been filed against a fair market value on the date of exercise equal to the exercise pricepartnership or to the ownership of shares have a fair market value on the date of exercise equal to the exercise price (c) payment through a broker in accordance with procedures permitted by Regulation T of the Federal Reserve, or (d) by such other method as the compensation committee may approve.
If a participant’s employment or relationship with us is terminated, the participant (or his or her designated beneficiary or estate representative in the case of death) may exercise his or her option within such period of time as is specified in the option agreement to the extent that the option is vested on the date of termination. In the absence of a specified time in the option agreement, the option will remain exercisable for three months following the date of termination, except in the case where termination is as a result of disability or death,business association in which case the option will remain exercisable for 12 months following the date of terminationthese persons were general partners, directors or death.
executive officers.
Shares Available For Option Grants. Subject to adjustment as provided below, there are 2,700,000 shares of our common stock reserved for issuance under the Option Plan. The maximum number of shares which may be the subject of an option grant to any individual in a single year is 1,200,000 shares. If an option expires or is terminated or canceled without having been exercised or settled in full, the terminated portion of the option will become available for future grant under the Option Plan (unless the Option Plan has been terminated). If the exercise or purchase price of an option is paid for through the tender of shares, or withholding obligations are met through the tender or withholding of shares, those shares tendered or withheld will again be available for issuance under the Option Plan.
Amendment and Termination of the Option Plan. The Option Plan will automatically terminate in 2016. In addition, the Option Plan may be amended or terminated by our board of directors, except that no amendment maybe made without stockholder approval if such approval is necessary to comply with any tax or regulatory requirement.

Change in Control. The compensation committee enjoys discretion with respect to the treatment of outstanding options upon the occurrence of a “Change in Control.” The term “Change in Control” is defined under the Option Plan to mean:
·  a sale of all or substantially all of our assets or our liquidation or dissolution;
·  a merger or consolidation in which our stockholders immediately prior to the transaction own less than a majority of the voting securities of the surviving corporation;
·  the sale or disposition of assets equal to or greater than 40% of the total gross fair market value of the assets of the Company immediately prior to such sale or disposition; or
·  any person (other than our existing stockholders who beneficially own, directly or indirectly, more than 20% of the voting power of our outstanding shares of common stock) coming to own more than 50% of the voting power of our outstanding shares of common stock.
If we are not the surviving corporation in a change in control (or survive only as a subsidiary of another corporation), unless the compensation committee determines otherwise, all outstanding options that are not exercised shall be assumed by, or replaced with comparable options or rights by the surviving corporation (or a parent of the surviving corporation). However, the compensation committee may, instead take any of the following alternative courses of action at that time:
·  determine that outstanding options shall automatically accelerate and become fully exercisable;
·  require that optionees surrender their outstanding options in exchange for a payment by us, in cash or shares as determined by the committee, in an amount equal to the amount by which the then fair market value of our shares subject to the optionee’s unexercised options exceeds the exercise price of the options; or
·  after giving optionees an opportunity to exercise their outstanding options, terminate any or all unexercised options at such time as the committee deems appropriate.
Federal Income Tax Consequences
The following discussion of certain relevant federal income tax consequences applicable to stock options granted under the Option Plan is a brief summary only, and reference is made to the Code and the regulations and interpretations issued thereunder for a complete statement of all relevant federal tax consequences. This summary is not intended to be exhaustive and does not address state, local or foreign tax consequences.
Inapplicability of Section 409A. Section 409A of the Code will not apply to the Option Plan because by its terms, no options granted under the Option Plan will provide for the deferral of compensation (i.e., each option grant will meet the following three conditions: (i) the exercise price is required to be not less than the fair market value of the underlying shares of our common stock on the grant date; (ii) the number of shares subject to the option are required to be fixed on the date of grant; and (iii) the option cannot include any feature for the deferral of compensation).
Incentive Stock Options. ISOs are intended to be eligible for the favorable federal income tax treatment accorded “incentive stock options” under the Code. There generally are no federal income tax consequences to the optionee or the Company by reason of the grant or exercise of an ISO. However, the exercise of ISOs may increase the optionee’s alternative minimum tax liability, if any.

If an optionee holds stock acquired through exercise of an ISO for at least two years from the date on which the Option is granted and at least one year from the date on which the shares are transferred to the optionee upon exercise of the option, any gain or loss on a disposition of such stock will be long-term capital gain or loss. Generally, if the optionee disposes of the stock before the expiration of either of these holding periods (a “disqualifying disposition”), at the time of disposition, the optionee will realize taxable ordinary income equal to the lesser of (a) the excess of the stock’s fair market value on the date of exercise over the exercise price, or (b) the optionee’s actual gain, if any, on the purchase and sale. The optionee’s additional gain, or any loss, upon the disqualifying disposition will be a capital gain or loss. Capital gains currently are generally subject to lower tax rates than ordinary income. Slightly different rules may apply to optionees who acquire stock subject to certain repurchase options.
To the extent the optionee recognizes ordinary income by reason of a disqualifying disposition, we will generally be entitled (subject to the requirement of reasonableness and the satisfaction of a tax reporting obligation) to a corresponding business expense deduction in the tax year in which the disqualifying disposition occurs.
Non-Statutory Stock Options. Generally, there are no tax consequences to the optionee or us by reason of the grant of an NSO. Upon exercise of an NSO, the optionee normally will recognize taxable ordinary income equal to the excess of the stock’s fair market value on the date of exercise over the option exercise price. Generally, with respect to employees, the Company is required to withhold payroll and income taxes from regular wages or supplemental wage payments in an amount based on the ordinary income recognized. Subject to the requirement of reasonableness and the satisfaction of a reporting obligation, we will generally be entitled to a business expense deduction equal to the taxable ordinary income realized by the optionee. Upon disposition of the stock, the optionee will recognize a capital gain or loss equal to the difference between the selling price and the purchase price (to the extent not recognized as taxable income as described above). Slightly different rules may apply to optionees who acquire stock subject to certain repurchase options or who are subject to Section 16(b) of the Securities Exchange Act of 1934, as amended.



PROPOSAL 4:PROPOSAL 2: RATIFICATION OF APPOINTMENTSELECTION OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

By reason of the reverse merger of us and Dyadic-Florida consummated in October 2004, the historical financial statements of Dyadic-Florida have become the historical financial statements of us. Ernst & Young LLP had been the independent registered public accounting firm of our wholly-owned subsidiary Dyadic-Florida before the merger and has since been our independent registered public accounting firm.
Ernst & Young LLPMayer Hoffmann McCann P.C. (“MHM”), audited our consolidated financial statements for the year ended December 31, 2005.2019. We had no disagreements with Ernst & Young LLPMHM on accounting and financial disclosures. The audit committeeAudit Committee has appointed Ernst & Young LLPMHM to serve as our independent registered public accounting firm for the year ending December 31, 2006.2020. MHM has advised the Company that it has no direct or indirect financial interest in the Company. Substantially all MHM’s personnel, who work under the control of MHM shareholders, are employees of wholly-owned subsidiaries of CBIZ, Inc. (“CBIZ”), which provides personnel and various services to MHM in an alternative practice structure.

We are not required to submitThe Audit Committee has reviewed the appointmentfees described below and concluded that the payment of such fees is compatible with maintaining MHM’s independence.

The following table presents fees billed, by our independent registered public accounting firm for professional services, in the years indicated, by category, as described in the notes to a votethe table.
Years Ended December 31,
20192018
Audit fees (1)
$138,700  $146,000  
Audit-related fees (2)
11,000  25,500  
Tax fees (3)
13,500  42,900  
Total fees$163,200  $214,400  
___________
Notes:
(1) Audit fees consist of fees billed for professional services by MHM for audit and quarterly review of our stockholdersconsolidated financial statements or services that are normally provided by the accountant in connection with statutory and regulatory filing or engagement for ratification. However,those years related to our periodic and current OTC Markets (2018), NASDAQ Capital Markets, and SEC filings and registration statements.
22




(2) Audit-related fees consist of fees billed for professional services by MHM for assurance and related services that are reasonably related to the performance of the audit committee has recommendedor quarterly review of our consolidated financial statements that our board submit this matterare not reported under “Audit fees” above.
(3) Tax fees consist of fees billed for tax professional services by MHM with respect to stockholders as a matterthe IRS audit and by an affiliate of good corporate practice, which our board is doing. If stockholders fail to ratifyMHM for the appointment, the audit committee will reconsider whether to retain Ernst & Young LLP, and may retain that firm or another without re-submitting the matter to our stockholders. Even if our stockholders ratify the appointment, the audit committee may, in its discretion, direct the appointment of a different independent registered public accounting firm at any time during the year if it determines that such a change would be advisable and in the best interests of us and our stockholders.Netherlands subsidiary.

We expect one or more representatives of Ernst & Young LLPMHM to be present at the annual meeting.Annual Meeting. They will have the opportunity to make a statement if they desire to do so, and we expect them to be available to respond to appropriate questions.

Vote Required
Vote Required
The affirmative vote of the holders of a majority of all shares casting votes, either in person or by proxy, at the annual meetingAnnual Meeting is required to ratify the appointment of Ernst & Young LLPMHM as our independent registered public accounting firm for the year ending December 31, 2006.
Recommendation2020. You may vote FOR, AGAINST or ABSTAIN with respect to the ratification of the Board
Dyadic’s boardappointment of directors unanimously recommends a vote “FOR” this proposal.
Audit and Non-Audit Fees
Audit Fees
For the year ended December 31, 2005, Ernst & Young LLP billed us $398,179 in the aggregate for professional services rendered for the audit ofMHM as our consolidated statements, reviews of the financial statements included in our Quarterly Reports on Form 10-Q for the quarterly period ended March 31, June 30 and September 30, and the review of our registration statement on Form S-3 (formerly a registration statement on Form SB-2).
For the year ended December 31, 2004, Ernst & Young LLP billed us $709,977 in the aggregate for professional services rendered for the audit of our consolidated statements, reviews of the financial statements included in our Quarterly Reports on Form 10-Q for the quarterly period ended March 31, June 30 and September 30, and the review of our registration statement on Form SB-2.


Audit-Related Fees
For the years ended December 31, 2005 and 2004, Ernst & Young LLP did not bill us for audit-related fees, as no audit-related fees were performed by them during such years.
Tax Fees
For the years ended December 31, 2005 and 2004, Ernst & Young LLP did not bill us for tax fees, as no tax services were performed by them during such years.
All Other Fees
For the years ended December 31, 2005 and 2004, Ernst & Young LLP did not bill us for other services, as no other services were by performed by them during such years.
The audit committee has determined that the provision of services by the auditors reported hereunder had no impact on either of their independence.
Audit Committee’s Pre-Approval Policies and Procedures
Consistent with SEC policies regarding auditor independence, the audit committee is responsible for appointing, setting compensation and overseeing the work of the independent registered public accounting firm. In recognitionA properly executed proxy marked ABSTAIN with respect to this proposal will not be voted FOR or AGAINST this proposal. Broker non-votes will not be considered as votes cast FOR or AGAINST this proposal. Brokers have discretion to vote shares with respect to this proposal, unless a shareholder directs their broker otherwise.

Recommendation of the Board

The Company’s Board recommends a vote FORthis responsibility, the audit committee has established aproposal.

Pre-Approval of Services

Our Audit Committee’s policy is to pre-approve all audit and permissible non-audit services provided by our independent auditors. These services may include audit services, audit-related services, tax services and other services. Pre-approval is generally provided for up to one year and any pre-approval is detailed as to the particular service or category of services. The independent auditor and management are required to periodically report to the Audit Committee regarding the extent of services provided by the independent auditor in accordance with this pre-approval. Any proposed services not included within the list of pre-approved services or any proposed services that will cause the Company to exceed the pre-approved aggregate amount requires specific pre-approval by the Audit Committee. All audit fees, audit-related fees, tax fees, and other fees listed in the table above were approved by the Audit Committee pursuant to its pre-approval policies and procedures.

Audit Committee Report

The Audit Committee reports as follows:
The Company’s management has the primary responsibility for the Company’s financial statements and the reporting process, including disclosure controls and the system of internal control over financial reporting. The Audit Committee, in its oversight role has:
Reviewed and discussed the annual audited financial statements as of and for the fiscal year ended December 31, 2019 with management;
Discussed with the Company’s independent registered public accountants the overall scope of, and plans for, their respective audits and has met with the independent registered public accountants, with and without management present, to discuss the Company’s financial reporting process and internal accounting firm.controls in addition to other matters required to be discussed by Auditing Standard No. 1301, Communications with Audit Committees, as adopted by the Public Company Accounting Oversight Board (“PCAOB”), as may be modified or supplemented;
23
Prior to engagement



Received from the independent registered public accountants written disclosures and the letter regarding the independence of the independent registered public accounting firm foraccountants required by the next year’s audit, management will submitPCAOB, and has discussed with the independent registered accountants their independence from the Company and its management;
An established charter outlining the practices it follows. The Audit Committee’s charter is available on the Company’s website at www.dyadic.com under the heading “Investors”; and
Procedures that require the pre-approval by the Audit Committee of all fees paid to, and all services performed by, the audit committee for approval an aggregateCompany’s independent registered public accountants. The Audit Committee approves the proposed services, including the nature, type and scope of services expectedservice contemplated and the related fees, to be rendered by the firm during that year for eachthe year. In addition, engagements may arise during the course of the four categoriesyear that are outside the scope of services. Priorthe initial services and fees approved by the Audit Committee. Any such additional engagements are approved by the Audit Committee or by the Audit Committee Chair pursuant to engagement,authority delegated by the audit committee pre-approves these services byAudit Committee. For each category of service. The fees are budgeted, and the audit committee requiresproposed service, the independent registered public accounting firmaccountants are required to confirm that the provision of such services does not impair their independence. Pursuant to the Sarbanes-Oxley Act of 2002, the fees and services provided as noted above were authorized and approved by the Audit Committee in compliance with the pre-approval procedures described herein.

Based on the Audit Committee’s review and discussions with management to report actual fees versusand the budget periodically throughout the year by category of service. During the year, circumstances may arise when it may become necessary to engage theCompany’s independent registered public accounting firm for additional services not contemplatedaccountants as described in this report, the original pre-approval. In those instances, the audit committee requires specific pre-approval before engaging the independent registered public accounting firm.
The audit committee may delegate pre-approval authority to one or more of its members. The member to whom such authority is delegated must report, for informational purposes only, any pre-approval decisionsAudit Committee recommended to the audit committee at its next scheduled meeting.
MISCELLANEOUS
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a)Board of Directors that the Securities Exchange Actaudited Consolidated Financial Statements as of 1934 requires that our directors and executive officers, and persons who own more than 10 percent of our common stock, to file withfor the Securities and Exchange Commission initial reports of ownership and reports of changes in ownership of common stock. Officers, directors and greater than 10 percent stockholders are required by SEC regulation to furnish us with all Section 16 reports they file.
To our knowledge, based solely on a review of the copies of such reports furnished to us and representations that no other reports were required, we believe that all Section 16 filing requirements applicable to our officers, directors and 10 percent beneficial owners were complied with during thefiscal year ended December 31, 2005, other than a late filing for2019, be included in the 2019 Form 4 in December 2005 by director Stephen J. Warner for sales10-K.


Audit Committee of our common stock in November and December 2005.the Board of Directors

Jack L. Kaye, Chairman
Michael P. Tarnok
Arindam Bose



PROPOSAL 3: ADVISORY VOTE ON COMPENSATION OF
Annual Report
THE COMPANY’S NAMED EXECUTIVE OFFICERS

Proposal 3 seeks an advisory vote on Form 10-KSB
We have mailed copies of our 2005 annual report with this proxy statement to holders of shares of our common stock asthe compensation of the record date. We will provide without charge,Company’s Named Executive Officers. Shareholders are urged to each holderread the “Compensation and Other Information Concerning Officers” section of shares of common stock as ofthis Proxy Statement and the record date, a copy“Executive Compensation” section of our Annual Report on Form 10-KSB10-K, which discusses the Company’s executive compensation policies and procedures and contains tabular information and narrative discussion about the compensation of the Named Executive Officers.

As an advisory vote, this proposal is not binding upon the Company. However, the Compensation Committee, which is responsible for determining and setting the Named Executive Officers’ executive compensation, values the opinions expressed by shareholders in their vote on this proposal, and will consider the outcome of the vote when making future compensation decisions for the year ended December 31, 2005,Named Executive Officers.

Vote Required

The votes that shareholders cast FOR must exceed the votes that unit owners cast AGAINST to approve the advisory vote on compensation of our Named Executive Officers. You may vote FOR, AGAINST, of ABSTAIN with respect to the advisory vote on compensation of our Names Executive Officers. A properly executed proxy marked ABSTAIN with respect to this proposal will not be voted FOR of AGAINST this proposal. Broker non-votes will not be considered as filed withvotes cast FOR or AGAINST this proposal.

Recommendation of the SEC, uponBoard

The Board recommends that you consider and vote FOR the written requestfollowing resolution: “Resolved, that the shareholders approve, on an advisory basis, the compensation of anythe Company’s Named Executive Officers, as disclosed in the Company’s Proxy Statement and Form 10-K pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the “Compensation and Other Information Concerning Officers” and “Executive Compensation” sections of such holderdocuments.”

Because your vote is advisory on Proposal 3, it will not be binding on the Board or the Company. However, the Board and the Compensation Committee will review the voting results and take them into consideration when making future decisions regarding the Named Executive Officers’ compensation.

SHAREHOLDER PROPOSALS FOR THE 2021 ANNUAL MEETING

Shareholders of the Company wishing to include proposals in the proxy material relating to the 2021 Annual Meeting of Shareholders must submit the same in writing so as to be received at the executive offices of the Company on or before January 9, 2021. Such proposals must also meet the other requirements of the rules of the Securities and Exchange Commission relating to shareholder proposals. Proposals should be addressed to the Secretary of Dyadicthe Company at its offices, at 140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477. We will provide copies of

For any exhibit to the Annual Report on Form 10-KSB upon written request and upon reimbursement of any reasonable expenses incurred by us in furnishing the exhibit.
Stockholder Proposals
Pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, some stockholder proposals may be eligibleproposal that is not submitted for inclusion in ournext year’s proxy statement for our 2007 annual meeting(as described in the preceding paragraph) but is instead sought to be presented directly at the 2021 Annual Meeting of stockholders. To be eligible for inclusionShareholders, the rules of the SEC permit the individuals named as proxies to vote shares represented by properly executed proxies in our 2007 proxy statement, any such proposals must be delivered in writing toeach individual’s discretion if the SecretaryCompany receives notice of Dyadicthe proposal no earlier than March 1, 2021 but no later than December 28, 2006,March 31, 2021. Notices of intention to present proposals at the 2021 Annual Meeting of Shareholders should be addressed to Secretary of the Company at its offices, at 140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477.



25




FORWARD-LOOKING STATEMENTS
This proxy statement contains forward-looking statements that involve risks and must meetuncertainties, as well as assumptions that, if they do not fully materialize or prove incorrect, could cause our business, results or condition to differ materially from those expressed or implied by the requirementsforward-looking statements. The forward-looking statements include, without limitation, statements related to the timing and expected impact of Rule 14a-8the completion of the Transaction and related transactions. You can identify these and other forward-looking statements by the use of words such as “will,” “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “intends,” “potential,” “continue,” or the negative of those terms, or other comparable terminology.
Risks and uncertainties that may affect our business, results or condition include, but are not limited to, factors discussed in our publicly available filings, including information set forth under the Securities Exchange Act of 1934. The submission of a stockholder proposal does not guarantee that it will be includedcaption “Risk Factors” in our Annual Report filed on Form 10-K. Any forward-looking statement made in this proxy statement.
Stockholders who do not wish to follow the SEC rules in proposing a matter for action at the 2007 annual meeting of stockholders must notify Dyadic in writing of the information required by Dyadic’s amended and restated bylaws dealing with stockholder proposals. The notice must be delivered to Dyadic’s Secretary not later than the close of business on March 14, 2007 nor earlier than February 12, 2007.
Other Matters
Asstatement speaks only as of the date ofon which we make it. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. We have no duty to, and do not intend to, update or revise the forward-looking statements in this proxy statement, our board of directors does notexcept as may be required by law.

OTHER MATTERS
We know of anyno other matters that will be presented for consideration at the annual meeting other than as described in this proxy statement.Annual Meeting. If however, any other matters are properly broughtcome before the annual meeting, it is intended thatAnnual Meeting, the persons named as proxies willshall vote the shares they represent in accordance with their best judgmentjudgment. Discretionary authority with respect to such matters.
By Orderother matters is granted by the execution of the Boardenclosed proxy. It is important that you return your proxy promptly and that your shares be represented. You are urged to vote either by internet, phone or, if you received paper copies of Directors,the proxy materials, by mail. If by mail, please mark, date, and sign and return the proxy in the accompanying reply envelope, per the instructions on the proxy card.
                                                                           Mark A. Emalfarb signature      
26
Mark A. Emalfarb
Chairman, President and Chief Executive Officer



37

INCORPORATION OF INFORMATION BY REFERENCE
Table of ContentsWe “incorporate by reference” into this proxy statement the following information, which can be accessed from our website at www.dyadic.com

DYADIC INTERNATIONAL, INC.
2001 EQUITY COMPENSATION PLAN
As Amended and Restated Effective January 1, 2005
RECITALS:
WHEREAS, effective as of May 22, 2001, the Company adopted the Dyadic International, Inc. 2001 Equity Compensation Plan (the “Plan”) to provide (i) designated employees of the Company and its subsidiaries, (ii) certain consultants and advisors who perform services for the Company or its subsidiaries and (iii) non-employee members of the Board of Directors of the Company (the “Board”),is filed with the opportunity to receive grants of incentive stock options, nonqualified stock options, stock awards and performance units; and
WHEREAS, the Company believed that the Plan would encourage the participants to contribute materially to the growth of the Company, thereby benefiting the Company’s shareholders, and would align the economic interests of the participants with those of the shareholders; and
WHEREAS, section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), as added by the American Jobs Creation Act of 2004, made certain changes to the rules applicable to amounts deferred under nonqualified deferred compensation plans on or after January 1, 2005; and
WHEREAS, the Company now wishes to amend and restate the Plan effective January 1, 2005, to comply with section 409A of the Code, and to make certain other changes to the Plan.
NOW, THEREFORE, the Company hereby amends and restates the Plan in its entirety to read as follows:
1.Administration.
(a)Committee. The Plan shall be administered by a committee appointed by the Board (the “Committee”, which may consist of two or more persons who are “outside directors” as defined under section 162(m) of the Code, and related Treasury regulations and “non-employee directors” as defined under Rule 16b-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). However, the Board may ratify or approve any grants as it deems appropriate.
(b)Committee Authority. The Committee shall have the sole authority to (i) determine the individuals to whom grants shall be made under the Plan, (ii) determine the type, size and terms of the grants to be made to each such individual, (iii) determine the time when the grants will be made and the duration of any applicable exercise or restriction period, including the criteria for exercisability and the acceleration of exercisability, (iv) amend the terms of any previously issued grant, and (v) deal with any other matters arising under the Plan. Notwithstanding the authority granted to the Committee in (iii) and (iv) above, the Plan shall prohibit the acceleration of the time or schedule of any payment of deferred compensation, except to the extent permitted under section 409A of the Code and the Treasury regulations thereunder.


(c)Committee Determinations. The Committee shall have full power and authority to administer and interpret the Plan, to make factual determinations and to adopt or amend such rules, regulations, agreements and instruments for implementing the Plan and for the conduct of its business as it deems necessary or advisable, in its sole discretion. The Committee’s interpretations of the Plan and all determinations made by the Committee pursuant to the powers vested in it hereunder shall be conclusive and binding on all persons having any interest in the Plan or in any awards granted hereunder. All powers of the Committee shall be executed in its sole discretion, in the best interest of the Company, not as a fiduciary, and in keeping with the objectives of the Plan and need not be uniform as to similarly situated individuals.
2.Grants.
Awards under the Plan may consist of grants of incentive stock options as described in Section 5 (“Incentive Stock Options”), nonqualified stock options as described in Section 5 (“Nonqualified Stock Options”), Incentive Stock Options and Nonqualified Stock Options are collectively referred to as “Options,” stock awards as described in Section 6 (“Stock Awards”), and performance units as described in Section 7 (“Performance Units”) (hereinafter collectively referred to as “Grants”). All Grants shall be subject to the terms and conditions set forth herein and to such other terms and conditions consistent with this Plan as the Committee deems appropriate and as are specified in writing by the Committee to the individual in a grant instrument or an amendment to the grant instrument (the “Grant Instrument”). The Committee shall approve the form and provisions of each Grant Instrument. Grants under a particular Section of the Plan need not be uniform as among the grantees.
3.Shares Subject to the Plan.
(a)Shares Authorized. Subject to adjustment as described below, the aggregate number of shares of common stock of the Company (“Company Stock”) that may be issued or transferred under the Plan is 4,478,475 shares. The maximum aggregate number of shares of Company Stock that shall be subject to Grants made under the Plan to any individual during any calendar year shall be 1,200,000 shares, subject to adjustment as described below. The shares may be authorized but unissued shares of Company Stock or reacquired shares of Company Stock, including shares purchased by the Company on the open market for purposes of the Plan. If and to the extent Options granted under the Plan terminate, expire, or are canceled, forfeited, exchanged or surrendered without having been exercised or if any Stock Awards or Performance Units are forfeited, the shares subject to such Grants shall again be available for purposes of the Plan.
(b)Adjustments. If there is any change in the number or kind of shares of Company Stock outstanding (1) by reason of a stock dividend, spinoff, recapitalization, stock split, or combination or exchange of shares, (ii) by reason of a merger, reorganization or consolidation in which the Company is the surviving corporation, (iii) by reason of a reclassification or change in par value, or (iv) by reason of any other extraordinary or unusual event affecting the outstanding Company Stock as a class without the Company’s receipt of consideration, or if the value of outstanding shares of Company Stock is substantially reduced as a result of a spinoff or the Company’s payment of an extraordinary dividend or distribution, the maximum number of shares of Company Stock available for Grants, the maximum number of shares of Company Stock that any individual participating in the Plan may be panted in any year, the number of shares covered by outstanding Grants, the kind of shares issued under the Plan, and the price per share or the applicable market value of such Grants may be appropriately adjusted by the Committee to reflect any increase or decrease in the number of, or change in the kind or value of, issued shares of Company Stock to preclude, to the extent practicable, the enlargement or dilution of rights and benefits under such Grants; provided, however, that any fractional shares resulting from such adjustment shall be eliminated. Any adjustments determined by the Committee shall be final, binding and conclusive.
4.Eligibility for Participation.
(a)Eligible Persons. All employees of the Company and its subsidiaries (“Employees”), including Employees who are officers or members of the Board, and members of the Board who are not Employees (“Non-Employee Directors”) shall be eligible to participate in the Plan. Consultants and advisors who perform services for the Company or any of its subsidiaries (“Key Advisors”) shall be eligible to participate in the Plan if the Key Advisors render bona fide services to the Company or its subsidiaries, the services are not in connection with the offer and sale of securities in a capital-raising transaction and the Key Advisors do not directly or indirectly promote or maintain a


 market for the Company’s securities.
(b)Selection of Grantees. The Committee shall select the Employees, Non-Employee Directors and Key Advisors to receive Grants and shall determine the number of shares of Company Stock subject to a particular Grant in such manner as the Committee determines. Employees, Key Advisors and Non-Employee Directors who receive Grants under this Plan shall hereinafter be referred to as “Grantees.”
5.Granting of Options.
(a)Number of Shares. The Committee shall determine the number of shares of Company Stock that will be subject to each Grant of Options to Employees, Non-Employee Directors and Key Advisors.
(b)Type of Option and PriceSEC.
(i)The Committee may grant Incentive Stock Options that are intended to qualify as “incentive stock options” within the meaning of section 422 of the Code or Nonqualified Stock Options that are not intended so to qualify or any combination of Incentive Stock Options and Nonqualified Stock Options, all in accordance with the terms and conditions set forth herein. Incentive Stock Options may be granted only to Employees. Nonqualified Stock Options may be granted to Employees, Non-Employee Directors and Key Advisors.
(ii)The purchase price (the “Exercise Price”) of Company Stock subject to an Option shall be determined by the Committee and shall be equal to or greater than the Fair Market Value (as defined below) of a share of Company Stock on the date the Option is granted; provided, however, that an Incentive Stock Option may not be granted to an Employee who, at the time of grant, owns stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or any parent or subsidiary of the Company, unless the Exercise Price per share is not less than one hundred ten percent (110%) of the Fair Market Value of Company Stock on the date of grant.
(iii)If the Company Stock is publicly traded, then the Fair Market Value per share shall be determined as follows: (x) if the principal trading market for the Company Stock is a national securities exchange or the Nasdaq National Market, the last reported sale price thereof on the relevant date or (if there were no trades on that date) the latest preceding date upon which a sale was reported or (y) if the Company Stock is not principally traded on such exchange or market, the mean between the last reported “bid” and “asked” prices of Company Stock on the relevant date, as reported on Nasdaq or, if not so reported, as reported by the National Daily Quotation Bureau, Inc. or as reported in a customary financial reporting service, as applicable and as the Committee determines. If the Company Stock is not publicly traded or, if publicly traded, is not subject to reported transactions or “bid” or “asked” quotations as set forth above, the Fair Market Value per share shall be as determined by the Committee.
(c)Option Term. The Committee shall determine the term of each Option. The term of any Option shall not exceed ten years from the date of grant. However, an Incentive Stock Option that is granted to an Employee who, at the time of grant owns stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company, or any parent or subsidiary of the Company, may not have a term that exceeds five years from the date of grant.
(d)Exercisability of Options. Options shall become exercisable in accordance with such terms and conditions, consistent with the Plan, as may be determined by the Committee and specified in the Grant Instrument. The Committee may waive or accelerate the satisfaction of an exercise term or condition of any or all outstanding Options at any time for any reason in the event the Exercise Price was equal to or greater than the Fair Market Value of the underlying shares of Company Stock on the date of grant, to the extent permitted under section 409A of the Code and the Treasury regulations thereunder.
(e)Termination of Employment, Disability or Death.


       (i)Except as provided below, an Option may only be exercised while the Grantee is employed by, or providing service to, the Company as an Employee, Key Advisor or member of the Board. In the event that a Grantee ceases to be employed by, or provide service to, the Company for any reason other than Disability, death, or termination for Cause (as defined below), any Option which is otherwise exercisable by the Grantee shall terminate unless exercised within 90 days after the date on which the Grantee ceases to be employed by, or provide service to, the Company (or within such, other period of time as may be specified by the Committee), but in any event no later than the date of expiration of the Option term. Except as otherwise provided by the Committee any of the Grantee’s Options that are not otherwise exercisable as of the date on which the Grantee ceases to be employed by, or provide service to, the Company shall terminate as of such date.
(ii)In the event the Grantee ceases to be employed by, or provide service to, the Company on account of a termination for Cause by the Company, any Option held by the Grantee shall terminate as of the date the Grantee ceases to be employed by, or provide service to, the Company. In addition, notwithstanding any other provisions of this Section 5, if the Committee determines that the Grantee has engaged in conduct that constitutes Cause at any time while the Grantee is employed by, or providing service to, the Company or after the Grantee’s termination of employment or service, any Option held by the Grantee shall immediately terminate and the Grantee shall automatically forfeit all shares underlying any exercised portion of an Option for which the Company has not yet delivered the share certificates, upon refund by the Company of the Exercise Price paid by the Grantee for such shares. Upon any exercise of an Option, the Company may withhold delivery of share certificates pending resolution of an inquiry that could lead to a finding resulting in a forfeiture.
(iii)In the event the Grantee ceases to be employed by, or provide service to, the Company because the Grantee is Disabled, any Option which is otherwise exercisable by the Grantee shall terminate unless exercised within one year after the date on which the Grantee ceases to be employed by, or provide service to, the Company (or within such other period of time as may be specified by the Committee), but in any event no later than the date of expiration of the Option term.
Except as otherwise provided by the Committee, any of the Grantee’s Options which are not otherwise exercisable as of the date on which the Grantee ceases to be employed by, or provide service to, the Company shall terminate as of such date.
(iv)If the Grantee dies while employed by, or providing service to, the Company or within 90 days after the date on which the Grantee ceases to be employed or provide service on account of a termination specified in Section 5(e)(i) above (or within such other period of time as may be specified by the Committee), any Option that is otherwise exercisable by the Grantee shall terminate unless exercised within one year after the date on which the Grantee ceases to be employed by, or provide service to, the Company (or within such other period of time as may be specified by the Committee), but in any event no later than the date of expiration of the Option term. Except as otherwise provided by the Committee, any of the Grantee’s Options that are not otherwise exercisable as of the date on which the Grantee ceases to be employed by, or provide service to, the Company shall terminate as of such date.
(v)For purposes of this Section 5(e), and Sections 6 and 7:
(A)The term “Company” shall mean the Company and its parent and subsidiary corporations or other entities, as determined by the Committee.
                                (B)“Employed by, or provide service to, the Company” shall mean employment or service as an Employee, Key Advisor or member of the Board (so that, for purposes of exercising Options and satisfying conditions with respect to Stock Awards and Performance Units, a Grantee shall not be considered to have terminated employment or service until the Grantee ceases to be an Employee, Key Advisor and member of the Board), unless the Committee determines otherwise.
                                (C)“Disability” shall mean a Grantee’s becoming disabled within the meaning of section 22(e)(3) of the Code.



(D)“Cause” shall mean, except to the extent specified otherwise by the Committee, a finding by the Committee that the Grantee (i) has breached his or her employment or service contract with the Company, (ii) has engaged in disloyalty to the Company, including, without limitation, fraud, embezzlement, theft, commission of a felony or proven dishonesty in the course of his or her employment or service, (iii) has disclosed trade secrets or confidential information of the Company to persons not entitled to receive such information or (iv) has engaged in such other behavior detrimental to the interests of the Company as the Committee determines.
(f)Exercise of Options. A Grantee may exercise an Option that has become exercisable, in whole or in part, by delivering a notice of exercise to the Company with payment of the Exercise Price. The Grantee shall pay the Exercise Price for an Option as specified by the Committee (w) in cash, (x) with the approval of the Committee, by delivering shares of Company Stock owned by the Grantee (including Company Stock acquired in connection with the exercise of an Option, subject to such restrictions as the Committee deems appropriate) and having a Fair Market Value on the date of exercise equal to the Exercise Price or by attestation (on a form prescribed by the Committee) to ownership of shares of Company Stock having a Fair Market Value on the date of exercise equal to the Exercise Price, (y) pay through a broker in accordance with procedures permitted by Regulation T of the Federal Reserve Board, or (z) by such other method as the Committee may approve. The Committee may authorize loans by the Company to Grantees in connection with the exercise of an Option, upon such terms and conditions as the Committee, in its sole discretion, deems appropriate. Shares of Company Stock used to exercise an Option shall have been held by the Grantee for the requisite period of time to avoid adverse accounting consequences to the Company with respect to the Option. The Grantee shall pay the Exercise Price and the amount of any withholding tax due at the time of exercise.
(g)Limits on Incentive Stock Options. Each Incentive Stock Option shall provide that, if the aggregate Fair Market Value of the stock on the date of the grant with respect to which Incentive Stock Options are exercisable for the first time by a Grantee during any calendar year, under the Plan or any other stock option plan of the Company or a parent or subsidiary, exceeds $100,000, then the Option, as to the excess, shall be treated as a Nonqualified Stock Option. An Incentive Stock Option shall not be granted to any person who is not an Employee of the Company or a parent or subsidiary (within the meaning of section 424(f) of the Code).
6.Stock Awards.
The Committee may issue or transfer shares of Company Stock to an Employee, non-Employee Director or Key Advisor under a Stock Award, upon such terms as the Committee deems appropriate. The following provisions are applicable to Stock Awards:
(a)General Requirements. Shares of Company Stock issued or transferred pursuant to Stock Awards may be issued or transferred for consideration or for no consideration, and subject to restrictions or no restrictions, as determined by the Committee. The Committee may, but shall not be required to, establish conditions under which restrictions on Stock Awards shall lapse over a period of time or according to such other criteria as the Committee deems appropriate, including, without limitation, restrictions based upon the achievement of specific performance goals. The period of time during which the Stock Awards will remain subject to restrictions will be designated in the Grant Instrument as the “Restriction Period.”
(b)Number of Shares. The Committee shall determine the number of shares of Company Stock to be issued or transferred pursuant to a Stock Award and the restrictions applicable to such shares.
(c)Requirement of Employment or Services. If the Grantee ceases to be employed by, or provide service to, the Company (as defined in Section 5(e)) during a period designated in the Grant Instrument as the Restriction Period, or if other specified conditions are not met, the Stock Award shall terminate as to all shares covered by the Grant as to which the restrictions have not lapsed, and those shares of Company Stock must be immediately returned to the Company. The Committee may, however, provide for complete or partial exceptions to this requirement as it deems appropriate.


(d)Restrictions on Transfer and Legend Stock Certificate. During the Restriction Period, a Grantee may not sell, assign, transfer, pledge or otherwise dispose of the shares of a Stock Award except to a Successor Grantee under Section 11(a). Each certificate for a share of a Stock Award shall contain a legend giving appropriate notice of the restrictions in the Grant. The Grantee shall be entitled to have the legend removed from the stock certificate covering the shares subject to restrictions when all restrictions on such shares have lapsed. The Committee may determine that the Company will not issue certificates for Stock Awards until all restrictions on such shares have lapsed, or that the Company will retain possession of certificates for shares of Stock Awards until all restrictions on such shares have lapsed.
(e)Right to Vote and to Receive Dividends. Unless the Committee determines otherwise, during the Restriction Period, the Grantee shall have the right to vote shares of Stock Awards and to receive any dividends or other distributions paid on such shares, subject to any restrictions deemed appropriate by the Committee, including, without limitation, the achievement of specific performance goals. In the event the Grantee has the right to receive dividends or other distributions paid on shares of any Stock Award, the Grant Instrument shall be prepared to comply with the applicable requirements of section 409A of the Code and shall be interpreted in a manner consistent with such requirements.
(f)Lapse of Restrictions. All restrictions imposed on Stock Awards shall lapse upon the expiration of the applicable Restriction Period and the satisfaction of all conditions imposed by the Committee. The Committee may determine, as to any or all Stock Awards, that the restrictions shall lapse without regard to any Restriction Period.
(g)Code Section 409A. The terms and conditions set forth in Grant Instruments for Stock Awards shall be prepared to comply with the applicable requirements of section 409A of the Code and interpreted in a manner consistent with such requirements to the extent the Committee believes the Stock Award is subject to such requirements.
7.Performance Units.
(a)General Requirements. The Committee may grant performance units (“Performance Units”) to an Employee or Key Advisor. Each Performance Unit shall represent the right of the Grantee to receive an amount based on the value of the Performance Unit, if performance goals established by the Committee are met. The value of a Performance Unit shall equal the Fair Market Value of a share of Company Stock. The Committee shall determine the number of Performance Units to be granted and the requirements applicable to such Units.
(b)Performance Period and Performance Goals. When Performance Units are granted, the Committee shall establish the performance period during which performance shall be measured (the “Performance Period”), performance goals applicable to the Units (“Performance Goals”) and such other conditions of the Grant as the Committee deems appropriate. Performance Goals may relate to the financial performance of the Company or its operating units, the performance of Company Stock, individual performance, or such other criteria as the Committee deems appropriate. Performance Units shall be subject to the following criteria:
(i)Minimum Duration of Performance Period. The Committee shall not establish a Performance Period which has a duration of less than twelve (12) consecutive months.
(ii)Pre-established Performance Goals. The Committee shall establish the Performance Goals in writing no later than ninety (90) days after the commencement of the Performance Period, provided that the outcome is substantially uncertain at the time the Performance Goals are established.
(iii)Initial Deferral Election. An Employee or Key Advisor receiving a Grant of Performance Units must make a deferral election no later than the date which is six (6) months before the end of the Performance Period, provided that in no event may a deferral election be made after such Performance Goals have become both substantially certain to be paid and readily ascertainable.


(iv)Code Section 409A. The terms and conditions set forth in a Grant of Performance Units shall comply with the applicable requirements of section 409A of the Code and interpreted in a manner consistent with such requirements to the extent the Committee believes a Grant of Performance Units is subject to such requirements.
(c)Payment with respect to Performance Units. At the end of each Performance Period, the Committee shall determine to what extent the Performance Goals and other conditions of the Performance Units are met, the value of the Performance Units (if applicable), and the amount, if any, to be paid with respect to the Performance Units. Payments with respect to Performance Units shall be made in cash, in Company Stock or in a combination of the two, as determined by the Committee.
(d)Requirement of Employment or Service. If the Grantee ceases to be employed by, or provide service to, the Company (as defined in Section 5(e)) during a Performance Period, or if other conditions established by the Committee are not met, the Grantee’s Performance Units shall be forfeited. The Committee may, however, provide for complete or partial exceptions to this requirement as it deems appropriate.
8.Qualified Performance-Based Compensation.
(a)Designation as Qualified Performance-Based Compensation. The Committee may determine that Performance Units or Stock Awards granted to an Employee shall be considered “qualified performance-based compensation” under Section 162(m) of the Code. The provisions of this Section 8 shall apply to Grants of Performance Units and Stock Awards that are to be considered “qualified performance-based compensation” under section 162(m) of the Code.
(b)Performance Goals. When Performance Units or Stock Awards that are to be considered “qualified performance-based compensation” are granted, the Committee shall establish in writing (i) the objective performance goals that must be met in order for restrictions on the Stock Awards to lapse or amounts to be paid under the Performance Units, (ii) the Performance Period during which the performance goals must be met, (iii) the threshold, target and maximum amounts that may be paid if the performance goals are met, and (iv) any other conditions that the Committee deems appropriate and consistent with the Plan and section 162(m) of the Code. The performance goals may relate to the Employee’s business unit or the performance of the Company and its subsidiaries as a whole, or any combination of the foregoing. The Committee shall use objectively determinable performance goals based on one or more of the following criteria: stock price, earnings per share, net earnings, operating earnings, return on assets, shareholder return, return on equity, growth in assets, achievement of regulatory approvals or patents, sales, market share or strategic business criteria consisting of one or more objectives based on meeting specified revenue goals, market penetration goals, geographic business expansion goals, cost targets, scientific milestones, commercial milestones, goals relating to acquisitions or divestitures, joint ventures or strategic partnerships.
(c)Establishment of Goals. The Committee shall establish the performance goals in writing either before the beginning of the Performance Period or during a period ending no later than the earlier of (i) ninety (90) days after the commencement of the Performance Period or (ii) the date on which twenty-five percent (25%) of the Performance Period has been completed, or such other date as may be required or permitted under applicable regulations under sections 162(m) and 409A of the Code. The performance goals shall satisfy the requirements for “qualified performance-based compensation,” including the requirement that the achievement of the goals be substantially uncertain at the time they are established and that the goals be established in such a way that a third party with knowledge of the relevant facts could determine whether and to what extent the performance goals have been met. The Committee shall not have discretion to increase the amount of compensation that is payable upon achievement of the designated performance goals.
(d)Initial Deferral Election. A Grantee receiving a Grant of qualified performance-based compensation must make any deferral election allowed under Section 9 no later than the date which is six (6) months before the end of the Performance Period, provided that in no event may a deferral election be made after such Performance Goals have become both substantially certain to be paid and readily ascertainable.


(e)Code Section 409A. The terms and conditions set forth in a Grant of qualified performance-based compensation shall comply with the applicable requirements of section 409A of the Code and interpreted in a manner consistent with such requirements to the extent the Committee believes a Grant of qualified performance-based compensation is subject to such requirements.
(f)Maximum Payment. Performance Units and Stock Awards under this Section 8 may be granted to an Employee with respect to not more than 250,000 shares of Company Stock for any Performance Period.
(g)Announcement of Grants. The Committee shall certify and announce the results for each Performance Period to all Grantees immediately following the announcement of the Company’s financial results for the Performance Period. If and to the extent that the Committee does not certify that the performance goals have been met, the grants of Stock Awards or Performance Units for the Performance Period shall be forfeited.
(h)Death, Disability, Change of Control or Other Circumstances. The Committee may provide in the award that Performance Units shall be payable or restrictions on Stock Awards shall lapse, in whole or in part, in the event of the Grantee’s death or Disability (as defined in Section 5(e) above) during the Performance Period, or under other circumstances consistent with the regulations and rulings under sections 162(m) and 409A of the Code, and the provisions of Section 13 shall apply in the event of a Change of Control.
9.Deferrals.
The Committee may permit or require a Grantee to defer receipt of the payment of cash or the delivery of shares that would otherwise be due to such Grantee in connection with any Option, the lapse or waiver of restrictions applicable to Stock Awards, or the satisfaction of any requirements or objectives with respect to Performance Units. Awards shall comply with the applicable requirements of section 409A of the Code and be interpreted in a consistent manner whenever (a) the Grantee is permitted to defer receipt of the payment of cash or the delivery of stock, or (b) the Committee’s lapse or waiver of restrictions brings the compensatory arrangement within the requirements of section 409A of the Code.
10.Withholding of Taxes.
(a)Required Withholding. All Grants under the Plan shall be subject to applicable federal (including FICA), state and local tax withholding requirements. The Company shall have the right to deduct from all Grants paid in cash, or from other wages paid to the Grantee, any federal, state or local taxes required by law to be withheld with respect to such Grants. In the case of Options, Stock Awards and other Grants paid in Company Stock, the Company may require that the Grantee or other person receiving or exercising Grants pay to the Company the amount of any federal, state or local taxes that the Company is required to withhold with respect to such Grants, or the Company may deduct from other wages paid by the Company the amount of any withholding taxes due with respect to such Grants.
(b)Election to Withhold Shares. If the Committee so permits, a Grantee may elect to satisfy the Company’s income tax withholding obligation with respect to Options, Stock Awards or Performance Units paid in Company Stock by having shares withheld up to an amount that does not exceed the Grantee’s minimum applicable withholding tax rate for federal (including FICA), state and local tax liabilities. The election must be in a form and manner prescribed by the Committee and may be subject to the prior approval of the Committee.
11.Transfer of Grants.
(a)Nontransferability of Grants. Except as provided below, only the Grantee may exercise rights under a Grant during the Grantee’s lifetime. A Grantee may not transfer those rights except by will or by the laws of descent and distribution or, with respect to Grants other than Incentive Stock Options, if permitted in any specific case by the Committee, pursuant to a domestic relations order. When a Grantee dies, the personal representative or other person entitled to succeed to the rights of the Grantee (“Successor Grantee”) may exercise such rights. A Successor Grantee must furnish proof satisfactory to the Company of his or her right to receive the Grant under the Grantee’s will or under the applicable laws of descent and distribution.


(b)Transfer of Nonqualified Stock Options. Notwithstanding the foregoing, the Committee may provide, in a Grant Instrument, that a Grantee may transfer Nonqualified Stock Options to immediate family members, or one or more trusts or other entities for the benefit of or owned by immediate family members, consistent with the applicable securities laws, according to such terms as the Committee may determine; provided that the Grantee receives no consideration for the transfer of an Option and the transferred Option shall continue to be subject to the same terms and conditions as were applicable to the Option immediately before the transfer.
12.Change of Control of the Company.
As used herein, a “Change of Control” shall be deemed to have occurred if:
(a)Any “person” (defined to have the meaning in this definition of Change of Control as is assigned that term in sections 13(d) and 14(d) of the Exchange Act) other than an “Excluded Shareholder” (as defined herein) becomes a “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the voting power of the then outstanding securities of the Company; provided that a Change of Control shall not be deemed to occur as a result of a transaction in which the Company becomes a subsidiary of another corporation and in which the shareholders of the Company, immediately prior to the transaction, will beneficially own, immediately after the transaction, shares entitling such shareholders to more than fifty percent (50%) of all votes to which all shareholders of the parent corporation would be entitled in the election of directors (without consideration of the rights of any class of stock to elect directors by a separate class vote); the term “Excluded Shareholder” meaning, for purposes of this definition of Change of Control, any person who is the beneficial owner, directly or indirectly of more than twenty percent (20%) of the voting power of the then outstanding securities of the Company; or
(b)The shareholders of the Company approve (or, if shareholder approval is not required, the Board approves) an agreement providing for (i) the merger or consolidation of the Company with another corporation where the shareholders of the Company, immediately prior to the merger or consolidation, will not beneficially own, immediately after the merger or consolidation, shares entitling such shareholders to more than fifty percent (50%) of all votes to which all shareholders of the surviving corporation would be entitled in the election of directors (without consideration of the rights of any class of stock to elect directors by a separate class vote) or (ii) the sale or other disposition of assets equal to or greater than forty percent (40%) of the total gross fair market value of all assets of the Company immediately prior to such sale or disposition.
13.Consequences of a Change Control.
(a)Assumption of Grants. Upon a Change of Control where the Company is not the surviving corporation (or survives only as a subsidiary of another corporation), unless the Committee determines otherwise, all outstanding Options that are not exercised shall be assumed by, or replaced with comparable options or rights by the surviving corporation (or a parent of the surviving corporation), and other outstanding Grants shall he converted to similar grants of the surviving corporation (or a parent of the surviving corporation).
(b)Other Alternatives. Notwithstanding the foregoing, the Committee may provide in the Grant Instrument that one or more of the following actions shall occur in the event of a Change of Control: (i) outstanding Options shall automatically accelerate and become fully exercisable and that the restrictions and conditions on outstanding Stock Awards shall immediately lapse, (ii) Grantees holding Performance Units shall receive a payment in settlement of such Performance Units in an amount determined by the Committee, (iii) Grantees shall surrender their outstanding Options in exchange for a payment by the Company, in cash or Company Stock as determined by the Committee, in an amount equal to the amount by which the then Fair Market Value of the shares of Company Stock subject to the Grantee’s unexercised Options exceeds the Exercise Price of the Options, or (iv) giving Grantees an opportunity to exercise their outstanding Options, terminate any or all unexercised Options at such time as the Committee deems appropriate. Such surrender, termination or settlement shall take place as of the date of the Change of Control or such other date as the Committee may specify. The Committee shall have no obligation to take any of the foregoing actions, and, in the absence of any such actions, outstanding Grants shall continue in effect according to their terms (subject to any assumption pursuant to Subsection (a)).


14.Requirements for Issuance or Transfer of Shares.
(a)Limitations on Issuance or Transfer of Shares. No Company Stock shall be issued or transferred in connection with any Grant hereunder unless and until all legal requirements applicable to the issuance or transfer of such Company Stock have been complied with to the satisfaction of the Committee. The Committee shall have the right to condition any Grant made to any Grantee hereunder on such Grantee’s undertaking in writing to comply with such restrictions on his or her subsequent disposition of such shares of Company Stock as the Committee shall deem necessary or advisable, and certificates representing such shares may be legended to reflect any such restrictions. Certificates representing shares of Company Stock issued or transferred under the Plan will be subject to such stop-transfer orders and other restrictions as may be required by applicable laws, regulations and interpretations, including any requirement that a legend be placed thereon.
(b)Lock-Up Period. If so requested by the Company or any representative of the underwriters (the “Managing Underwriter”) in connection with any underwritten offering of securities of the Company under the Securities Act of 1933, as amended (the “Securities Act”) a Grantee (including any successors or assigns) shall not sell or otherwise transfer any shares or other securities of the Company during the 30-day period preceding and the 180-day period following the effective date of a registration statement of the Company filed under the Securities Act for such underwriting (or such shorter period as may be requested by the Managing Underwriter and agreed to by the Company) (the “Market Standoff Period”). The Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such Market Standoff Period. Certificates representing Company stock issued upon exercise of Options or otherwise pursuant to the Plan shall bear such legend regarding the lock-up period obligations as counsel to the Company shall determine.
(c)Sales to Competitors. Prior to the initial public offering of shares of Company common stock, no Company stock issued in connection with any Grant hereunder may be sold, assigned or otherwise transferred to any competitor of the Company or any entity which owns in excess of one percent (1%) of the voting stock of any such competitor, provided Grantee has actual knowledge of such ownership. Certificates representing shares of Company stock so issued in connection with a Grant hereunder shall bear such legend regarding sales to competitors and other obligations as counsel to the Company shall determine.
15.Amendment and Termination of the Plan.
(a)Amendment. The Board may amend or terminate the Plan at any time; provided, however, that the Board shall not amend the Plan without shareholder approval if (i) such approval is required in order for Incentive Stock Options granted or to be granted under the Plan to meet the requirements of section 422 of the Code, (ii) such approval is required in order to exempt compensation under the Plan from the deduction limit under section 162(m) of the Code, or (iii) such approval is required by applicable stock exchange requirements. When amending or terminating the Plan, the Board shall act in a manner consistent with section 409A of the Code and no Board action shall cause the application of the twenty percent (20%) penalty or immediate tax recognition under section 409A of the Code.
(b)Shareholder Approval for “Qualified Performance-Based Compensation”. If Performance Units or Stock Awards are granted as “qualified performance-based compensation” under Section 8 above, the Plan must be reapproved by the shareholders no later than the first shareholders meeting that occurs in the fifth year following the year in which the shareholders previously approved the provisions of Section 8, if required by section 162(m) of the Code or the regulations thereunder.
(c)Termination of Plan. The Plan shall terminate on the day immediately preceding the tenth anniversary of its effective date, unless the Plan is terminated earlier by the Board or is extended by the Board with the approval of the shareholders.
(d)Termination and Amendment of Outstanding Grants. A termination or amendment of the Plan that occurs after a Grant is made shall not materially impair the rights of a Grantee unless the Grantee consents or unless the Committee acts under Section 21(b). The termination of the Plan shall not impair the power and authority of the Committee with respect to an outstanding Grant. Whether or not the Plan has terminated, an outstanding Grant may be terminated or amended under Section 21(b) or may be amended by agreement of the Company and the Grantee consistent with the Plan.

(e)Governing Document. The Plan shall be the controlling document. No other statements, representations, explanatory materials or examples, oral or written, may amend the Plan in any manner. The Plan shall be binding upon and enforceable against the Company and its successors and assigns.
16.Funding the Plan.
This Plan shall be unfunded. The Company shall not be required to establish any special or separate fund or to make any other segregation of assets to assure the payment of any Grants under this Plan. In no event shall interest be paid or accrued on any Grant, including unpaid installments of Grants.
17.Rights of Participants.
Nothing in this Plan shall entitle any Employee, Key Advisor, Non-Employee Director or other person to any claim or right to be granted a Grant under this Plan. Neither this Plan nor any action taken hereunder shall be construed as giving any individual any rights to be retained by or in the employ of the Company or any other employment rights.
18.No Fractional Shares.
No fractional shares of Company Stock shall be issued or delivered pursuant to the Plan or any Grant. The Committee shall determine whether cash, other awards or other property shall be issued or paid in lieu of such fractional shares or whether such fractional shares or any rights thereto shall be forfeited or otherwise eliminated.
19.Heading.
Section headings are for reference only. In the event of a conflict between a title and the content of a Section, the content of the Section shall control.
20.Effective Date of the Plan.
The Plan was effective May 22, 2001, and the amendment and restatement shall be effective January 1, 2005.
21.Miscellaneous.
(a)Grants in Connection with Corporate Transactions and Otherwise. Nothing contained in this Plan shall be construed to (i) limit the right of the Committee to make Grants under this Plan in connection with the acquisition, by purchase, lease, merger, consolidation or otherwise, of the business or assets of any corporation, firm or association, including Grants to employees thereof who become Employees of the Company, or for other proper corporate purposes, or (ii) limit the right of the Company to grant stock options or make other awards outside of this Plan. Without limiting the foregoing, the Committee may make a Grant to an employee of another corporation who becomes an Employee by reason of a corporate merger, consolidation, acquisition of stock or property, reorganization or liquidation involving the Company or any of its subsidiaries in substitution for a stock option or stock award grant made by such corporation. The terms and conditions of the substitute grants may vary from the terms and conditions required by the Plan and from those of the substituted stock incentives. The Committee shall prescribe the provisions of the substitute grants.
(b)Compliance with Law. The Plan, the exercise of Options and the obligations of the Company to issue or transfer shares of Company Stock under Grants shall be subject to all applicable laws and to approvals by any governmental or regulatory agency as may be required. With respect to persons subject to section 16 of the Exchange Act, it is the intent of the Company that the Plan and all transactions under the Plan comply with all applicable provisions of Rule 16b-3 or its successors under the Exchange Act. In addition, it is the intent of the Company that the Plan and applicable Grants under the Plan comply with the applicable provisions of section 162(m), section 409A and section 422 of the Code. To the extent that any legal requirement of section 16 of the Exchange Act or section 162(m), section 409A or section 422 of the Code as set forth in the Plan ceases to be required under section 16 of the

Exchange Act or section 162(m), section 409A or section 422 of the Code, that Plan provision shall cease to apply. The Committee may revoke any Grant if it is contrary to law or modify a Grant to bring it into compliance with any valid and mandatory government regulation. The Committee may also adopt rules regarding the withholding of taxes on payments to Grantees. The Committee may, in its sole discretion, agree to limit its authority under this Section.
(c)Savings Provision. In the event any provision of this Plan shall be deemed to cause the application of the twenty percent (20%) penalty or immediate tax recognition under section 409A of the Code, the provision that causes either the application of the penalty or immediate tax recognition shall become null and void, and the Plan shall be construed and enforced as if the provision causing the negative tax consequences had never been contained herein.
(d)Governing Law. The validity, construction, interpretation and effect of the Plan and Grant Instruments issued under the Plan shall be governed and construed by and determined in accordance with the laws of Florida, without giving effect to the conflict of laws provisions thereof.





DYADIC INTERNATIONAL, INC.
2006 STOCK OPTION PLAN
The purpose of the Dyadic International, Inc. 2006 Stock Option Plan (the “Plan”) is to provide (i) designated Employees of DYADIC INTERNATIONAL, INC. (the “Company”) and its subsidiaries, (ii) Key Advisors who perform consulting or advisory services for the Company or its Subsidiaries and (iii) Non-Employee Directors who serve on the Board of Directors of the Company (the “Board”) with the opportunity to receive grants of incentive stock options and nonqualified stock options. The Company believes that the Plan will encourage the participants to contribute materially to the growth of the Company, thereby benefiting the Company’s stockholders, and will align the economic interests of the participants with those of the stockholders. A Glossary of defined terms used in this Plan is set forth in Section 18 hereof.
1.Administration.
(a)Committee. The Plan shall be administered by the Compensation Committee of the Board, a majority of whose members are “outside directors” as defined under section 162(m) of the Code and related Treasury regulations, and “non-employee directors” as defined under Rule 16b-3 under the Exchange Act (the “Committee”). However, the Board may ratify or approve any grants as it deems appropriate.
(b)Committee Authority. The Committee shall have the sole authority to (i) determine the individuals to whom grants shall be made under the Plan, (ii) determine the type, size and terms of the Grants to be made to each such individual, (iii) determine the time when the Grants will be made and the duration of any applicable exercise or restriction period, including the criteria for exercisability and the acceleration of exercisability, (iv) amend the terms of any previously issued grant, and (v) deal with any other matters arising under the Plan. In the event the Committee determines section 409A of the Code may be applicable to an Option granted hereunder, the Plan shall prohibit the acceleration of the time or schedule of payment of compensation hereunder, except to the extent permitted under section 409A of the Code and the applicable Treasury regulations thereunder.
(c)Committee Determinations. The Committee shall have full power and authority to administer and interpret the Plan, to make factual determinations and to adopt or amend such rules, regulations, agreements and instruments for implementing the Plan and for the conduct of its business as it deems necessary or advisable, in its sole discretion. The Committee’s interpretations of the Plan and all determinations made by the Committee pursuant to the powers vested in it hereunder shall be conclusive and binding on all persons having any interest in the Plan or in any awards granted hereunder. All powers of the Committee shall be executed in its sole discretion, in the best interest of the Company, not as a fiduciary, and in keeping with the objectives of the Plan and need not be uniform as to similarly situated individuals.
2.Grants.
Grants of Options under the Plan may consist of Incentive Stock Options as described in Section 5 or Nonqualified Stock Options as described in Section 5. All Grants shall be subject to the terms and conditions set forth herein and to such other terms and conditions consistent with this Plan as the Committee deems appropriate and as are specified in a Grant Instrument or amendment thereto. The Committee shall approve the form and provisions of each Grant Instrument. Grants under a particular Section of the Plan need not be uniform as among the grantees.
3.Shares Subject to the Plan.
(a)Shares Authorized. Subject to adjustment as described below, the aggregate number of shares of Company Stock that may be issued or transferred under the Plan is 2,700,000 shares. The maximum aggregate number of shares of Company Stock that shall be subject to Grants made under the Plan to any individual during any calendar year shall be 1,200,000 shares, subject to adjustment as described below. The shares may be authorized but

unissued shares of Company Stock or reacquired shares of Company Stock, including shares purchased by the Company on the open market for purposes of the Plan. If and to the extent Options granted under the Plan terminate, expire, or are canceled, forfeited, exchanged or surrendered without having been exercised, the shares subject to such Grants shall again be available for purposes of the Plan.
(b)Adjustments. If there is any change in the number or kind of shares of Company Stock outstanding (i) by reason of a stock dividend, spinoff, recapitalization, stock split, or combination or exchange of shares, (ii) by reason of a merger, reorganization or consolidation in which the Company is the surviving corporation, (iii) by reason of a reclassification or change in par value, or (iv) by reason of any other extraordinary or unusual event affecting the outstanding Company Stock as a class without the Company’s receipt of consideration, or if the value of outstanding shares of Company Stock is substantially reduced as a result of a spinoff or the Company’s payment of an extraordinary dividend or distribution, the maximum number of shares of Company Stock available for Grants, then in that event (A) the maximum number of shares of Company Stock that any individual participating in the Plan may be panted in any year, (B) the number of shares covered by outstanding Grants, (C) the kind of shares issued under the Plan, and (D) the price per share or the applicable market value of such Grants may be appropriately adjusted by the Committee to reflect any increase or decrease in the number of, or change in the kind or value of, issued shares of Company Stock to preclude, to the extent practicable, the enlargement or dilution of rights and benefits under such Grants; provided, however, that any fractional shares resulting from such adjustment shall be eliminated. Any adjustments determined by the Committee shall be final, binding and conclusive.
4.Eligibility for Participation.
(a)Eligible Persons. All Employees of the Company and its Subsidiaries, including Employees who are officers or members of the Board, and Non-Employee Directors shall be eligible to participate in the Plan. Key Advisors who perform services for the Company or any of its Subsidiaries shall be eligible to participate in the Plan if (i) they render bona fide services to the Company or its Subsidiaries, (ii) the services are not in connection with the offer and sale of securities in a capital-raising transaction and (iii) such Key Advisors do not directly or indirectly promote or maintain a market for the Company’s securities.
(b)Selection of Grantees. The Committee shall select the Employees, Non-Employee Directors and Key Advisors to receive Grants and shall determine the number of shares of Company Stock subject to a particular Grant in such manner as the Committee determines. Employees, Key Advisors and Non-Employee Directors who receive Grants under this Plan shall hereinafter be referred to as “Grantees.”
5.Granting of Options.
(a)Number of Shares. The Committee shall determine the number of shares of Company Stock that will be subject to each Grant of Options to Employees, Non-Employee Directors and Key Advisors.
(b)Type of Option and Price.
(i)The Committee may grant Incentive Stock Options that are intended to qualify as “Incentive Stock Options” within the meaning of section 422 of the Code or Nonqualified Stock Options that are not intended so to qualify or any combination of Incentive Stock Options and Nonqualified Stock Options, all in accordance with the terms and conditions set forth in this Plan. Incentive Stock Options may be granted only to Employees. Nonqualified Stock Options may be granted to Employees, Non-Employee Directors and Key Advisors.
(ii)The purchase price (the “Exercise Price”) of Company Stock subject to an Option shall be determined by the Committee and shall be equal to or greater than the Fair Market Value (as defined below) of a share of Company Stock on the date the Option is granted; provided, however, that an Incentive Stock Option shall not be granted to an Employee who, at the time of grant, owns stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or any parent or subsidiary of the Company, unless the Exercise Price per share is not less than one hundred ten percent (110%) of the Fair Market Value of Company Stock on the date of grant.


(iii)While the Company Stock is publicly traded, the Fair Market Value per share shall be determined as follows: (x) if the principal trading market for the Company Stock is a national securities exchange or the Nasdaq National Market, the last reported sale price thereof on the relevant date or (if there were no trades on that date) the latest preceding date upon which a sale was reported. or (y) if the Company Stock is not principally traded on such exchange or market, the mean between the last reported “bid” and “asked” prices of Company Stock on the relevant date, as reported on Nasdaq or, if not so reported, as reported by the National Daily Quotation Bureau, Inc. or as reported in a customary financial reporting service, as applicable and as the Committee determines. If the Company Stock ever ceases to be publicly traded or, if publicly traded, is not subject to reported transactions or “bid” or “asked” quotations as set forth above, the Fair Market Value per share shall be as determined by the Committee.
(c)Option Term. The Committee shall determine the term of each Option. The term of any Option shall not exceed ten (10) years from the date of grant. However, an Incentive Stock Option that is granted to an Employee who, at the time of owns stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company, or any parent or subsidiary of the Company, may not have a term that exceeds five years from the date of grant.
(d)Exercisability of Options. Options shall become exercisable in accordance with such terms and conditions, consistent with the Plan, as may be determined by the Committee and specified in the Grant Instrument. The Committee may waive or accelerate the satisfaction of an exercise term or condition of any or all outstanding Options at any time for any reason.
(e)Termination of Employment, Disability or Death.
(i)Except as provided below, an Option may only be exercised while the Grantee is employed by, or providing service to, the Company as an Employee, Key Advisor or member of the Board. In the event that a Grantee ceases to be employed by the Company (in the case of an Employee), serve on the Board (in the case of a Non-Employee Director) or provide service to, the Company (in the case of a Key Advisor) for any reason other than Disability, death, or termination for Cause, any Option which is otherwise exercisable by the Grantee shall terminate unless exercised within 90 days after the date on which the Grantee ceases to be employed by, serve on the Board of, or provide service to, the Company, as applicable, or within such other period of time as may be specified by the Committee, but in any event no later than the date of expiration of the Option term. Except as otherwise provided by the Committee any of the Grantee’s Options that are not otherwise exercisable as of the date on which the Grantee ceases to be employed by, or provide service to, the Company shall terminate as of such date.
(ii)In the event the Grantee ceases to be employed by the Company (in the case of Employees), serve on the Board (in the case of a Non-Employee Director) or provide service to the Company (in the case of a Key Advisor) on account of a termination for Cause by the Company, any Option held by that Grantee shall terminate as of the date such Grantee ceases to be employed by, serve on the Board or provide service to, the Company, as applicable. In addition, notwithstanding any other provisions of this Section 5, if the Committee determines that the Grantee has engaged in conduct that constitutes Cause at any time while the Grantee is employed by, serving on the Board or providing service to, as applicable, the Company or after the Grantee’s termination of employment, Board membership or service, as applicable, any Option held by that Grantee shall immediately terminate and that Grantee shall automatically forfeit all shares underlying any exercised portion of an Option for which the Company has not yet delivered the share certificates, upon refund by the Company of the Exercise Price paid by that Grantee for such shares. Upon any exercise of an Option, the Company may withhold delivery of share certificates pending resolution of an inquiry that could lead to a finding resulting in a forfeiture.
(iii)In the event the Grantee ceases to be employed by, serve on the Board or provide service to, the Company, as applicable, because the Grantee is Disabled, any Option which is otherwise exercisable by that Grantee shall terminate unless exercised within one year after the date on which that Grantee ceases to be employed by, be on the Board or provide service to, the Company, as applicable (or within such other period of time as may be specified by the Committee), but in any event no later than the date of expiration of the Option term. Except as otherwise provided by the Committee, any of a Grantee’s Options which are not otherwise exercisable as of the date on which the Grantee ceases to be employed by, serve on the Board or provide service to, the Company, as applicable, shall terminate as of such date.


(iv)If the Grantee dies while employed by, serving on the Board or providing service to, the Company, as applicable, or within 90 days after the date on which the Grantee ceases to be employed, serve on the Board or provide service on account of a termination specified in Section 5(e)(i) above (or within such other period of time as may be specified by the Committee), any Option that is otherwise exercisable by that Grantee shall terminate unless exercised within one year after the date on which that Grantee ceases to be employed by, serve on the Board or provide service to, the Company, as applicable (or within such other period of time as may be specified by the Committee), but in any event no later than the date of expiration of the Option term. Except as otherwise provided by the Committee, any of the Grantee’s Options that are not otherwise exercisable as of the date on which the Grantee ceases to be employed by, or provide service to, the Company shall terminate as of such date.
(f)Exercise of Options. A Grantee may exercise an Option that has become exercisable, in whole or in part, by delivering a notice of exercise to the Company with payment of the Exercise Price. The Grantee shall pay the Exercise Price for an Option as specified by the Committee (w) in cash, (x) with the approval of the Committee, by delivering shares of Company Stock owned by the Grantee (including Company Stock acquired in connection with the exercise of an Option, subject to such restrictions as the Committee deems appropriate) and having a Fair Market Value on the date of exercise equal to the Exercise Price or by attestation (on a form prescribed by the Committee) to ownership of shares of Company Stock having a Fair Market Value on the date of exercise equal to the Exercise Price, (y) pay through a broker in accordance with procedures permitted by Regulation T of the Federal Reserve Board, or (z) by such other method as the Committee may approve. The Committee may authorize loans by the Company to Grantees in connection with the exercise of an Option, upon such terms and conditions as the Committee, in its sole discretion, deems appropriate. Shares of Company Stock used to exercise an Option shall have been held by the Grantee for the requisite period of time to avoid adverse accounting consequences to the Company with respect to the Option. The Grantee shall pay the Exercise Price and the amount of any withholding tax due at the time of exercise.
(g)Limits on Incentive Stock Options. Each Incentive Stock Option shall provide that, if the aggregate Fair Market Value of the stock on the date of the grant with respect to which Incentive Stock Options are exercisable for the first time by a Grantee during any calendar year, under the Plan or any other stock option plan of the Company or a parent or subsidiary, exceeds $100,000, then the Option, as to the excess, shall be treated as a Nonqualified Stock Option. An Incentive Stock Option shall not be granted to any person who is not an Employee of the Company or a parent or subsidiary (within the meaning of section 424(f) of the Code).
6.Withholding of Taxes.
(a)Required Withholding. All Grants under the Plan shall be subject to any applicable federal (including FICA), state and local tax withholding requirements. The Company shall have the right to deduct from other wages paid to the Grantee, any federal, state or local taxes required by law to be withheld with respect to such Grants or any exercise thereof. In the case of Options paid in Company Stock, the Company may require that the Grantee or other person receiving or exercising Grants pay to the Company the amount of any federal, state or local taxes that the Company is required to withhold with respect to such Grants, or the Company may deduct from other wages paid by the Company the amount of any withholding taxes due with respect to such Grants.
(b)Election to Withhold Shares. If the Committee so permits, a Grantee may elect to satisfy the Company’s income tax withholding obligation with respect to Options paid in Company Stock by having shares withheld up to an amount that does not exceed the Grantee’s minimum applicable withholding tax rate for federal (including FICA), state and local tax liabilities. The election must be in a form and manner prescribed by the Committee and may be subject to the prior approval of the Committee.
7.Transfer of Grants.
(a)Nontransferability of Grants. Except as provided below, only the Grantee may exercise rights under a Grant during the Grantee’s lifetime. A Grantee may not transfer those rights except by will or by the laws of descent and distribution or, with respect to Grants other than Incentive Stock Options, if permitted in any specific case by the Committee, pursuant to a domestic relations order. When a Grantee dies, such Grantee’s Successor Grantee may exercise such rights, provided that any such Successor Grantee must furnish proof satisfactory to the Company of his or her right to receive the Grant under the Grantee’s will or under the applicable laws of descent and distribution.

(b)Transfer of Nonqualified Stock Options. Notwithstanding the foregoing, the Committee may provide, in a Grant Instrument, that a Grantee may transfer Nonqualified Stock Options to immediate family members, or one or more trusts or other entities for the benefit of or owned by immediate family members, consistent with the applicable securities laws, according to such terms as the Committee may determine; provided that the Grantee receives no consideration for the transfer of an Option and the transferred Option shall continue to be subject to the same terms and conditions as were applicable to the Option immediately before the transfer.
8.Consequences of a Change of Control.
(a)Assumption of Grants. Upon the occurrence of a Change of Control in which the Company is not the surviving corporation (or survives only as a subsidiary of another corporation), unless the Committee determines otherwise, all outstanding Options that are not exercised shall be assumed by, or replaced with comparable options or rights by the surviving corporation (or a parent of the surviving corporation), and other outstanding Grants shall he converted to similar grants of the surviving corporation (or a parent of the surviving corporation).
(b)Other Alternatives. Notwithstanding the foregoing, in the event of a Change in Control, the Committee may, but shall not be obligated to, take any of the following actions with respect to any or all outstanding Grants: the Committee may (i) determine that outstanding Options shall automatically accelerate and become fully exercisable, (ii) require that Grantees surrender their outstanding Options in exchange for a payment by the Company, in cash or Company Stock as determined by the Committee, in an amount equal to the amount by which the then Fair Market Value of the shares of Company Stock subject to the Grantee’s unexercised Options exceeds the Exercise Price of the Options or (iii) after giving Grantees an opportunity exercise their outstanding Options, terminate any or all unexercised Options at such time as the Committee deems appropriate. Such surrender, termination or settlement shall take place as of the date of the Change of Control or such other date as the Committee may specify. The Committee shall have no obligation to take any of the foregoing actions, and, in the absence of any such actions, outstanding Grants shall continue in effect according to their terms (subject to any assumption pursuant to Subsection (a)).
9.Requirements for Issuance or Transfer of Shares.
(a)Limitations on Issuance or Transfer of Shares. No Company Stock shall be issued or transferred in connection with any Grant hereunder unless and until all legal requirements applicable to the issuance or transfer of such Company Stock have been complied with to the satisfaction of the Committee. The Committee shall have the right to condition any Grant made to any Grantee hereunder on such Grantee’s undertaking in writing to comply with such restrictions on his or her subsequent disposition of such shares of Company Stock as the Committee shall deem necessary or advisable, and certificates representing such shares maybe legended to reflect any such restrictions. Certificates representing shares of Company Stock issued or transferred under the Plan will be subject to such stop-transfer orders and other restrictions as may be required by applicable laws, regulations and interpretations, including any requirement that a legend be placed thereon.
(b)Lock-Up Period. If so requested by the Company or any representative of the underwriters (the “Managing Underwriter”) in connection with any underwritten offering of securities of that Company under the Securities Act a Grantee (including any successors or assigns) shall not sell or otherwise transfer any shares or other securities of the Company during the 30-day period preceding and the 180-day period following the effective date of a registration statement of the Company filed under the Securities Act for such underwriting (or such shorter period as may be requested by the Managing Underwriter and agreed to by the Company) (the “Market Standoff Period”). The Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such Market Standoff Period. Certificates representing Company stock issued upon exercise of Options or otherwise pursuant to the Plan shall bear such legend regarding the lock-up period obligations as counsel to the Company shall determine.


10.Amendment and Termination of the Plan.
(a)Amendment. The Board may amend or terminate the Plan at any time; provided, however, that the Board shall not amend the Plan without stockholder approval if (i) such approval is required in order for Incentive Stock Options granted or to be granted under the Plan to meet the requirements of section 422 of the Code, (ii) such approval is required in order to exempt compensation under the Plan from the deduction limit under section 162(m) of the Code, or (iii) such approval is required by applicable stock exchange requirements. When amending or terminating the Plan, no Board action shall cause the application of the requirements, the twenty percent (20%) penalty or immediate tax recognition under section 409A of the Code.
(b)Termination of Plan. The Plan shall terminate on the day immediately preceding the tenth anniversary of its effective date, unless the Plan is terminated earlier by the Board or is extended by the Board with the approval of the stockholders.
(c)Termination and Amendment of Outstanding Grants. A termination or amendment of the Plan that occurs after a Grant is made shall not materially impair the rights of a Grantee unless the Grantee consents or unless the Committee acts under Section 16(b) hereunder. The termination of the Plan shall not impair the power and authority of the Committee with respect to an outstanding Grant. Whether or not the Plan has terminated, an outstanding Grant may be terminated or amended under Section 16(b) hereunder or may be amended by agreement of the Company and the Grantee consistent with the Plan.
(d)Governing Document. The Plan shall be the controlling document. No other statements, representations, explanatory materials or examples, oral or written, may amend the Plan in any manner. The Plan shall be binding upon and enforceable against the Company and its successors and assigns.
11.Funding the Plan.
This Plan shall be unfunded. The Company shall not be required to establish any special or separate fund or to make any other segregation of assets to assure the payment of any Grants under this Plan. In no event shall interest be paid or accrued on any Grant, including unpaid installments of Grants.
12.Rights of Participants.
Nothing in this Plan shall entitle any Employee, Key Advisor, Non-Employee Director or other person to any claim or right to be granted a Grant under this Plan. Neither this Plan nor any action taken hereunder shall be construed as giving any individual any rights to be retained by or in the employ of the Company or any other employment rights.
13.No Fractional Shares.
No fractional shares of Company Stock shall be issued or delivered pursuant to the Plan or any Grant. The Committee shall determine whether cash, other awards or other property shall be issued or paid in lieu of such fractional shares or whether such fractional shares or any rights thereto shall be forfeited or otherwise eliminated.
14.Heading.
Section headings are for reference only. In the event of a conflict between a title and the content of a Section, the content of the Section shall control.
15.Effective Date of the Plan.
Subject to approval by the Company’s stockholders, the Plan shall be effective on April 19, 2006, the date of the adoption of this Plan by the Board of Directors of the Company.
16.Miscellaneous.
(a)Grants in Connection with Corporate Transactions and Otherwise. Nothing contained in this Plan shall be construed to (i) limit the right of the Committee to make Grants under this Plan in connection with the acquisition, by purchase, lease, merger, consolidation or otherwise, of the business or assets of any corporation, firm or association, including Grants to employees thereof who become Employees of the Company, or for other proper corporate purposes, or (ii) limit the right of the Company to grant stock options or make other awards outside of this Plan. Without limiting the foregoing, the Committee may make a Grant to an employee of another corporation who becomes an Employee by reason of a corporate merger, consolidation, acquisition of stock or property, reorganization or liquidation involving the Company or any of its Subsidiaries in substitution for a stock option or stock award grant made by such corporation. The terms and conditions of the substitute grants may vary from the terms and conditions required by the Plan and from those of the substituted stock incentives. The Committee shall prescribe the provisions of the substitute grants.
(b)Compliance with Law. The Plan, the exercise of Options and the obligations of the Company to issue or transfer shares of Company Stock under Grants shall be subject to all applicable laws and to approvals by any governmental or regulatory agency as may be required. With respect to Grantees subject to section 16 of the Exchange Act, it is the intent of the Company that the Plan and all transactions under the Plan comply with all applicable provisions of Rule 16b-3 or its successors under the Exchange Act. In addition, it is the intent of the Company that the Plan and applicable Grants under the Plan comply with the applicable provisions of section 162(m), section 409A and section 422 of the Code. To the extent that any legal requirement of section 16 of the Exchange Act, or section 162(m), section 409A and section 422 of the Code as set forth in the Plan ceases to be required under section 16 of the Exchange Act, or section 162(m), section 409A and section 422 of the Code, that Plan provision shall cease to apply. The Committee may revoke any Grant if it is contrary to law or modify a Grant to bring it into compliance with any valid and mandatory government regulation. The Committee may also adopt rules regarding the withholding of taxes on payments to Grantees. The Committee may, in its sole discretion, agree to limit its authority under this Section.
(c)Savings Provision. In the event any provision of this Plan shall be deemed to cause the application of the twenty percent (20%) penalty or immediate tax recognition under section 409A of the Code, the provision that causes either the application of the penalty or immediate tax recognition shall become null and void, and the Plan shall be construed and enforced as if the provision causing the negative tax consequences had never been contained herein.
(d)Governing Law. The validity, construction, interpretation and effect of the Plan and Grant Instruments issued under the Plan shall be governed and construed by and determined in accordance with the laws of Florida, without giving effect to the conflict of laws provisions thereof.
18.Glossary.
The following terms shall have the meaning assigned them below:
Board” shall mean the Board of Directors of the Company.
Cause” shall mean, except to the extent specified otherwise by the Committee, a finding by the Committee that the Grantee (i) has breached his or her employment or service contract with the Company, in the case     of Employees or Key Advisors, or breached his fiduciary duties to the Company or otherwise been removed from the Board by the action of the Board, in the case of a Non-Employee Director, (ii) has engaged in disloyalty to the Company, including, without limitation, fraud, embezzlement, theft, commission of a felony or proven dishonesty in the course of his or her employment or service, (iii) has disclosed trade secrets or confidential information of the Company to persons not entitled to receive such information or (iv) has engaged in such other behavior detrimental to the interests of the Company as the Committee determines.
Change of Control” shall mean the occurrence of any of the following events:
(i)Any “person” (defined to have the meaning in this definition of Change of Control as is assigned that term in sections 13(d) and 14(d) of the Exchange Act) other than an “Excluded Stockholder”

        (as defined herein) becomes a “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the voting power of the then outstanding securities of the Company; provided that a Change of Control shall not be deemed to occur as a result of a transaction in which the Company becomes a subsidiary of another corporation and in which the stockholders of the Company, immediately prior to the transaction, will beneficially own, immediately after the transaction, shares entitling such stockholders to more than fifty percent (50%) of all votes to which all stockholders of the parent corporation would be entitled in the election of directors (without consideration of the rights of any class of stock to elect directors by a separate class vote); the term “Excluded Stockholder” meaning, for purposes of this definition of Change of Control, any person who is the beneficial owner, directly or indirectly of more than twenty percent (20%) of the voting power of the then outstanding securities of the Company;
(ii)The stockholders of the Company approve (or, if stockholder approval is not required, the Board approves) an agreement providing for (i) the merger or consolidation of the Company with another corporation where the stockholders of the Company, immediately prior to the merger or consolidation, will not beneficially own, immediately after the merger or consolidation, shares entitling such stockholders to more than fifty percent (50%) of all votes to which all stockholders of the surviving corporation would be entitled in the election of directors (without consideration of the rights of any class of stock to elect directors by a separate class vote), (ii) the liquidation or dissolution of the Company; or (iii) the sale or other disposition of assets equal to or greater than forty percent (40%) of the total gross fair market value of all assets of the Company immediately prior to such sale or disposition; or
(iii)Any person other than an Excluded Person has commenced a tender offer or exchange offer for thirty percent (30%) or more of the voting power of the then outstanding stock of the Company.
Code” shall mean the Internal Revenue Code of 1986, as amended.
Committee” shall mean the Compensation Committee of the Board.
Company” shall mean Dyadic International, Inc., a Delaware corporation.
Company Stock” shall mean shares of common stock of the Company.
Disability” shall mean a Grantee’s becoming disabled within the meaning of section 22(e)(3) of the Code.
Employees” shall mean all employees of the Company and its Subsidiaries, including Employees who are officers or members of the Board.
Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.
Exercise Price” shall mean the purchase price of Company Stock subject to an Option under a Grant.
Key Advisors” shall mean consultants and advisors who perform services for the Company or any of its Subsidiaries.
“Grantee” shall mean Key Advisors and Non-Employee Directors who receive Grants under this Plan.
Grants” shall mean awards of Options made by the Committee under the Plan.
Grant Instruments” shall mean the written instrument evidencing the Committee’s Grant of an Option to a Participant, or an amendment thereto.
Incentive Stock Options” shall mean Options qualifying as such within the meaning of section 422 of the Code.
Managing Underwriter” shall have the meaning assigned that term in Section 9(b) of the Plan.
Market Standoff Period” shall have the meaning assigned that term in Section 9(b) of the Plan.
Non-Employee Directors” shall mean members of the Board who are not Employees.
Non-Qualifying Options” shall mean Options that do not qualify as Incentive Stock Options.
Options” means Incentive Stock Options and Non-Qualifying Options, without distinction.
Plan” shall mean the Dyadic International, Inc. 2006 Stock Option Plan.
Securities Act” shall mean the Securities Act of 1933, as amended.
Subsidiary” shall mean any corporation or other legal entity of which the Company owns, directly or indirectly, 50% or more of the stock or other equity interests, the holders of which are generally entitled to vote for the election of the board of directors or other governing body of such corporation or other legal entity.
Successor Grantee” shall mean the personal representative or other person entitled to succeed to the rights of a Grantee following his or her death.





PROXY
FORM OF PROXY
DYADIC INTERNATIONAL, INC.
PROXY FOR 2006 ANNUAL MEETING OF STOCKHOLDERS
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
JUNE 12, 2006
The undersigned stockholder(s) of Dyadic International, Inc., a Delaware corporation (the “Company”), hereby revoking any proxy heretofore given, does hereby appoint Mark A. Emalfarb and Wayne Moor, and each of them, with full power to act alone, the true and lawful attorneys-in-fact and proxies of the undersigned, with full powers of substitution, and hereby authorize(s) them and each of them, to represent the undersigned and to vote all shares of common stock of the Company that the undersigned is entitled to vote at the 2006 Annual Meeting of Stockholders of the Company to be held on June 12, 2006 at 10:00 a.m., local time, at the Doubletree Hotel located at 4431 PGA Boulevard, Palm Beach Gardens, Florida 33410, and any and all adjournments and postponements thereof, with all powers the undersigned would possess if personally present, on the following proposals, each as described more fully in the accompanying proxy statement, and any other matters coming before said meeting.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” ALL OF NOMINEES FOR CLASS II DIRECTOR NAMED IN PROPOSAL 1 AND THE OTHER PROPOSALS.
1.To elect the following nominees as Class II directors, each for a three-year term ending in 2009: Stephen J. Warner and Harry Z. Rosengart
               FOR the nominees above (except as marked below)WITHHELD for all nominees above
(INSTRUCTION: To withhold authority to vote for any individual nominee, write that nominee’s name in the space provided below)

2.To approve the Amended and Restated Dyadic International, Inc. 2001 Equity Compensation Plan effective as of January 1, 2005.
FORAGAINSTABSTAIN
3.To approve the Dyadic International, Inc. 2006 Stock Option Plan.
FORAGAINSTABSTAIN
4.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2006.
5.To transact any other business as may properly be brought before the annual meeting.
This proxy will be voted in the manner directed herein by the undersigned. IF NO DIRECTION IS GIVEN, THIS PROXY WILL BE VOTED “FOR” THE ELECTION OF THE NOMINEES FOR CLASS II DIRECTOR NAMED IN PROPOSAL 1 AND THE OTHER PROPOSALS AND IN THE DISCRETION OF THE PROXIES ON SUCH OTHER MATTERS AS MAY PROPERLY COME BEFORE THE ANNUAL MEETING OR ANY ADJOURNMENTS OR POSTPONEMENTS THEREOF TO THE EXTENT PERMITTED UNDER APPLICABLE LAW.
Receipt of the Notice of 2006 Annual Meeting of Stockholders and accompanying Proxy Statement, together with the Annual Report on Form 10-KSBand Consolidated Financial Statements for the fiscal year ended December 31, 20052019 filed on Form 10-K.
The information incorporated by reference is hereby acknowledged.considered to be a part of this proxy statement as if stated herein. At your request, we will provide to you a copy of any or all of the above documents that have been incorporated by reference into this proxy statement at no cost.
Requests for additional copies of this proxy statement or the enclosed proxy card, as well as requests for additional information, may be made by writing or calling us at the following address or telephone number:
140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477, Attention: Heidi Zosiak, telephone: (561) 743-8333 or Broadridge Financial Solutions, Inc., 51 Mercedes Way, Edgewood, NY 11717, telephone: (631) 257-4339.
BY ORDER OF THE BOARD OF DIRECTORS

/s/ Mark Emalfarb
Mark Emalfarb
President and Chief Executive Officer

May 12, 2020
Jupiter, Florida
IMPORTANT — PLEASE MARK, SIGN, DATE AND RETURN PROMPTLY USING THE ENCLOSED ENVELOPE.


NOTE:Please sign exactly as your name appears on this proxy. Joint owners should each sign personally. If signing as attorney, executor, administrator, trustee or guardian, please include your full title. Corporate or partnership proxies should be signed by an authorized officer.

Signature(s) ___________________Date ___________, 2006
Signature(s) ___________________Date ___________, 2006
dyadicinternationalinc4830.jpg
28



2
dyadicinternationalinc48301.jpg
29